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Abstract 
Ever since the discovery that mutations in the voltage-gated sodium channel 1.7 protein are 
responsible for human congenital insensitivity to pain, the voltage-gated sodium channel 
(NaV) family of ion channels has been the subject of intense research with the hope of 
discovering novel analgesics. We now know that NaV1.7 deletion in select neuronal 
populations yield different phenotypes, with the deletion of NaV1.7 in all sensory neurons 
being successful at abolishing mechanical and heat-induced pain. However, it is rapidly 
becoming apparent that a number of pain syndromes are not modulated by NaV1.7 at all, such 
as oxaliplatin-mediated neuropathy. It is particularly interesting to note that the loss of 
NaV1.7 function is also associated with the selective inhibition of pain mediated by specific 
stimuli, such as that observed in burn-induced pain where NaV1.7 gene knockout abolished 
thermal allodynia but did not affect mechanical allodynia. Accordingly, significant interests 
exist in delineating the contribution of other NaV isoforms in modality-specific pain 
pathways. Two other isoforms, NaV1.6 and NaV1.8, are now specifically implicated in some 
NaV1.7-independent conditions such as oxaliplatin-induced cold allodynia. Such selective 
contributions of specific ion channel isoforms to pain highlight the need to discover other 
putative protein targets involved in mediating nociception.  
 
The aim of my work is therefore to discover selective molecular inhibitors of NaV1.6 and 
NaV1.8, to find useful cell models for peripheral nociceptors, to investigate the roles of 
NaV1.6 and NaV1.8 in an animal model of burn-induced pain, and to screen for putative new 
targets for analgesia in burn-related pain. 
 
Chapter 2 of this thesis describes activity-guided discovery of novel NaV1.6 and NaV1.8-
modulting peptides from crude spider venoms. Crude venom from Poecilotheria metallica 
successfully reduced NaV1.8-mediated voltage changes in HEK293-expressing cells. A new 
NaV1.8-inhibitory peptide was sequenced from the venom and named Pme1a. However, 
Pme1a exhibited TRPV1 agonist activity and induced nocifensive behaviours, such as paw 
licking, after injection into the hind paws of mice, indicating the peptide was not a selective 
NaV1.8 modulator and was unsuitable as a tool for NaV1.8 investigation. 
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With the unsuccessful exploration of spider venoms for new specific inhibitors, I then 
investigated in vitro cell models as tools to research specific nociceptor subtypes that express 
NaV1.6 or NaV1.8. In Chapter 3, I provide the first complete transcriptome of three common 
in vitro neuronal cell lines (SH-SY5Y, F-11, and ND7/23) to examine whether they were 
appropriate for investigating the functions of NaV1.6 and NaV1.8, and to identify if the cell 
lines resemble in vivo dorsal root ganglion (DRG) neuronal subclasses. The three cell lines 
examined all expressed proteins belonging to similar pathways and of similar proportions to 
native DRG neurons. However, they did not express any cellular markers in a fashion that 
represented any known subclasses of DRG neurons. Therefore, it is unlikely that any of the 
cell lines examined are appropriate models for NaV1.6 or NaV1.8 function, and highlights the 
need for careful selection of models in in vitro work. 
 
As investigations for selective NaV1.6 and NaV1.8 modulators and appropriate in vitro cell 
models both proved to be unsuccessful, I then turned to animal models to study modality-
specific contributions of NaV isoforms. Chapter 4 describes the establishment of a murine 
model of peripheral burn injury to assess the involvement of NaV1.6 and NaV1.8 in burn-
induced pain. The inhibition of NaV1.6 and no other NaV isoforms significantly reduced burn-
induced mechanical allodynia, a NaV1.7-independent pain modality, indicating NaV1.6 plays 
a vital role in this NaV1.7-independent condition. However, immunofluorescence studies 
revealed NaV1.6 expression was not changed in the affected DRGs. I therefore decided to 
conduct a transcriptomic investigation to examine whether the expression of other pain-
related ion channel gene were changed, and to discover if genes differentially expressed in 
the affected DRG neurons could be potential pharmacological targets for analgesia. 
 
The results of the transcriptomic investigation of DRGs affected by the burn model are 
discussed in Chapter 5. A total of 30 genes were found to be differentially expressed, 
including genes known to be involved in nociception (such as neuropeptide Y) as well as 
genes with no known association to nociception (such as lipase, family member N). It should 
be noted that none of the NaV isoforms were differentially expressed, indicating that NaV 
channels may alter pain sensitivity through modulated function rather than expression. 
Selective inhibitors of the protein products of the genes found to be up-regulated were then 
tested in the burn-induced pain mouse model. Proglumide, an inhibitor of the cholecystokinin 
B receptor, exhibited a significant anti-allodynic effect in burn-induced mechanical allodynia 
and was synergistic with oxycodone. Some genes found to be differentially expressed in burn 
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injury were also identified in the cell lines covered in Chapter 3, and the cell lines can 
potentially be used as in vitro models to rapidly profile the effects of inhibitors of these 
proteins in peripheral neurons. 
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Chapter 1: Literature review 
 
1.1 Foreword 
Pain has been an integral part of the human experience for millennia, yet, it is only recently 
that we have begun to decipher the neurological roots of this phenomenon. Inefficient 
analgesia persists across the medical field, particularly in chronic neuropathic pain, 
conditions in which pain is no longer associated with acute injury but has become a chronic 
condition. The proportion of Australians who suffer from chronic pain has been estimated to 
be 20% of the population, and the financial losses endured by Australia due to chronic pain 
was placed at $7.0 billion of healthcare expenditure and $15.8 billion of non-health financial 
cost in 2007 alone
1
. 
 
The expression of a certain voltage-gated sodium channel (NaV) isoform, NaV1.7, on dorsal 
root ganglia (DRG) neurons, has been found to be associated with the capacity to feel pain 
and with various neuropathic pain conditions in humans. However, it is becoming 
increasingly clear that NaV1.7 is not responsible for all pain types. Evidence of other NaV 
isoforms being associated with neuropathic pain conditions warrants further investigation for 
these other isoforms, in particular NaV1.6 and NaV1.8, which have been linked to oxaliplatin-
induced neuropathic pain
2
 and inflammatory neuropathic pain conditions
3
 respectively.  
 
Burn-induced mechanical allodynia is a condition not completely alleviated by the loss of 
functional NaV1.7. Burn injuries remain a significant burden for the global medical system, 
with approximately 265,000 burn-related deaths and 11 million burn patients needing medical 
treatment in 2004
4
. Moreover, as burn patients are known to exhibit resistance towards 
opioids and necessitating opioid doses that are higher than standard for analgesia, there is a 
real need for the discovery of more efficient drug targets for burn-induced pain
5
. NaV1.7 
knockout mice did not develop burn-induced thermal allodynia, but mechanical allodynia was 
not affected by the loss of NaV1.7, indicating that burn-induced pain is likely to be mediated 
by other channels and receptors in sensory neurons in addition to NaV1.7. 
 
This chapter reviews the existing body of literature on the pathophysiology and neurological 
pathways involved in somatic pain, including the various ion channels and receptors involved 
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in different levels of pain sensation and transmission. The neuroanotomical pathways of pain 
signalling, from peripheral DRG neurons to the central spinal and thalamic tracts, are 
discussed first. The chapter then covers ion channels and receptors responsible for signal 
transduction, with a focus on transient receptor potential (TRP) channels, acid-sensing ion 
channels, and voltage-gated ion channels found along the ending and axon of peripheral DRG 
neurons. The voltage-gated ion channels include voltage-gated calcium (CaV), potassium 
(KV), and sodium (Nav) isoforms, all of which are known to contribute to the propagation of 
the action potential along the sensory neuron.  
 
Finally, this chapter focuses on literature concerning the prominent role of NaV isoforms in 
pain, covering NaV structure, known modulators, and with a specific focus on the evidence 
towards the involvement of NaV1.6, 1.7, and 1.8 isoforms in pain, both in physiologically 
normal and neuropathic pain conditions. The chapter concludes by outlining the hypothesis 
and aims of the thesis, and leads into Chapter 2 - Discovery of Selective Voltage-gated 
Sodium Channel Inhibitors from Spider Venoms. 
 
Parts of this chapter have been adopted from a previously published review that arose out of 
this thesis, published by Biochemical Pharmacology
6
. 
 
1.2 Pathways of Pain Signal Transmission 
1.2.1 Peripheral dorsal root ganglion neurons and subclasses 
The perception of pain from external sources starts from the peripheral neurons detecting 
noxious stimuli, which may be mechanical, chemical, or thermal in nature. Nerve endings 
near the skin transduce these external stimuli into action potentials, with the resulting 
electrical signal being transmitted along the DRG neurons and into the spinal cord via the 
dorsal horn region, specifically through laminae I, II, V, and VI
7
. This nociceptive signal is 
carried further upstream via the spinoreticular and spinothalamic tracts into the thalamus
7
, 
where thalamo-cortico projections carry the signal into the forebrain and the cingulate, 
culminating in the cognition of, and sensory response to, pain
8
. 
 
The neurons responsible for sensing noxious stimuli and initiating our detection of pain are 
peripheral sensory neurons with cell bodies located in the DRGs near the spinal cord. These 
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DRG neurons are pseudo-unipolar in structure, with a single axon that splits off in two 
opposite directions, one branch extending towards the peripheral skin and the other towards - 
and through - the dorsal horn of the spinal cord
9
. As such, these neurons are uniquely 
positioned to receive signals from both peripheral nervous system (PNS) stimulation and 
central innervation, and have the capacity to transcribe proteins for both branches of the axon.  
 
There are two major classes of DRG neurons: those giving rise to myelinated A-fibres 
(subdivided into Aβ- and Aδ-fibres) and those giving rise to unmyelinated C-fibres. Heavily 
myelinated Aβ-fibres feature fast conduction velocities (30-100 metres per second), with cell 
bodies measuring more than 10 µm in diameter
7. Aδ-fibres, being less myelinated than Aβ-
fibres, transmit at a slower speed (12-30 metres per second) and have diameters between 2 
and 6 µm. C-fibres, due to their lack of myelination, feature very slow conduction velocities 
(0.5-2.0 metres per second), with small cells ranging in diameters between 0.4 and 1.2 µm. 
Aβ-fibres innervate specialised sensory receptors in the skin such as Meissner’s corpuscles, 
which are responsible for feeling innocuous touch. Traditionally, Aβ-fibres were thought to 
conduct signals resulting from innocuous touch and thermal stimuli
8
, although emerging 
evidence suggests that these fibre types can also contribute to aberrant signalling in painful 
states. Aδ-fibres, on the other hand, appear to mediate modality information in pain 
experienced by humans, as Aδ-fibre selective block removes the feeling of cold in noxious 
cold pain and leave patients feeling only pain
10
. In general, Aδ nociceptors facilitate rapid 
transmission of pain signals to the brain to allow reflexive withdrawal actions upon acute 
injury. As for other physiological noxious signals, C-fibres are considered the primary 
conductors of nociceptive signals from the nociceptive free nerve endings near the skin to the 
central nervous system (CNS), though at speeds slower than A-fibre signals.  
 
A-fibres and C-fibres are further classified according to the fibres’ sensitivity towards 
different stimuli. Evidence exists of two primary Aδ-fibres subtypes, with Type I Aδ-fibres 
being high threshold heat-sensitive fibres insensitive to capsaicin, which only fire at 
temperatures higher than 55 °C. In comparison, capsaicin-sensitive Type II Aδ-fibres fire at a 
lower thermal threshold, activating at approximately 40 °C
8. There exist other Aδ-fibres, 
some of which are selectively sensitive to innocuous and noxious heat, cold, or mechanical 
stimuli
11, 12
. Some of these fibres are polymodal, being responsive to multiple types of 
external stimuli. For example, Aδ-heat-mechano-sensitive fibres respond to noxious heat (> 
45 °C) and intense mechanical stimulus, and Aδ-cold-mechano-sensitive fibres respond to 
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noxious cold (< 15 °C) and mechanical stimulus. The presence of such Aδ-fibres enables 
discrimination between thermal stimuli of various intensity, differentiating nociceptive 
responses from those that are innocuous. 
 
Similarly, C-fibres can be divided into two major subclasses of mechano-sensitive and 
mechano-insensitive neurons. However, as with A-fibres, additional subclasses of C-fibre 
neurons exist, categorised by sensitivity to a diverse array of stimuli. Some of these C-fibre 
subclasses are sensitive to a single stimulus type (exclusively responsive to innocuous or 
noxious heat, cold, or mechanical stimuli
13-16
), while others are polymodal nociceptors 
responding to multiple stimuli
6, 17, 18
. Select C-fibres groups are also activated by noxious 
chemical stimuli and inflammatory mediators
19
 such as capsaicin
20
 and substance P
21
, serving 
as chemo-sensitive nociceptors. Allodynia, the sensation of feeling pain from normally 
innocuous stimuli, and hyperalgesia, hypersensitisation of tissues towards normally mildly 
painful stimuli, are thought to be caused by a combination of A- and C-fibre nociceptors, 
with each fibre type contributing to the exhibited symptoms in distinct ways. The distinction 
between pain signals conducted by Aδ-fibres and C-fibres can be observed in conditions such 
as capsaicin-induced pain
22
. Patients with A-fibre block were able to detect the burning 
sensation of capsaicin, but experienced a 75%
23
 reduction in pain from mechanical punctate 
stimuli. A-fibre block also did not affect long-term potentiation following high frequency 
electrical stimulation20. Spinal nerve ligation in rats caused a reduction in the mechanical 
threshold of high-threshold mechano-sensitive A-fibres, in addition to an increase in the area 
of A-fibres’ receptive fields and an increase in maximum instantaneous frequency24. In the 
same spinal nerve ligation model, however, the high-threshold mechano-sensitive C-fibres 
only exhibited a reduction in mechanical threshold
24
. This has led to the conclusion that C-
nociceptors predominantly mediate thermal hyperalgesia and allodynuia, whereas mechanical 
hypersensitivity is mediated by A-fibres instead
25, 26
. Even though this view has been 
challenged with the emerging evidence of unmyelinated fibres mediating mechanical 
allodynia in glabrous
27
 and in sunburnt hairy skin
28
, A-fibres are still postulated to be 
sensitised to mechanical stimuli following a noxious insult, contributing primarily to 
secondary mechanical allodynia and hyperalgesia. 
 
Other attempts to classify DRG neurons have separated the neurons into sub-classes 
according to differences in expression profile
7, 29, 30
. Trk, a specific family of tyrosine kinase 
receptors that function as neurotrophin receptors, exhibit selective expression in different 
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classes of sensory neurons. TrkA is expressed selectively in C-fibres, while TrkC is 
expressed in A-fibres
31
. Very little overlap is observed between TrkA-expressing and TrkC-
expressing neurons, though TrkB is expressed in both populations
31
. More recently, the 
advances of transcriptomic technology have enabled comprehensive analysis of the 
expression profiles of DRG neurons, allowing for more detailed neuronal subclasses to be 
discovered. Usoskin et al.
32
 proposed 11 different subclasses of DRG neurons based on 
unique cellular markers found using bioinformatics analysis, incorporating known cellular 
markers such as the expression of CGRP on nociceptors
33
, the expression of VGLUT3 on 
non-nociceptive low-threshold mechano-sensitive C-fibres
34, 35
, and the differential 
expression of Mrgpr proteins in different neuronal subclasses. More recently, Li et al.
36
 
further separated DRG neurons into 17 distinct classes, again using bioinformatic methods to 
analyse the transcriptome of each neuron. Li et al.
36
 also examined the behavioural responses 
and sensitivities of the 17 subclasses, establishing that conventional classifications according 
to sensitivity to stimuli does not directly translate to unique protein expression profiles
36
. 
However, these studies contradict known evidence in a number of ways, such as purporting 
that tyrosine hydroxylase (TH) exists in non-nociceptive low-threshold mechano-sensitive C-
fibres, despite the established practice of using TH as a sympathetic neuron marker for 
sympathetic neuron sprouting into DRGs
37-39
. The number of neurons sorted into the different 
categories was also concerning. Usoskin et al.
32
 harvested six DRGs each from 18 mice and 
analysed over 700 individual neurons, yet two of the DRG subclasses discovered only 
contained 12 neurons per subclass, drawing into question the statistical validity of this 
classification. What these studies established, however, was that conventional classification 
according to stimuli sensitivity does not directly reflect specific protein expression profiles in 
neurons. It is possible that the unique protein expression profiles found are in fact more 
indicative of the embryonic lineage of the PNS neurons rather than being strictly related to 
function, and as such, categorisation according to behavioural response and protein 
expression may not exactly align. Moreover, the process of transcription does not definitively 
lead to translation, and further studies involving proteomics would be needed to unravel the 
relationship between transcriptomic data and observed neuronal function. 
 
1.2.2 Central pain pathways and mediators 
Following transmission through the DRG neurons, the nociceptive signal is subsequently 
passed on to spinal cord neurons. Two separate groups of spinal cord neurons are involved in 
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transmitting peripheral signals to the brain and regulating the perception of and response to 
pain. Specific nociceptive neurons, those that exclusively respond to painful stimuli, are 
present in laminae I, II, V, and VI. ‘Classical’ nociceptive fibres, including polymodal C-
nociceptive fibres and high-threshold Aδ-nociceptive fibres, affect the neurons in these areas 
of the spinal cord. The neurons are organised somatotropically, allowing for rapid indication 
of the location of the signal
7, 40, 41
. In contrast, wide dynamic range (WDR) neurons are 
present in laminae I, II, IV, V, VI, X, and in the anterior horn. This group of neurons are 
essential in the suppression of pain in the Gate Control Theory
42
, and receives input from 
both noxious and innocuous sensory neurons, being involved with encoding the intensity of 
the sensation. 
 
Specific nociceptive neurons and WDR neurons project into various tracts that extend further 
into CNS structures, transmitting both nociceptive and innocuous sensory information to the 
brain. The spinothalamic tract, one of the first tracts recognised to mediate pain due to 
analgesia observed following transection
43
, projects into various areas of the thalamus. These 
areas, the lateral complex and the posterior medial complexes, regulate the sensory 
discrimination of pain and the motivational and emotional aspects of pain sensing 
respectively. The spinoreticular tract projects into the brain stem, where it is involved in the 
affective responses to pain, and the activation of CNS areas involved in descending control of 
pain
44
. The spinomesencephalic tract projects into the periaqueductal gray (PAG) matter, and 
is responsible for activating pain signal transmission and initiating central pain inhibitory 
pathways
45
. PAG activation by nociceptive signals usually results in excitation followed by 
inhibition
45, 46
 as well as aversive emotional responses towards pain, suggesting that neurons 
in the PAG play a role in the affective regulation of pain. Within the CNS, the thalamus is 
involved in the convergence of the multiple thalamic tracts and has a major role in regulating 
and gating sensory information. The ventroposterolateral nucleus is the main anatomical 
structure involved in processing excitatory signals relating to pain, while inhibitory pain 
circuits arise from the interaction between the ventroposterolateral and ventroposteromedial 
nuclei
7, 40, 45, 47
. 
 
Attempts to treat neuropathic pain at the spinal and thalamic stage, however, have been 
limited by the inability to distinguish between noxious and innocuous sensory signals. At the 
same time, several congenital pain conditions have been linked to mutations of specific ion 
channels present in peripheral nociceptive DRG neurons, indicating the importance of the 
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PNS in pain. Much of the recent efforts in pain research and drug discovery have therefore 
been directed towards ion channels present in DRG neurons, using gene knockout animal 
models and channel inhibition studies to decipher the nature of modality-specific pain 
sensing. The rest of the chapter will therefore discuss the ion channels that initiate and 
propagate sensory information in peripheral neurons, and illustrate their role in various pain 
conditions. 
 
1.3 Peripheral ion channels responsible for transducing pain signals 
Pain detection involves the process of sensory transduction, which describes the conversion 
of a thermal, mechanical, or chemical stimulus into depolarisation across the cellular 
membrane of cutaneous primary sensory nerves. Ion channels that transduce other stimuli 
into electrical signals are therefore vital in the initiation of the pain signal. The most famous 
family of ion channels involved in transduction is the transient receptor potential (TRP) 
channel family, which contains the capsaicin-sensitive channel TRPV1 and the menthol-
sensitive channel TRPM8, two channels that have served as the cornerstone of research into 
stimulus-specific sensory neurons, as outlined below. 
 
1.3.1 Capsaicin- and heat-sensitive TRPV1 
Capsaicin-sensitive vanilloid receptor subtype 1 (TRPV1), a non-selective cation channel, 
was first isolated as an ion channel directly activated by capsaicin and heat
48
. The channel has 
since then been confirmed to be activated by other noxious compounds such as 
endovanilloids
49
 and low pH
50
. Such findings suggest that TRPV1 may be responsible for 
detecting heat-induced pain. TRPV1 is also expressed almost exclusively in C-fibres
51
, 
neurons that are traditionally thought to be responsible for nociceptive and thermal sensation. 
However, TRPV1 knockout in mice did not completely remove noxious heat-induced 
neuronal activity
52
, nor did it reduce aversive behaviours upon challenge with noxious heat 
(up to 52 °C)
53
. While TRPV1 knockout animals certainly displayed reduced responses to 
capsaicin, it was evident that TRPV1 is not the only channel responsible for sensing heat and 
heat-induced pain. 
 
Despite being unable to alleviate noxious heat sensing, global TRPV1 knockout is effective 
in eliminating carrageenan-induced inflammatory responses in mice, successfully reducing 
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inflammatory hyperalgesia
53, 54
. Inflammatory pain was also related to increased expression 
of TRPV1 in rat DRG neurons
55
, indicating inflammatory responses, rather than noxious heat 
in normal physiological conditions, are more affected by TRPV1. As well as expression on 
peripheral C-fibres, TRPV1 has also been found to be expressed in the spinal cord and the 
CNS. TRPV1 block in peripheral neurons significantly reduced long-term potentiation of 
dorsal horn neurons to pain signals
20, 56
, and TRPV1 has been found to be involved in 
neuronal depression within hippocampal interneurons
57
, indicating that TRPV1 also plays a 
part in the central regulation and sensitisation of possibly pathological pain
58
. 
 
1.3.2 Menthol- and cold-sensitive TRPM8 
The transient receptor potential melastatin 8 channel (TRPM8)
59, 60
 has significantly 
advanced our understanding of the processes underlying the transduction of external cold into 
electrical signals. The channel is essential for the detection of environmental cold, with a 
series of potassium channels contributing to threshold adjustment and amplification of 
TRPM8-dependent cold transduction
18, 61, 62
. TRPM8 knockout mice show drastically reduced 
responses to innocuous cold
63-65
. Cultured trigeminal ganglion neurons from TRPM8 
knockout mice are also insensitive to menthol or innocuous cold (22 °C), with the number of 
cold-responsive cutaneous myelinated and unmyelinated nerve endings decreased 
significantly compared to controls
63
.  
 
However, as with TRPV1 and heat-related pain, the extent to which TRPM8 is essential for 
pathological forms of cold pain is controversial, with the results of existing studies often in 
conflict. TRPM8
 
knockout mice, mice treated with intrathecal TRPM8 antisense 
oligonucleotide, and mice with diphtheria toxin-mediated ablation of TRPM8-positive 
neurons all had reduced innocuous cold sensitivity. The three different strains also all 
exhibited reduced cold hypersensitivity following Complete Freund’s adjuvant (CFA)-
induced inflammation and chronic constriction injury (CCI), as examined by the acetone 
test
64, 66, 67
. However, TRPM8 knockout mice retained noxious cold sensitivity, and exhibited 
nocifensive behaviours similar to those of control mice at temperatures below 10 °C
63, 65
.  
 
A further confounding factor in studies assessing the contribution of TRPM8 to cold sensing 
and cold pain is the specificity and selectivity of pharmacological ‘tool’ compounds such as 
menthol. Many studies equate menthol-induced responses with selective TRPM8 activation. 
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However, the proto-typical TRPM8 agonist menthol is a promiscuous compound and can 
elicits responses in TRPM8-negative sensory neurons. In other studies, menthol has been 
found to inhibit nicotinic acetylcholine receptors
68
, inactivate voltage-gated calcium 
currents
69
, inhibit voltage-gated potassium channels
18
, and activate and/or desensitise 
TRPA1, another TRP channel
70
, demonstrating the varied targets of this compound and the 
difficulty of using menthol to assess TRPM8 activity. 
 
1.3.3 TRPA1 
Transient receptor potential ankyrin 1 (TRPA1) is considered a noxious cold and irritant 
sensor. The channel mediates, among others, the reaction to the pungent components of 
mustard, horseradish, and wasabi. TRPA1 is also activated by formaldehyde, bacterial 
endotoxins and proinflammatory mediators such as bradykinin, methylglyoxal, and prosta-
glandin E2
71-76
. TRPA1 expression in sensory neuronal populations has little overlap with 
TRPM8 expression, but TRPA1 is highly co-expressed with TRPV1 and can form functional 
heteromultimers with TRPV1
77
, adding to the functional complexity of this channel.  
 
The overwhelming majority of studies assessing TRPA1 activation by cold used cultured 
rodent DRG neurons, or rodent TRPA1 transfected into mammalian HEK293 cells, CHO 
cells, or Xenopus oocytes. Many such studies demonstrated TRPA1-mediated intracellular 
calcium increase or inward current upon exposure to cool temperatures (5–18 °C)30, 60, 75, 78-81. 
However, species- and tissue-specific differences in the cold sensitivity of TRPA1 soon 
became becoming apparent
82
. In fact, while the rodent TRPA1 channel is cold-sensitive, 
snake and drosophila TRPA1 channels are heat-sensitive
83-85
, and primate TRPA1 does not 
respond to cooling in in vitro systems
82
. Furthermore, the standard behavioural cold pain tests 
in mice are far less sensitive than commonly believed
86
, as seen in a functional MRI study in 
mice that showed altered central processing of noxious cold (15 °C) when no measurable 
aversive behaviour was observed. A number of studies also based their conclusions regarding 
the cold sensitivity of TRP channels on the perhaps erroneous assumption of the 
pharmacological specificity of compounds including isothioscyanates, icilin, and menthol
60, 
70, 74, 87-90
, the latter of which has been shown to be promiscuous in the previous section. 
 
Nevertheless, TRPA1 still plays a key role in a human model of ciguatoxin-induced cold 
allodynia, making it hard to deny a possible role for TRPA1 in cold sensing and cold pain. In 
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ciguatoxin-induced cold allodynia, de novo cold responses in previously cold-insensitive 
mouse DRG neurons emerged after treatment with ciguatoxin
86
. This phenomenon was 
shown to be mediated by TRPA1, and correlated well with a key contribution of TRPA1 to 
ciguatoxin-induced cold allodynia in mice
86
. A monogenic TRPA1 gain-of-function mutation 
is also linked to a hereditary disease of episodic debilitating pain, which is triggered by 
cold
91
. Comparable mechanisms of TRPA1 sensitisation to cold may also apply for cold 
hypersensitivity in inflammatory conditions, as well as in diabetic neuropathy
71, 72, 79, 92
.  
 
1.3.4 ASIC channels 
Acid-sensitive ionic channels (ASICs) is a family of non-voltage-gated cation channels 
directly activated by protons and pH < 6.9, and is densely expressed in unmyelinated DRG 
neurons in rats
93, 94
. Three subtypes of ASICs exist, namely ASIC1, ASIC2, and ASIC3
95
. 
ASIC1 and ASIC3 are activated in vitro at low pH levels comparable to those created via 
local inflammation
96
. These two isoforms are also expressed on peripheral nociceptors
95
, in 
the dorsal horn and in the PAG, anatomical areas involved in transmitting and regulation pain 
signals as described previously
95
. 
 
Interestingly, ASIC isoforms are also present in bone, in joints, and in muscle cells
95
, leading 
to investigations into the role of ASIC in local inflammatory conditions such as joint 
inflammation. ASIC expression was increased following arthritis, with ASIC inhibition 
preventing the development of secondary hyperalgesia, though primary hyperalgesia was 
unchanged compared to controls
97, 98
. The role of ASICs in mediating inflammation was 
further consolidated by the finding that non-steroidal anti-inflammatory drugs (NSAIDs) 
directly bind to ASICs and inhibit neuronal firing
99
, suggesting the involvement of ASICs in 
general inflammatory responses. 
 
Paradoxically, ASIC1 and ASIC2 knockout animals exhibited exaggerated responses in the 
formalin test, an inflammatory pain model
100
, suggesting specific pathways may exist for 
various inflammatory pain conditions. This suggestion is supported by the observation that 
the mambalgin toxin, extracted from the venom of black mamba snakes and known to inhibit 
all ASIC channels, provided effective analgesia in carrageenan-induced inflammation
101
. 
ASIC1 knockout and ASIC3 knockout animals also demonstrated normal responses for 
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noxious thermal and mechanical stimulation in the absence of inflammation
95
, indicating the 
channels do not extensively regulate other non-inflammatory pain modalities. 
 
1.4 Peripheral ion channels responsible for conducting pain signals 
Following transduction, pain signals are propagated along the DRG neuron axon to the spinal 
cord in a process described as conduction. Ion channels on the peripheral axons determine the 
neuronal resting potential, which in turn dictates the excitability of the sensory neuron and 
the speed and ease of conduction. These ion channels usually do not exist in the nerve 
endings close to the skin, but are present throughout the neuron as a mix of voltage-gated 
(including voltage-gated calcium, sodium, and potassium channels) and voltage-independent 
(such as background potassium channels) channels involved in conduction. Voltage-gated 
calcium (CaV) channels and both voltage-gated and voltage-independent potassium channels 
will be discussed in this section. The large body of literature concerning voltage-gated 
sodium (NaV) channels warrants a section of its own in Section 1.5. 
 
1.4.1 CaV channels 
Voltage-gated calcium channels (CaV) are heteromeric channels made of various subunits, 
including voltage-sensitive α-subunits, as well as β, γ, and α2δ subunits that function to 
regulate voltage dependencies and gating kinetics
102. Ten different α subunits have been 
identified, including CaV1.1-1.4, CaV2.1-2.3, and CaV3.1-3.3
103
. The different currents 
evoked by the activation of distinct CaV isoforms have led these α units to be classified 
according to their electrical properties, with CaV1.1-1.4 being classified as L-type (for ‘long-
lasting), CaV2.1 as P/Q-type (found in Purkinje neurons), CaV2.2 as N-type (intermediate 
between L- and T-type for voltage  dependence), CaV2.3 as R-type (found in cellular granule 
neurons), and CaV3.1-3.3 as T-type (for ‘transient’)
102
. Protein purification have determined 
that CaV isoforms exist physiologically as heteromers consisting of one α subunit, one β 
subunit, one α2δ subunit, and one γ subunit per functional channel104. While CaV isoforms are 
widely expressed in skeletal muscle, cardiac muscle, and peripheral and central neurons
102
, 
the expression of CaV isoforms in DRG neurons and the spinal cord have been shown to play 
significant roles in pain sensing, particularly those of the α2δ subunits, and the CaV2.2 and 
CaV3.2 isoforms. 
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The CaVα2δ subunits are poorly understood in terms of their effects on the regulation of 
functional CaV channels
105
, though these subunits are evidently involved in the conduction of 
pain signals. Pregabalin and gabapentin, two structurally similar neuropathic pain adjuvant 
medications that were originally designed to mimic the inhibitory CNS neurotransmitter γ-
aminobutyric acid (GABA), are in fact potent ligands for the CaVα2δ1 subunit and do not 
affect GABA pathways
106-108
. In the spinal nerve ligation (SNL) neuropathic pain model, 
which produces robust mechanical allodynia, CaVα2δ1 was found to be up-regulated in DRG 
neurons and caused dorsal horn sensitisation
109
. Curiously, transgenic CaVα2δ1 over-
expressing mice also exhibited dorsal horn neuron sensitisation in the form of increased 
frequency of excitatory post-synaptic currents, which was reversible upon gabapentin 
administration
110
. The expression of CaV on DRG neurons is also increased with increased 
transgenic CaVα2δ1 expression
111
. These findings suggest the efficacy of drugs that interact 
with CaVα2δ1work through the regulation of CaV present on the plasma membrane of 
neurons, rather than by controlling the conduction properties of peripheral pain signals. 
 
The spinal analgesic effects of CaV inhibitors is further demonstrated by the clinically used 
CaV2.2 N-type CaV inhibitor, ziconotide. Ziconotide is a peptide drug derived from the 
venom of the Conus Magus cone snail species
112
 and is administered as an intrathecal 
infusion, selectively inhibiting N-type CaV currents in laminae I and II of the dorsal horn. 
Despite the analgesic efficacy of ziconotide in post-operative
113
 and cancer pain
114
, the drug 
must be administered intrathecally due to its large molecular mass, making administration 
difficult and often requiring an implantable pump
112
. Ziconotide also exhibits CNS adverse 
effects such as sedation, blurred sight, and even psychosis, most likely due to the propagation 
of N-type CaV inhibitory effects throughout the CNS as the peptide diffuses through the 
spinal fluid and enters the brain, further illustrating the difficulty of dosing molecular targets 
present in the CNS. 
 
More recently CaV3.3, a T-type CaV isoform, was found to be exclusively present in C-low-
threshold mechanoreceptors (C-LTMR)
115
 in the PNS, prompting the inclusion of CaV3.3 as a 
new cellular marker for mechano-sensitive unmyelinated fibres. C-LTMRs also express large 
amounts of CaV3.2
115
, another T-type CaV isoform. CaV3.2 inhibition has been shown to 
successfully alleviate cold allodynia (20 °C) in human hairy skin following the induction of 
muscle pain
16
, prompting speculation about the role of CaVs in C-fibre-mediated 
thermosensation. While CaV-selective inhibition in central pain pathways has been 
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successfully targeted to modulate pain at a systematic level, peripherally expressed T-type 
CaV isoforms could become a new class of cellular markers that serve to untangle the details 
of peripheral pain signal conduction prior to transmission into the spinal cord 
 
1.4.2 Potassium channels 
Potassium channels in DRG sensory neurons, unlike their calcium and sodium channel 
counter parts, serve to hyperpolarise rather than depolarise the neuron. As a result, the 
presence of potassium channels makes the neuron less excitable. A large variety of potassium 
channels, encoded by over 40 different genes, are present throughout the body. The four main 
classes of potassium channels are voltage-gated potassium channels (KV), which are 
dependent on voltage for activation; 2-pore potassium channels (K2P), which act as 
background potassium leaks to regulate the resting potential of the neuron; calcium-activated 
potassium channels (KCA), which depend upon calcium levels to activate and regulate 
neuronal synaptic activity; and inward-rectifying potassium channels (Kir), which actively 
facilitate potassium currents into the neuron to regulate intracellular and extracellular 
potassium balance
116
. 
 
As potassium channels cause hyperpolarisation in neurons and result in reduced excitability, 
the presence and activation of KVs serve as a significant regulator of signalling in the PNS. 
KV7.2 and KV7.3, two proteins that form heteromers with each other in both Aδ and C-
fibres
117
, are the first potassium channels to become clinical targets for pain. The selective 
KV7.2/7.3 channel opener flupirtine is used clinically for pain
118, 119
 and has been shown to be 
effective in animal models of neuropathic injury
120
. Retigabine, a structural analog of 
flupirtine and also a KV7 channel opener, has also been found to inhibit spontaneous 
discharges in damaged neurons
121
. In particular, KV7 isoforms affect cancer pain
122
, and their 
suppression is related to the development of bone pain in cancer and dorsal horn 
hypersensitisation
122, 123
. The expression level of KV7 channels appear to increase following 
neuronal inflammation and damage
121
, indicating KV7 function to be a part of the 
homeostasis and compensatory system following injury to regain normal sensitivity. 
 
The other main branch of potassium channels, the K2P family, controls the membrane 
potential of the neuron at the resting state and conducts a voltage-insensitive, ‘leak’ 
potassium current. A total of 12 functional isoforms of K2P channels exist in DRG neurons, 
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classified according to their different properties into 6 subfamilies named TASK, TREK, 
TRESK, TRAAK, TWIK, and THIK
124
. TASK-3 has been revealed to be involved in the 
sensation of cold, with TASK-3 knockout mice displaying cold hypersensitivity and TASK 
channels being bilaterally down-regulated following the injection of CFA into the paw
124
. 
Another prominent K2P channel, TREK-1, is also involved in temperature sensing
62
 and is 
activated directly by increased temperature
125
, with TREK-1 knockout mice exhibiting 
marked heat allodynia compared to wild type animals
126
. TRAAK has also been implicated as 
one of the regulators of thermosensitivity
62
, suggesting other channels in the K2P family may 
also have yet-undiscovered roles in the modulation of sensory neurons. 
 
1.5 NaV channels – the ultimate cure? 
Out of all the ion channels and receptors present in peripheral sensory neurons, it is the 
voltage-gated sodium channel (NaV) family that has been pushed into the spotlight of pain 
research in recent years. The discovery that mutations of the NaV1.7 isoform resulted in 
human congenital insensitivity to pain, with affected patients being completely insensitive to 
painful stimuli and exhibiting no physiological abnormalities other than anosmia, was a 
validation of the indispensable role of NaV channels in pain
127-129
. Investigations using 
channel-selective venoms, bioinformatics methods, and in vitro high-throughput assays have 
all yielded valuable insight to the characteristics and distribution of NaV isoforms
30, 32, 130, 131
. 
Of all the NaV isoforms present in neurons, NaV1.7 was initially considered to have the most 
therapeutic potential for pain treatment, although it is now clear that NaV1.7 inhibition does 
not affect all pain conditions. Two other isoforms distributed throughout the nervous system, 
NaV1.6 and NaV1.8, have also been subjects of intense research concerning their role in the 
conduction of pain signals
2, 132-135
. NaV1.9 had also shown an involvement in pain
136, 137
, 
however a lack of NaV1.9 assays and NaV1.9 selective modulators have greatly hampered the 
isoform’s therapeutic potential. Various obstacles also remain in the path towards elucidating 
the molecular causes of different neuropathic pain conditions, even with the increased 
understanding of the roles of NaV isoforms. The rest of this review will therefore focus on 
NaV isoforms NaV1.7, NaV1.6, and NaV1.8, and will discuss existing literature regarding their 
known properties, and their contribution to various pain conditions. 
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1.5.1 Structure and properties of NaV channels 
NaV channels were first studied by Hodgkin and Huxley in their pioneering work with axonal 
conduction in the 1950s and 1960s
138
, showing that the channels mediated a voltage-
dependent inward current selective for sodium ions. Apart from neurons, NaV isoforms are 
also present in other excitable tissues such as muscle cells. The opening of NaV isoforms is 
responsible for the initiation of action potentials, causing the depolarisation phase of action 
potentials to occur, followed by rapid inactivation of NaV isoforms and subsequent 
repolarisation. This rapid voltage-gated closure, together with the activation of KV isoforms, 
causes the termination of the action potential. Spontaneous firing can therefore be triggered 
by over-excitatory NaV isoforms, potentially causing the sensation of pain in neuropathic pain 
conditions. 
 
NaV subunits are separated into α and β subunits, with α subunits being the main pore-
forming protein (Figure 1). Action potentials can be observed from transfected cells and 
oocytes expressing α subunits only, indicating that the α subunit is the only component 
required to allow sodium ion movement
139
. A total of 10 different isoforms of NaV α subunits 
have been found to date, including NaV1.1-1.9 and NaX, a voltage-insensitive channel found 
in glial cells within the CNS
140
. The NaV1.4 isoform is expressed in skeletal muscle cells, 
with NaV1.5 present in cardiac muscle cells. NaV1.1-1.3, as well as NaV1.6-1.9, are expressed 
on neurons. NaV1.1-1.3, 1.6, and 1.7 are known to be expressed abundantly in myelinated 
neurons, whereas NaV1.8 and 1.9 are expressed exclusively in unmyelinated neurons, 
exhibiting the selective expression of different NaV α subunits in various tissues. 
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Figure 1.1 Structure of the NaV α subunit and toxin binding sites 
The domains are labelled by Roman numerals above each domain (I-IV). The segments are 
labelled by Arabic numbers in each segment (1-6). The voltage sensor in segment 4 of each 
domain is denoted by ‘+’ signs. The locations of each toxin binding site is shaded with the 
corresponding colour as noted below the figure. Figure drawn in Adobe Illustrator® C56, 
version 16.0.3, based on information stated in Catterall et al.
141
 and Stevens et al.
142
. 
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NaV α subunits consist of six α-helical transmembrane segments (S1-S6), with each 
functional channel consisting of 4 homologous α subunits (domains I-IV) surrounding the 
pore. A loop entering the membrane region between segments S5-S6 creates the outer pore of 
the channel, selective for the entry of sodium ions
143
. Other extracellular loops connect the 
different transmembrane segments, and also attach the S5 and S6 segments to the pore. Large 
intracellular loops connect the four distinct α domains, with the N-terminal and C-terminal 
also being intracellular
143
. Cryo-electron microscropy has confirmed that on a 3D scale, NaV 
channels exhibit four-fold symmetry of transmembrane structures, with large intracellular and 
extracellular protein masses. The channel contains numerous inlets and outlets for the pore
144
, 
indicating the pore is split into four branches rather than being one simplistic opening. 
 
A voltage sensitive section is present in each of the S4 segments and is composed of one 
positively charged amino acid followed by two hydrophobic amino acids, repeating in a 
pattern to achieve a helical arrangement of positive charges in a transmembrane manner
139
. 
The voltage-dependent activation of the channels is achieved through the movement of 
charged amino acids due to the changed membrane potential
138
. Membrane depolarisation 
and increased positive intracellular charge results in outward movement of the positive 
charges in the S4 segment to open up the pore for sodium ion entry
145, 146
. The rapid 
inactivation of NaV channels is also reliant on the voltage-dependent movement of the 
inactivation gate between domains III and V, consisting of an intracellular loop that closes 
and binds to the pore from the inner pore side
139
. 
 
Acting as regulatory proteins, the β subunits of sodium channels modulate the properties of 
gating and the interaction between various cells. At least 4 β subunits have been identified so 
far, named β1 to β4147. Co-expression of functional β subunits together with pore-forming α 
subunits causes functional channels to activate and inactivate at the appropriate speed and 
with normal voltage sensitivity, while the expression of only α subunits in oocytes results in 
sodium channels with slower kinetics than that observed in physiological tissue
148
. The 
similarity between NaV β subunits and cell adhesion molecules
149
 also support the 
observation that the β2 subunits bind to the extracellular matrix component tenascin150, 
suggesting that the presence of β subunits may dictate the interaction of NaV isoforms with 
other neurons and supportive glial cells in the nervous system. 
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1.5.2 Neurotoxins as selective NaV isoform modulators 
Much of the structural and functional relationship between the segments and domains of  the 
NaV α subunits have been derived from studies using NaV-selective neurotoxins purified from 
the venoms of spiders, scorpions, cone snails, or vertebrates. Biochemical analysis using 
neurotoxins was one of the key methods used to investigate neuronal channels, playing an 
invaluable role in the initial discovery and identification of the various NaV isoforms
143, 147
. 
Tetrodotoxin (TTX) and saxitoxin, two drugs that bind to NaV isoforms with very high 
potency, were used to identify the location of the pore and the structures vital for sodium ion 
selectivity. This has led to the classification of NaV isoforms as tetrodotoxin-sensitive (TTX-
s) and tetrodoxin-resistant (TTX-r), two subclasses with distinct differences in distribution 
and sensitivity to the pore blocking toxin TTX. The TTX-r NaV isoforms NaV1.5, NaV1.8, 
and NaV1.9 are distributed in cardiac muscle (NaV1.5) and unmyelinated neurons (NaV1.8 
and NaV1.9), whereas the rest of the NaV family are TTX-s and are expressed in skeletal 
muscle (NaV1.4) and throughout the nervous system (NaV1.1, 1.2, 1.3, 1.6, and 1.7). Toxins 
are still used as experimental tools to detect the roles of different NaV isoforms and remain 
some of the most selective inhibitors of NaV isoforms, including the NaV isoform-selective 
conotoxins derived from cone toxin venoms
142
. 
 
Specific structures in the NaV α subunit are noted to be the binding sites for select toxins, 
classified by the location of the binding site as well as the effect of the neurotoxin (Table 
1.1). The bound neurotoxin may either directly occlude the pore, or alter the kinetics of 
channel activation and inactivation
142
. Binding site 1, the binding location of TTX and 
saxitoxin, is a pore-blocking site. Being one of the oldest toxin binding sites identified,  
binding site 1 was instrumental in identifying the structure of the NaV channel pore
151
. 
Binding site 1 consists of the loops connecting S5 and S6 in all domains, forming part of the 
pore structure itself. Apart from TTX and saxitoxin, the µ-conotoxin family of cone snail 
toxins also binds to this site, one example being KIIIA (derived from Conus kinoshitai)
152
. 
One spider toxin, hainantoxin-1, derived from the spider Ornithoctonus hainana, has also 
been noted to bind to binding site 1. Most other spider toxins, while having high potency and 
being selective to NaV isoforms, usually bind to other sites on the NaV structure. 
 
Binding site 2 functions by regulating channel activation and deactivation rather than 
interference with the pore. Binding site 2 appears to involve the S6 segment of domains I and 
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IV
153
, and is the binding site for many lipid soluble toxins from various sources such as 
poisonous frogs, alkaloids such as veratridine, toxins found in birds, and antillatoxins found 
in certain species of cyanobacteria
154, 155
. The binding of these toxins to binding site 2 results 
in a voltage-dependence shift towards more negative values, causing the neuron to be more 
sensitive. Binding site 2 toxins also prolong the activation of the channel by slowing or 
preventing the closure of the pore, resulting in long-lasting currents. The combined effects 
cause excessive neuronal firing in the organism, which contributes to the fatal toxicity of 
many toxins that bind to this site. 
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Binding site Neurotoxin classes Examples Effects 
1 Guanidium molecules. 
µ-conotoxins
142
, 
hainantoxin-1 
Tetrodotoxin (TTX), 
saxitoxin, µ-conotoxins  
such as KIIIA
152
 
Pore-blocker, inhibits 
neuronal firing 
2 Various lipid soluble 
toxins 
Veratridine, toxins found 
on poisonous frogs and 
vertebrates
154
, toxins from 
cyanobacteria
155
 
Modulates kinetics of 
the channel. Channel 
activators that increase 
voltage sensitivity and 
slow inactivation
153
 
3 Scorpion, sea 
anemone, and spider 
toxins 
α and β scorpion toxins156, 
spider toxins such as 
Tx4
157
 
Slow down and prevent 
voltage-dependent 
inactivation, causing 
prolonged channel 
opening
158
 
4 β scorpion toxins, 
spider toxins 
µ-agatoxins and β/δ-
agatoxins
159
 
Maintains voltage 
sensor segment at its 
outward position and 
prolongs pore 
opening
141
  
5 Toxins produced by 
marine dinoflagellates 
Brevetoxins and 
ciguatoxins
159
 
Brevetoxin inhibits 
neuronal firing, while 
ciguatoxin causes 
membrane potential 
oscillations
160
 
6 δ-conotoxins δ-SVIE, TxVIA, and other 
δ-conotoxins 
Slows NaV channel 
inactivation without 
affecting voltage-
dependency 
inactivation
161
 
 
Table 1.1 Families of neurotoxins that bind to NaV and their binding sites 
A total of six binding sites for neurotoxins have been identified and characterised in NaV α 
subunits. Distinct classes of neurotoxins bind to separate sites and exert different functions. 
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Site 1 controls the opening of the pore and directly affects the flow of sodium ions. All other 
sites affect the voltage-dependent gating of the pore and channel inactivation.  
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Binding site 3 is located at the extracellular loops between S3 and S4 segments in domain 
IV
162. Toxins that bind to this site include α and β scorpion toxins156, sea anemone toxins, and 
selective spider toxins. Studies indicate that the binding of neurotoxins to site 3 causes the S4 
voltage sensor segment to become stabilised in its outward position, disabling the movement 
of the voltage sensor and preventing fast, voltage-dependent inactivation of the channel
158
. 
The inactivation can be slowed or even prevented entirely, causing prolonged channel 
opening and slowly-inactivating currents. 
 
Toxin binding site 4 directly interferes with the voltage sensor, holding the voltage sensor 
segment in its outward position and maintaining the open state of the pore
163
. The binding site 
consists of the extracellular loops between S1-S2 and S3-S4 in domain II
141
, though the 
binding of  β scorpion toxins are also affected by the pore component of the S5-S6 loop in 
domain III, as well as involvement of the voltage sensor segment in domain III
164
. A number 
of spider toxins also bind to binding site 4, with examples including µ-agatoxins and β/δ-
agatoxins, extracted from the Agelenopsis family of spiders
142, 159
. Due to the delay of 
inactivation, many of the toxins that bind to this binding site are considered channel openers, 
Agatoxins, in particular, shift voltage-dependent activation to more negative voltages as well 
as slowing inactivation, contributing to channel opener effects. 
 
The location of toxin binding site 5 was determined to be S6 segment of domain I and S5 
segment of domain IV, and is the site for photoreactive toxins produced by marine 
dinoflagellates. These toxins include brevetoxin, produced by algal blooms, and ciguatoxin, 
produced by marine dinoflagellates and accumulated in carnivorous reef fish. Brevetoxin 
activates NaV isoforms through shifting voltage-dependent activation to lower thresholds, 
maintaining channels in the open configuration for longer, and slowing down voltage-
dependent inactivation
165
.  Ciguatoxin exhibits similar effects to brevetoxin, but also induces 
neuronal membrane potential oscillations
160
, indicating that the binding site may exert more 
effects than simple inhibition of inactivation. 
 
Toxin binding site 6, which has been suggested to be the loop connecting S3 and S4 segments 
in domain IV by investigations using the δ-conotoxin δ-SVIE166, remains relatively 
unexplored compared to other binding sites. To date, only δ-conotoxins, a class of conotoxins 
that slow down NaV inactivation without changing the voltage-dependency inactivation of the 
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channel
161
, have demonstrated evidence of binding to site 6, suggesting the mechanism of 
inactivation differs from that of other toxins attaching to the other binding sites. 
 
The various toxin binding sites have been instrumental in the discovery of loops and 
segments important for the functions and properties of the NaV channel, such as pore opening 
and voltage sensitivity. Mutation studies using toxin binding have further pinpointed specific 
mutations that would cause gain- or loss-of-function changes in the channel. However, 
despite biochemical evidence that NaV1.7 loss-of-function mutations are the main contributor 
towards congenital insensitivity to pain, NaV1.7-selective inhibition and NaV1.7 knockout 
mice do not exhibit a complete lack of pain sensation similar to that observed in human 
patients, bringing into light potential differences in pain pathways and ion channel 
distribution between humans and rodents and calling into question the presumed contribution 
of NaV1.7 towards the sensation of pain. 
 
1.5.3 NaV1.7 
A weighty body of literature concerning NaV1.7 has been accumulated since the definitive 
link between this TTX-s NaV isoform with the sensation of pain. NaV1.7 is expressed widely 
throughout the PNS, particularly in DRG neurons
167, 168
 and sympathetic neurons. NaV1.7 is 
also the main NaV isoform involved in signal conduction in the olfactory circuits
169
, 
corresponding to the lack of smell observed in human congenital insensitivity to pain. In the 
PNS, NaV1.7 is distributed in both A- and C-fibres, with all C-fibres in guinea pig DRG 
neurons exhibiting positive NaV1.7 immunoreactivity
168
. Not all A-fibres are positive for 
NaV1.7, though 90% of Aδ-fibres and 40% of Aβ-fibres express NaV1.7
168
. These numbers 
include nociceptive neurons as well as sensory neurons transmitting innocuous signals. 
NaV1.7 expression can be detected throughout the entire DRG neuron, distributed from the 
terminal tip of intra-dermal nerve ending in the skin
170
 to the DRG neuronal terminals in the 
spinal cord
171
. In myelinated neurons, NaV1.7 is preferentially expressed at the nodes of 
Ranvier, which are small unmyelinated sections of the axon between stretches of myelin to 
allow for saltatory conduction in myelinated fibres. NaV1.7 is therefore involved in 
conducting pain signals along the entire length of DRG neurons, from the periphery to the 
spinal cord.  
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NaV1.7 also exhibits gating kinetics that easily enhance neuronal excitability. Though NaV1.7 
is relatively resistant to inactivation from the closed state, the channel has rapid activation 
and inactivation kinetics, resulting in TTX-s currents that can be evoked by slow 
depolarisation of the neuron
172
. Compared to other TTX-s NaV isoforms such as NaV1.6, 
closed and non-refractory NaV1.7 channels inactivate more than seven times slower than the 
NaV1.6 isoform
173
, suggesting NaV1.7 may amplify sub-threshold potentials and contribute to 
spontaneous firing. At the same time, NaV1.7 recovered from refractory inactivation almost 
nine times slower compared to NaV1.6
173
, and the channel may conduct action potentials less 
frequently. More recently, NaV1.7 was shown to be involved in the initiation and the 
depolarisation phase of action potentials in nociceptive peripheral neurons
174
. NaV1.7 
inhibition stopped spontaneous firing in nociceptors invoked by slow depolarising voltage
174
, 
demonstrating NaV1.7 could contribute to multiple factors involved in action potential 
generation. 
 
Studies with NaV1.7 have been promising for select pain conditions and in reproducing pain 
insensitivity, as seen by the congenital insensitivity to pain exhibited by global NaV1.7 
knockout in mice
175
. However, global NaV1.7 knockout is lethal for newborn mice if 
sufficient husbandry support is not provided, as the lack of smell caused by the lack of 
NaV1.7 in olfactory circuits result in the neonatal mice being unable to find food and feed
175
. 
Upon reaching adulthood, the mice exhibited similar symptoms to human NaV1.7 null 
patients, maintaining normal sensitivity to innocuous stimuli but demonstrating complete 
insensitivity to noxious thermal, mechanical, and chemical stimuli
175
. The mice did not 
demonstrate allodynia invoked by inflammatory condition following CFA injection, nor 
exhibited aversive behaviour following peripheral injection of veratridine and grayanotoxins, 
both of which are NaV activators that bind to binding site 2
175
. These results confirm that 
NaV1.7 is involved in conduction of pain signals, and that global NaV1.7 knockout does 
interrupt normal physiological transmission of pain signals to the CNS. 
 
At the same time, other gene knockout and knockdown studies present conflicting 
information towards the contribution of NaV1.7 towards pain. Specific deletion of NaV1.7 
from NaV1.8-positive peripheral neurons in mice resulted in increased noxious pain 
thresholds and reduced inflammatory pain invoked by formalin and CFA, confirming the 
important role NaV1.7 plays in acute and inflammatory pain
176
. However, studies conducted 
by the same research group also revealed the knockout of NaV1.7 channels in NaV1.8-positive 
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neurons had no effect in alleviating neuropathic pain after spinal nerve ligation
177
. Thus, 
while it has since been found that the presence of NaV1.7 in peripheral sympathetic 
neurons
167
 interferes with pain sensations
178
, the fact remains that NaV1.7 knockout animals 
only appear to have reduced acute and inflammatory nociception, and do not demonstrate 
alleviated pain in neuronal damage models of neuropathic pain. 
 
Biochemical and expression studies concerning NaV1.7 in neuropathic pain also yield 
conflicting information concerning NaV1.7 expression changes following injury. TTX-s 
currents in unmyelinated C-fibres changed from slow-recovering, as observed with NaV1.7-
mediated currents, to fast-recovering currents following a nerve injury
179
, indicating the 
expression of TTX-s NaV isoforms was no longer predominated by NaV1.7. The expression of 
NaV1.7 was also lowered in mice DRG neurons for up to five days following spinal nerve 
ligation, indicating NaV1.7 does not contribute to over-excitation of the injured neuron
180
. 
The same trend was found in humans, with NaV1.7 expression found to be decreased after 
central or peripheral axotomy
181
. At the same time, NaV1.7 is accumulated and overexpressed 
in painful human neuromas
182
. Inflammation also increased NaV1.7 expression
183
, and 
inflammatory mediators such as nerve growth factors are thought to up-regulate NaV1.7 
expression
184
. Curiously, a rat model of painful diabetic neuropathy reported increased 
NaV1.7 expression
185
, as opposed to the NaV1.7 down-regulation found in mice and human 
nerve injury, leading to the proposition that NaV1.7 perhaps varies in its importance in pain 
pathways across species and in different pain conditions. 
 
A plethora of pain conditions have since been identified to be NaV1.7-independent. Neuronal 
injury models, such as chronic constriction injury and spinal nerve transection injury, were 
only alleviated when NaV1.7 was knocked out in all DRG neurons or knocked out in 
sympathetic peripheral neurons, and were not affected in mice with NaV1.7 knocked out only 
in NaV1.8-positive C-fibres
186
. At the same time, oxaliplatin-induced neuropathic pain, a 
condition that exhibits mechanical and cold allodynia, was not alleviated by NaV1.7 knockout 
even when NaV1.7 was also removed from sympathetic neurons
186
. Cancer-induced bone pain 
and resultant gait abnormalities were also not significantly affected by NaV1.7 knockout in all 
peripheral neurons
186
. There are also pain conditions that are only partially alleviated by 
NaV1.7 knockout in NaV1.8-positive neurons, such as allodynia following a burn injury
187
. 
Only thermal allodynia was abolished in NaV1.7 knockouts in a peripheral burn, and 
mechanical allodynia was unaffected. Symptoms arising from different modalities may 
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therefore still be mediated by different pain pathways and ion channels, even in pain 
conditions where NaV1.7 plays a recognised role. 
 
Highly potent and selective NaV1.7 activators and inhibitors derived from animal venoms 
have been considered as potential therapy for pain in the clinic. Yet much like the conflicting 
evidence seen in murine gene knockout models, peptides and small molecules with high 
potency towards NaV1.7 in vitro do not translate directly into analgesia. NaV1.7-selective 
peptides such as ProTX-II, a peptide toxin extracted from the Peruvian green-velvet tarantula 
spider Thrixopelma prurient and is at least 100 times more selective for NaV1.7 than other 
NaV isoforms in vitro, did not alleviate either acute or inflammatory pain in rats following 
intravenous administration
188
. However, the NaV1.7-selective activator OD1, a toxin 
extracted from the Iranian yellow scorpion Odontobuthus doriae, successfully invoked 
spontaneous pain behaviours such as licking and flicking of the foot when given peripherally 
in mice
189
, indicating the activation of NaV1.7 does result in nociceptive behaviour. While 
behaviours from OD1 injection were reversed by ProTx-III, another toxin highly selective for 
NaV1.7 inhibition
190
, this evidence still does not reveal the exact mechanisms by which 
NaV1.7 contributes to pain. The need to inhibit NaV1.7 activity in sympathetic neurons 
indicates that NaV1.7 may not, in fact, be a vital transmitter in all nociceptive neurons as 
previously thought, and that it is likely that other NaV isoforms are involved in pain signal 
conduction, especially in pain models not completely abolished by NaV1.7 inhibition.  
 
1.5.4 NaV1.6 
NaV1.6 is one of the most widely distributed NaV isoforms in the peripheral as well as the 
central nervous system. Similar to NaV1.7, NaV1.6 is expressed in unmyelinated C-fibres and 
at the nodes of Ranvier in myelinated A-fibres
191
. In terms of the extent of expression, 
NaV1.6 is expressed from the dermal terminals and skin receptors to the DRG soma in the 
peripheral axon, and is expressed up to the dorsal root entry in the spinal cord in the central 
DRG axon
191
, as opposed to the expression of NaV1.7 up to the neuronal terminal in the 
spinal cord. Immunostaining studies indicate that NaV1.6 is expressed with high density at the 
nodes of Ranvier, and the lack of immunostaining with other NaV α subunit antibodies 
indicate NaV1.6 may be the dominant NaV isoform in nodes of Ranvier in myelinated 
neurons
192
. The expression of NaV1.6 in the CNS is distributed throughout the presynaptic 
and postsynaptic membranes of the CNS neurons
192
, suggesting that NaV1.6 is heavily 
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involved in central synaptic transmission as well as peripheral signal transmission. 
Malfunctions of the NaV1.6 isoform are known to lead to central transmission disturbance, 
with evidence suggesting that NaV1.6 is involved in hyperexcitation during epilepsy
193
. 
 
NaV1.6 appears to affect resurgent currents, a peculiar phenomenon observed first in Purkinje 
neurons in the cerebellum, when prolonged depolarisation followed by mild repolarisation 
resulted in a TTX-s inward sodium current
194
. Such currents activate slowly as the membrane 
is repolarised, followed by deactivation
194
. NaV1.6 knockout mice exhibit disturbed resurgent 
sodium current in Purkinje neurons
195
, even though other NaV α subunits such as NaV1.1 also 
mediate resurgent currents
196
. Compared to the NaV1.7 isoform, NaV1.6 also developed and 
recovered from closed-state inactivation much faster
173
, suggesting NaV1.6 is capable of 
firing at a higher frequency than NaV1.7.  
 
Evidence towards the redistribution of NaV1.6 following neuronal injury also lends weight to 
the potential contribution of NaV1.6 in abnormal pain sensation. A combined partial axotomy 
and chronic suture lesion in the infraorbital nerve of the rat found an increased density of 
NaV1.6 expression in myelinated neurons following the injury, together with an increased 
length of the nodes of Ranvier and increased expression of NaV1.6 in the nodes
197
. Studies 
with nerve injury and neuronal inflammation rodent models also indicate that NaV1.6 could 
be associated with spontaneous firing following an insult. The spinal nerve ligation model 
elicited spontaneous activity in myelinated sensory neurons soon after the injury, as well as at 
the entry of peripheral sympathetic nerve endings into the DRG. Both processes are 
considered vital in the establishment of neuropathic pain. The injection of small inhibitory 
NaV1.6 RNA into affected DRGs to locally knock down NaV1.6 channel expression reduced 
high frequency and repetitive firing from the nerves in rats, as well as a reduction in 
mechanical allodynia symptoms
38
. It is also interesting to note that NaV1.6 knockdown 
reduced sympathetic sprouting into the DRGs, with immunostaining revealed that 
sympathetic sprouting had a propensity for NaV1.6-positive DRG neurons
38
. Moreover, 
NaV1.6 knockdown did not reduce action potentials evoked by external stimuli, but only 
dampened spontaneous activity in the affected DRG neurons
38
, offering intriguing insight 
into the role NaV1.6 plays in action potential transmission. 
 
Experiments involving local NaV1.6 knockdown during DRG inflammation yielded similar 
results. Myelinated nerves which were affected by inflammation and became spontaneously 
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active expressed more NaV1.6 channels compared to other myelinated neurons, with the local 
injection of small interfering NaV1.6 RNA successfully blocking spontaneous activity and 
reducing aversive behaviour in the rats
198
. Unmyelinated C-fibres were found to be minimally 
affected
198
, suggesting NaV1.6 may only play a major role in myelinated sensory neurons. At 
the same time, a semisection of the rat spinal cord resulted in increased contralateral 
expression of NaV1.6 on unmyelinated DRG neurons
199
, suggesting NaV1.6 could redistribute 
throughout the organism following neuronal injury. It is also very likely that NaV1.6, similar 
to NaV1.7, only affects certain pain conditions and modalities, particularly as NaV1.6 
expression is decreased in painful diabetic neuropathy in rats, a model in which NaV1.7 
expression is increased
185
. 
 
As of now, NaV1.6 has already been found to be intimately involved in some clinically 
relevant pain conditions, one of those being ciguatoxin-induced pain and cold allodynia
200
. 
Ciguatoxin is a toxin that binds to toxin binding site 5 in NaV channels, and is produced by 
marine dinoflagellate that accumulate in large reef fish. Human ingestion results in ciguatera, 
a condition characterised by severe diarrhoea and neurological disturbances such as 
dysaesthesia and specifically cold allodynia
201
. Previous studies have indicated that TTX-s 
NaV isoforms as well as NaV1.8 mediate ciguatoxin-induced neuronal hyperexcitability 
through activating cold-specific pathways
86
. Further research indicates that when GIIIA, a 
NaV1.6-selective inhibitor conotoxin, is peripherally administered together with the selective 
NaV1.8 inhibitor A-803467, a significant decrease in pain behaviours such as flinching was 
observed in mice with ciguatoxin-induced cold allodynia
200
. The administration of GIIIA 
alone also significantly reduced flinching in mice, with the implication that NaV1.6 could be 
the main contributor to the excitatory effects of ciguatoxin in myelinated neurons. 
 
NaV1.6 inhibition was also successful at alleviating dysaesthesia caused by oxaliplatin and 
cisplatin, two platinum-based chemotherapy drugs known to cause neurotoxicity
133
. 
Peripherally administered oxaliplatin elicited cold allodynia in mice, resulting in behaviours 
such as flicking and licking and paw shaking when the mice were exposed to 10 °C one hour 
after injection
2
. Examinations using selective inhibitors of all NaV isofroms expressed in 
neurons as well as TRPA1, TRPV1, and TRPM8 blockers and knockout mice indicated that 
only GIIIA administration was successful at alleviating cold allodynia. Moreover, the co-
administration of 4-aminopyridine, a KV inhibitor, and Cn2, a NaV1.6 activator extracted 
from the venom of the scorpion Centruroides noxius
202
, successfully replicated cold allodynia 
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observed following oxaliplatin administration
2
, concluding that the activation of NaV1.6 and 
the inhibition of repolarising KV isoforms forms the backbone of oxaliplatin-induced cold 
allodynia symptoms. Mechanical allodynia in mice following peripheral administration of 
cisplatin was also only alleviated by NaV1.6 inhibition. Experimental groups of mice were 
injected with TTX, the NaV1.1/1.2/1.4 inhibitor TIIIA, the NaV1.7-selective inhibitor ProTx-
II, or the NaV1.6-selective inhibitor GIIIA
133
. GIIIA was the only compound that successfully 
reverted mechanical threshold to normal levels, cementing the notion that NaV1.6 is 
responsible for certain NaV1.7-independent pain conditions, and that the roles NaV1.6 play in 
other NaV1.7-independent conditions most certainly warrant further examination. 
 
1.5.5 NaV1.8 
NaV1.8 is a TTX-r channel preferentially expressed on C-fibres in peripheral sensory 
neurons, and has been considered one of the indispensable markers of peripheral nociceptors. 
As discussed previously, conditional knockout of other NaV isoforms are often conducted on 
NaV1.8-positive neurons, as this is assumed to include all nociceptive C-fibres. NaV1.8 
exhibits slow inactivation kinetics, resulting in long action potentials
203
. At the same time, 
NaV1.8 also exhibits high firing frequency due to its fast recovery from inactivation
179
, 
leading to prolonged electrical activity of the neuron. Similar to NaV1.6 and NaV1.7, NaV1.8 
also generates resurgent currents, although resurgent currents generated by NaV1.8 activate 
and inactivate much slower than those generated by NaV1.6
204
. Such properties of NaV1.8 
indicate that this isoform could be involved in protracting neuronal firing and making 
neurons more prone to spontaneous firing. 
 
A vital function of NaV1.8 is the detection of pain in cold temperatures. NaV1.8 is responsible 
for maintaining the excitability of peripheral nociceptors at noxious cold temperatures (< 10 
°C)
205
, particularly as TTX-s NaV isoforms are inactivated with decreasing temperature, to 
which NaV1.8 excitability is completely unaffected
205
. Similar to that seen with other PNS 
NaV isoforms, NaV1.8 mutations cause neuropathy in human patients. Gain-of-function 
NaV1.8 mutations further accelerate channel recovery from inactivation and exaggerates 
channel responses to slow depolarisations, culminating in hyperexcitability of nociceptive C-
fibres in patients with idiopathic painful small fibre neuropathy
206
. Transgenic mice with 
gain-of-function NaV1.8 mutations displayed increased mechanically evoked action potentials 
in A- and C-fibres, with fibres firing continuously even after the removal of the mechanical 
41 
 
stimulus
134
. However, this did not lead to a decrease in noxious mechanical threshold in the 
transgenic mice, pointing to a potential role for NaV1.8 in thermal pain sensing but a less vital 
role in mechanical pain sensing. 
 
Additional studies have investigated the involvement of NaV1.8 using NaV1.8 knockout mice. 
Neuromas formed by saphenous nerve sectioning exhibited significantly less 
mechanoexcitability and spontaneous firing in NaV1.8 knockout mice (19% vs 0.4% at 22 
days after the injury)
207
. While NaV1.8 is responsible for maintaining nociceptive signal 
transmission in cold temperatures, and NaV1.8
-\-
 mice also failed to show signs of cold 
allodynia following spared nerve injury
137
, the NaV1.8 knockout mice exhibited no difference 
in heat sensitivity (up to 56 °C)
137
. The expression of NaV1.8 was reduced in the soma of 
DRG neurons that were injured by a sciatic nerve ligation injury, but was significantly 
increased in intact and adjacent axons throughout the sciatic nerve
135
. These findings suggest 
the involvement of NaV1.8 in overall C-fibre hyperexcitability following injuries. 
 
The contribution of NaV1.8 in different pain conditions has also been further assessed, with 
NaV1.8 appearing to take a more active role in inflammatory and neuropathic pain compared 
to pain following acute injury or surgery. Mechanical allodynia after CFA administration was 
significantly reduced with local NaV1.8 antisense oligodeoxynucleotides, and mechanical 
allodynia following chronic constriction injury was also reduced following local NaV1.8 
knockdown
3
. However, pain following skin-incision and vincristine-induced neuropathic pain 
was not changed by NaV1.8 knockdown
3
, leading to the notion that NaV1.8 may not be 
involved in acute pain transmission. Conflicting information, however, has emerged 
regarding the generalisation of such findings, with double NaV1.7/NaV1.8 knockout mice 
exhibiting mechanical allodynia following spinal nerve ligation despite the lack of two major 
NaV isoforms in nociceptors
177
. Such findings indicate the need to examine the contribution 
of NaV isoforms specific to each pain condition, as it is now evident that different conditions, 
even though they result in similar symptoms in animal models and human patients, likely 
exhibit drastically different molecular changes following the insult. 
 
1.6 Summary 
Pain is much more than a measurement of the intensity of the external stimuli. It is a 
sensation that involves transducing non-electrical stimuli into action potentials at the dermal 
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nerve endings of DRG neurons, conducting the signal along the DRG neuronal axons to the 
dorsal horn in the spinal cord, and further transmission into the thalamus and higher cognitive 
centres. Ion channels expressed in DRG neurons in the PNS are vital in the conduction of 
action potentials along the axon, as well as controlling the excitability of cellular membranes 
to modulate the frequency and threshold of action potential generation. NaV1.6, NaV1.7, and 
NaV1.8 have been the most likely candidates for novel molecular targets for analgesia, due to 
their selective expression in peripheral sensory neurons as well as their noted role in 
channelopathies related to pain. It is also now evident that different pain conditions exhibit 
vastly different molecular changes in nociceptive neurons, and an examination of the 
contribution of NaV channels in individual conditions is required to develop specific and 
successful novel analgesics based on NaV activity. 
 
1.7 Hypothesis and Aims 
Based on the crucial contribution of NaV isoforms to pain as discussed above, as well as 
increasing recognition that NaV1.6 and NaV1.8 contribute to modality-specific pain pathways, 
this thesis will explore the following hypothesis and aims: 
 
1.7.1 Hypothesis 
NaV1.6 and NaV1.8 play important roles in NaV1.7-independent pain conditions. 
 
1.7.2 Aims 
1. To discover NaV1.6- or NaV1.8-selective channel modulators. 
2. To evaluate whether in vitro cell models are representative of known DRG neuron 
subclasses. 
3. To investigate the role of NaV1.6 and NaV1.8 in burn-induced mechanical allodynia, a 
NaV1.7-independent pain symptom. 
4. To investigate transcriptomic changes in DRG neurons during burn-induced pain. 
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Chapter 2: Discovery of Selective Voltage-gated Sodium Channel 
Inhibitors from Spider Venoms 
 
2.1 Foreword 
Peptides extracted from naturally occurring toxins have offered a wealth of selective ion 
channel modulators
208
, as well as being potential drug leads that target nociceptive neurons. 
Almost all spiders and scorpions are armed with a venom apparatus and secrete a cocktail of 
various toxins designed to paralyse and kill prey, offering a large number of potential 
neurotoxins that can be used to explore the mysteries of sensory neurons. I therefore 
conducted an investigation into the biological activity of a collection of scorpion and spider 
crude venoms on NaV1.6 and NaV1.8 isoforms, utilising cells stably transfected with human 
NaV1.6 or NaV1.8. An assay-guided fractionation method was used to find putative novel 
NaV1.6 and NaV1.8 inhibitors, which may be used as pharmacological tools. 
 
I would like to acknowledge the contributions of the following parties towards this chapter: 
Dr. Volker Herzog for the supply of crude venoms; the Australian Proteome Analysis Facility 
(APAF) in Sydney, Australia, for sequence identification of the novel peptide using Edman 
degradation; and Dr. Aihua Jin and Dr. Mu Yu (Institute of Molecular Biosciences, 
University of Queensland, Australia) for further analysis of the peptide sequence using 
tandem mass spectrometry (MS/MS).  
 
2.2 Introduction 
Some of the pharmacologically active compounds that have been used experimentally in 
animal models of pain to affect NaV1.6 and NaV1.8 channel activities are GIIIA, 4,9-anhydro-
TTX, and A-803467. GIIIA is a conotoxin extracted from the venom of cone snails
130
, 4,9-
anhydro-TTX is a metabolite of TTX
209
, and A-803467 is a small molecule inhibitor
210
. 
However, a number of concerns persist for these compounds, as outlined below. 
 
GIIIA, a µ-conotoxin extracted from the venom of the cone snail Conus geographus, has 
known inhibitory effects on the skeletal muscle NaV isoform NaV1.4
130
. GIIIA was initially 
considered to be ineffective at neuronal NaV isoforms
130
. Further studies then determined 
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GIIIA also inhibits NaV1.1, NaV1.2, and NaV1.6, and is 30-fold more selective for NaV1.4 
over NaV1.6 (GIIIA IC50 = 0.019 µM in NaV1.4 and IC50 = 0.68 µM in NaV1.6)
211
. GIIIA also 
exhibits different effects in different species, with the human NaV1.4 isoform being resistant 
to GIIIA-mediated inhibition
130
 despite the high potency of the toxin in the rat NaV1.4 
isoform
130
. In order to examine the effect of NaV1.6, GIIIA is administered together with 
TIIIA, another conotoxin-derived peptide that inhibits NaV1.1, 1.2, 1.3, and NaV1.4
212
, but 
not NaV1.6. The differential inhibitory activity of the two peptides allows for assessment of 
the effect of NaV1.6 inhibition independent of NaV1.1, NaV1.2, and NaV1.4 inhibition in 
animal models
2, 133, 200. An existing peptide with the opposite action to GIIIA is the β-
scorpion toxin Cn2, which functions as a potent NaV1.6-selective activator
202
. Cn2 injections 
have been used in animals as a model of local NaV1.6 activation
2
. However, as a channel 
activator, Cn2 cannot be used to investigate the effect of NaV1.6 inhibition in clinically 
relevant pain conditions, necessitating the discovery of inhibitory compounds with better 
selectivity than GIIIA. 
 
Another compound that has been reported to selectively inhibit NaV1.6 is 4,9-anhydro-
TTX
209
, a metabolite of tetrodotoxin (TTX). This metabolite is reported to selectively inhibit 
NaV1.6 over other NaV isoforms with approximately 50-fold higher selectivity (4,9-anhydro-
TTX IC50 = 7.8 nM for NaV1.6. NaV1.3, the NaV isoform it inhibits with the second-highest 
potency, has IC50 = 341 nM)
209
. However, work in my lab has not been able to successfully 
replicate these findings, drawing into question both the potency and selectivity of the 
compound. 4,9-anhydro-TTX is also sparingly soluble in aqueous solutions and preferentially 
dissolves in ethanol, posing a safety concern in animal work. More characterisation studies 
both in vitro and in animals are therefore required before 4,9-anhydro-TTX can be considered 
a good selective tool for studies on NaV1.6 or as a possible drug lead. 
 
A-803467 is a NaV1.8-inhibitory small molecule discovered through structural-activity 
studies
210
. Prior to its discovery, NaV1.8 inhibition could only be achieved through gene 
knockout or local gene knockdown using interfering RNA and antisense oligonucleotides in 
animals
3, 137, 177
. A-803467, however, is known to preferentially bind to the inactivated state 
of the NaV1.8 channel
210
 rather than the resting state. Furthermore, evidence obtained from 
global NaV1.8 knockout mice, local NaV1.8 knockdown mice, and A-803467-mediated 
NaV1.8 inhibition are contradictory in some conditions. NaV1.8 global knockout mice 
maintained robust mechanical allodynia following spinal nerve ligation injury
177
, but 
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demonstrated significantly prolonged latency to paw withdrawal when challenged with 
thermal stimuli in the Hargreave's Test, as well as reduced nociceptive behaviours in the 
formalin inflammatory pain model
177
. In contrast, antisense oligonucleotides targeting NaV1.8 
as well as A-803467 administration achieved mechanical allodynia reduction in spinal nerve 
ligation
210, 213
 as well as in chronic nerve constriction
3, 210
 models. To further complicate the 
relationship between gene knockout and protein inhibition data, A-803467 did not affect the 
response of mice in the formalin inflammatory pain model
210
. The results of these studies 
suggest NaV1.8 expression changes may not be the determinant of neuropathic pain 
development and maintenance, and functional inhibitors that hinder the activity of NaV1.8 
channels in the affected neurons would be more appropriate for evaluating the contribution of 
NaV1.8 activity in pain. 
 
One under-explored source of potent and selective NaV modulators is from venoms, in 
particular from spiders. Crude venoms secreted by spiders contain a mixture of many 
components, which can be loosely classified into three groups: low molecular mass organic 
molecules (molecular weight < 1 000 Daltons), polypeptides (molecular weight 3 000 - 10 
000 Daltons), and high molecular mass proteins (molecular weight > 10 000 Daltons)
214
. 
Other minor components in the crude venom include ions, acids, amino acids, and 
neurotransmitters such as histamine and dopamine
214
. While the acids and neurotransmitters 
contained in spider venoms do affect neurons in vivo, the majority of neurotoxins extracted 
from spider venoms fall into the polypeptide group. 
 
Polypeptides found in many spider venoms share similarities, such as a medium range of 
molecular weight and structural inflexibility due to the presence of disulfide bridges
214
. These 
differences allow polypeptides to be easily separated from other components in the crude 
venom via methods such as HPLC (high performance liquid chromatography) and MALDI 
(matrix-assisted laser desorption/ionisation). A large number of peptides have been isolated 
from spider venoms to date, with the first spider toxin family discovered to act upon NaV 
channels being the µ-agatoxins, which are derived from the venom of the highly venomous 
funnel-web spiders
215
. Analyses into crude spider venoms using MALDI indicate the 
presence of two main clusters of polypeptide masses, with one cluster between 3500-4500 
Daltons (Da) and another between 6500-7000 Da. It is therefore speculated that two separate 
groups of polypeptides exists, with one exhibiting moderate length and molecular mass, and 
another group consisting of long peptides with more than four disulfide bridges
208
. 
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Peptides exhibit selectivity between different ion channels, between channels in different 
tissues, as well as between species, particularly as many spider peptides are selective for 
insect NaV isoforms compared to mammalian targets. Peptides binding to sites within 
different NaV domains (see Chapter 1, section 1.5.2) also cause diverse results. Toxins 
targeting the voltage sensor portions of domains I, II, and III affect voltage-gated opening of 
the NaV channel, whereas the voltage sensor portion from domain IV dictates NaV 
inactivation
216
. Curiously, despite the observed promiscuity of many spider toxins, the amino 
acid sequence homology between the voltage sensor of the various ion channels is low, 
suggesting that peptides may have evolved to target the general structure of the sensor rather 
than specific amino acids exhibited in the various channels
216
. 
 
This chapter therefore set out to explore possible polypeptides in crude scorpion and spider 
venoms that may exhibit inhibitory activity against NaV1.6 or NaV1.8 in order to discover 
potential inhibitory peptides targeting these ion channels. 
 
2.3 Materials and methods 
2.3.1 Materials 
All materials were obtained from Sigma-Aldrich (Castle Hill, New South Wales, Australia) 
unless otherwise stated. Dr. Volker Herzig (Institute for Molecular Bioscience, University of 
Queensland) generously provided all venom samples. All crude venom samples, as well as 
freeze-dried venom fractions and isolated peptide, were reconstituted with 1:1000 BSA 
(bovine serum albumin, Alfa Aesar, MA, USA; Cat# J65966) dissolved in PSS (physiological 
saline solution; for composition see Appendix 2.1). Membrane Potential dye and Calcium 4 
No-Wash dye stock solution were reconstituted using 10 mL of PSS per vial of powder, and 
stored at -20 ˚C for up to 3 months. 
 
2.3.2 Animals 
Male wild-type C57BL/6 mice age 6-8 weeks and weighing 20 - 23 grams were used. Ethical 
approval for in vivo experiments involving live animals was obtained from the University of 
Queensland animal ethics committee under the ethics approval number 
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PHARM/512/12/RAMACIOTTI. Experiments were conducted in accordance with the 
Animal Care and Protection Regulation Queensland (2012), the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes, 8th edition (2013) and the 
International Association for the Study of Pain Guidelines for the Use of Animals in 
Research. 
 
All animals were housed in groups of 2-4 per cage in a stable environment under 12 hour 
light-dark cycles and had access to standard rodent chow and water ad libitum. A red 
polycarbonate Mouse House (Tecniplast, Italy) and shredded paper nesting material were 
supplied for enrichment. All animals were obtained from University of Queensland 
Biological Resources (Brisbane, Australia).  
 
2.3.3 Cell culture 
HEK293 cells stably expressing human NaV1.6 (hNaV1.6) ion channels were obtained from 
Scottish Biomedical (Glasgow, UK). Cells were grown in MEM (Minimum Essential Media; 
for composition see Appendix 2.2) with 10% FBS (foetal bovine serum, Life Technologies, 
Mulgrave, Victoria, Australia) and 2 mM L-glutamine (GlutaMax
TM
, Life Technologies, 
Mulgrave, Victoria, Australia). 
 
CHO (Chinese hamster ovary cells) cells stably expressing hNaV1.8 were obtained from 
ChanTest (Cleveland, OH, USA). Cells were grown in Ham’s F12 media (Life Technologies, 
Mulgrave, Victoria, Australia; for composition see Appendix 2.3) with 10% FBS. To 
maintain selective pressure for NaV expression, this culture media was supplemented with 
blasticidin (10 µg/mL; Life Technologies, Mulgrave, Victoria, Australia), hygromycin (250 
µg/mL; Life Technologies, Mulgrave, Victoria, Australia), and zeocin (400 µg/mL; Life 
Technologies, Mulgrave, Victoria, Australia). 
 
Un-transfected HEK293 cells (American Type Culture Collection, VA, USA) were 
transfected (to be described in Section 2.3.4) with rat TRPV1 (rTRPV1) ion channels. Cells 
were grown in DMEM (Dulbecco’s Modified Eagle Medium, Life Technologies, Mulgrave, 
Victoria, Australia; for composition see Appendix 2.4) with 10% FBS and 2 mM L-
glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with hygromycin (50 µg/mL). 
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All cells were incubated at 37°C and 95% O2/5% CO2. Cells were passaged every 3-5 days at 
a 1:5 dilution ratio or when approximately 90% confluent. All cells were seeded in T75 cm
2
 
Corning® (Corning, MA, USA) cell culture flasks unless otherwise stated. In order to 
passage cells, cells were briefly removed from incubation and maintained in room 
temperature and growth media was removed from the flask. At least 5 mL/75 cm
2
 of DPBS 
(Dulbecco’s Phosphate Buffered Saline, Life Technologies, Mulgrave, Victoria, Australia; 
for composition see Appendix 2.5) was added into the flask to briefly wash the cells and was 
then removed from the flask. 0.25% trypsin/EDTA (0.25% trypsin/ethylenediaminetetraacetic 
acid in Hank’s Balanced Salt Solution, Life Technologies, Mulgrave, Victoria, Australia; for 
composition see Appendix 2.6) was then added at a concentration of 1 mL/75 cm
2
, and the 
cells were dislodged by gently tapping the sides of the flask. The dislodged cell suspension 
was diluted with a further 9 mL of the appropriate growth media. The cells were passaged 
according to aforementioned ratios in a new T75 cm
2
 flask using new growth media. 
 
2.3.4 Transfection 
Un-transfected HEK293 cells (American Type Culture Collection, VA, USA) were routinely 
maintained in DMEM containing 10% FBS and 2 mM L-glutamine. Cells were split every 3-
6 days in a ratio of 1:5 using 0.25% trypsin/EDTA. Cells were plated on T75 cm
2
 (Nunc, 
Denmark) tissue culture flasks 24 hours prior to transfection, and were transfected with rat 
TRPV1 plasmid DNA (D. Julius, Department of Physiology, University of California, 
Berkeley, CA, USA) using Lipofectamine
TM
 2000 (Life Technologies, Mulgrave, Victoria, 
Australia) according to the manufacturer's instructions. Twenty-four hours after transfection, 
cells were plated on 384-well plates and used for Ca
2+
 48 hours after plating.  
 
2.3.5 Fluorescent membrane potential and Ca
2+
 assays 
All cells were seeded onto 384-well black-walled imaging plates (Corning, MA, USA) at a 
density of 10,000 - 15,000 cells per well 48 hour prior to membrane potential or calcium 
imaging experiments, and were incubated with 95% O2/5% CO2 for 48 hours. HEK293 cells 
expressing NaV1.6 or TRPV1 were seeded onto uncoated plates (Corning, Cat No #3542). 
CHO cells expressing NaV1.8 were seeded onto PDL (poly D-lysine) coated 384-well plates 
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(ViewPlate-384, Perkin Elmer, Victoria, Australia). Cells were seeded to ensure ~90% 
confluency on the day of the experiment. 
 
HEK293 cells expressing NaV1.6 or TRPV1 were incubated at 37°C prior to imaging 
experiments in culture media as described in Section 2.3.3. CHO cells expressing NaV1.8 
were incubated in Ham’s F12 media (Life Technologies, Mulgrave, Victoria, Australia; for 
composition see Appendix 2.3) with 10% FBS. The NaV1.8 CHO cells express a tetracycline-
inducible vector, therefore the culture media for CHO cells was supplemented with 
tetracycline (1 µg/mL) from tetracycline stock solution (for composition see Appendix 2.7), 
freshly added before incubation. CHO cells expressing NaV1.8 was incubated at 37°C with 
95% O2/5% CO2 for 24 hours following seeding, then incubated at 25°C with 95% O2/5% 
CO2 for a further 24 hours to induce increased NaV1.8 expression. 
 
Membrane Potential dye (Corning, MA, USA) and Calcium 4 No-Wash dye (Corning, MA, 
USA) stock solutions were further diluted 1:10 in PSS for use in experiments. Cells were 
incubated in the dye for 30 minutes prior to imaging. Membrane Potential dye was used for 
all fluorescence experiments except for TRPV1 experiments, for which the Calcium 4 No-
Wash dye was used. For CHO cells expressing NaV1.8, 1 µg/mL of tetrodotoxin (Sapphire 
Bioscience, Redfern, New South Wales, Australia) was added into the final volume of the 
dye to inhibit TTX-s NaV calcium responses. 
 
All plates with dye were incubated at 37 ˚C with 95% O2/5% CO2. Membrane potential or 
Ca
2+
 responses were measured using a FLIPR
TETRA
 (Molecular Devices, CA, USA) 
fluorescent plate reader. Membrane Potential dye assays were exposed to excitation at 510-
545 nM and emission at 565-625 nM. Calcium 4 No-Wash dye assays were exposed to 
excitation at 470-495 nM and emission at 515-575 nM. Camera gain and intensity were 
adjusted for each plate to yield a minimum of 1000-1500 arbitrary fluorescence units (AFU) 
baseline fluorescence. 
 
Each assay with NaV1.6-expressing HEK293 cells or NaV1.8-expressing CHO cells consisted 
of two additions of solutions into the plate. The first addition (10 µL) consists of the 
compound tested for inhibitory activity (crude venom samples, freeze-dried venom fractions, 
purified peptide, or buffer solution). All compounds added, apart from the buffer solution, 
were reconstituted in the buffer solution (1:1000 BSA dissolved in PSS). Prior to the first 
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addition for HEK293 cells expressing NaV1.6, 10 baseline fluorescence readings were taken, 
followed by fluorescent readings every 2 seconds for 150 reads. Prior to first addition for 
CHO cells expressing NaV1.8, 10 baseline fluorescence readings were taken, followed by 
fluorescent readings every 2 seconds for 150 reads. 
 
The second addition (10 µL) for NaV1.6-expressing HEK293 cells or NaV1.8-expressing 
CHO cells consists of a known agonist to the NaV isoform. Veratridine (100 µM; Sapphire 
Bioscience, New South Wales, Australia) was used as the agonist for assays involving 
HEK293 cells expressing NaV1.6. Deltamethrin (150 µM) was used as the agonist for assays 
involving CHO cells expressing NaV1.8. Both agonists were constituted from powder in 
DMSO as stock solutions and diluted with PSS. Maximum final DMSO concentration in 
experimental solutions did not exceed 0.001%. Prior to the second addition for HEK293 cells 
expressing NaV1.6, 10 baseline fluorescence readings were taken, followed by fluorescent 
readings every 1 seconds for 600 reads. Prior to the second addition for CHO cells expressing 
NaV1.8, 10 baseline fluorescence readings were taken, followed by fluorescent readings every 
5 seconds for 450 reads. 
 
For calcium response assays involving capsaicin and activation of TRPV1 using HEK293 
cells expressing rTRPV1, only one addition was used. Prior to the addition of potential 
agonists, 10 baseline fluorescence readings were taken, followed by the addition of capsaicin 
or Pme1a, after which fluorescent readings were conducted every 1 second for 300 seconds. 
Capsaicin stock solution was prepared in ethanol and stored at -80 ˚C. Stock solution of 
capsaicin was diluted with PSS. Maximum final ethanol concentration in capsaicin solution 
did not exceed 0.001%. Pme1a was reconstituted with 1:1000 BSA dissolved in PSS. 
 
2.3.6 High Performance Liquid Chromatography (HPLC) 
Solvent A (aqueous solvent) was constituted with 0.1% trifluoroacetic acid in Milli-Q water, 
and Solvent B (organic solvent) was constituted with 0.05% trifluoroacetic acid in 
acetonitrile (VWR International, Queensland, Australia). 
 
For the fractionation of the H. hainanum crude venom, a Vydac 218TP C18 300Å 250mm 
column (Grace, MD, USA; Cat# 218TP54) was used. HPLC solvent B concentration gradient 
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was as follows: 0-25% over 40 minutes, then 25-50% over 60 minutes, then 50-100% over 10 
minutes. The flow rate was 0.70 mL/minute and fractions were collected every minute. 
 
For the fractionation of the P. metallica crude venom, a Vydac 218TP C18 300Å 250mm 
column (Grace, MD, USA; Cat# 218TP54) was used. HPLC solvent B concentration gradient 
was as follows: 0% until minute 5, then 0-50% over 50 minutes, then 50-100% over 20 
minutes. The flow rate was 0.70 mL/minute and fractions were collected every minute. 
 
All fractions were then freeze-dried before reconstitution and testing. All experiments were 
conducted on an UltiMate 3000 HPLC machine (Dionex, Victoria, Australia). 
 
2.3.7 Matrix-assisted laser desorption/ionisation (MALDI) 
MALDI was conducted to determine the mass of peptides found in fractions. The matrix 
consists of 10 mg/mL CHCA (α-Cyano-4-hydroxycinnamic acid) dissolved in 50% 
acetonitrile, 0.1% formic acid (VWR International, Queensland, Australia), and 
approximately 50% Milli-Q water. 0.5 µL of the matrix suspension was mixed with 0.5 µL of 
venom fraction (not freeze-dried, with HPLC solvent of the appropriate polarity) and spotted 
on a MALDI plate (TOF 4700 MALDI sample plate 192-well, Applied Biosystems, Victoria, 
Australia). Laser intensity was set at 3500 and MALDI analysis was conducted on a 4700 
Proteomics Analyser (Applied Biosystems, Victoria, Australia). 
 
2.3.8 Sequence identification 
Edman’s degradation reaction was performed by APAF (Australian Proteome Analysis 
Facility, Sydney, New South Wales, Australia) with reduction/alkylation for the purpose of 
N-terminal sequence identification. The sample was solubilised in ammonium bicarbonate 
(50 mM) and acetonitrile (35%) then reduced using dithiothreitol (25 mM) at 56 °C for 30 
minutes. It was then alkylated using iodoacetamide at room temperature for 30 minutes. The 
sample mixture was desalted prior to sequence analysis using RP-HPLC with a Zorbax 
300SB-C18 column (3 x 150 mm). The target peaks of interest were collected and reduced to 
minimal volume under vacuum. The sample tube was also washed with a solution of 60% 
isopropanol containing 0.1% trifluoroacetic acid to extract any adsorbed peptide. The 
combined extracts were loaded onto a precycled, Biobrene-treated disc and subjected to 35 
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cycles of Edman N-terminal sequencing. The complete sequence was found using MS/MS 
(Tandem mass spectrometry) by Dr. Aihua Jin and Dr. Mu Yu (Institute of Molecular 
Biosciences, University of Queensland, Australia). 
 
2.3.9 Animal behaviour studies 
Purified Pme1a peptide was freeze-dried and reconstituted in PSS (for composition see 
Appendix 2.1) with 1:1000 BSA, and administered by shallow intraplantar injection into the 
left hind paw of mice (10 µL injection volume) under 3% isoflurane anaesthesia. Mice were 
allowed to recover in individual polyvinyl circular containers (25 cm in diameter) placed on a 
plastic surface at room temperature. Spontanous pain was observed as licking, lifting and/or 
flinching of the affected hind paw. Mice were allowed to roam freely and spontaneous pain 
was measured in 5 minute intervals over 10 minutes, counted by a blinded observer. All 
nocifensive responses during the observation period were recorded. 
 
2.3.10 Data analysis 
Data were plotted and analysed by GraphPad Prism, version 6.00. Statistical significance was 
defined as P-value < 0.05 and was determined by unpaired t-test assuming equal variance. 
Data is expressed as the mean ± standard error of the mean (SEM). FLIPR
TETRA
 data was 
analysed using ScreenWorks, version 3.2 (Molecular Devices, CA, USA). HPLC data was 
exported from Chromeleon (Dionex, Victoria, Australia).  
 
2.4 Results 
2.4.1 Screening of crude spider and scorpion venoms on HEK293 cells expressing human 
NaV1.6 channels 
Various species of scorpion and spider crude venoms (6 scorpion and 18 spider species) were 
tested in cell-based high-throughput assay via the FLIPR
TETRA
 system, using HEK293 cells 
stably expressing the human NaV1.6 (hNaV1.6) isoform. Reconstituted venom or control 
solutions were added as the first addition, and the known NaV1.6 activator veratridine was 
added as the second addition. 
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All 6 scorpion species tested (Parabuthus schlechteri, Parabuthus granulatus, Hottentotta 
gentili, Buthus albengai, Parabuthus transvaalicus, and Parabuthus villosus) elicited 
spontaneous membrane potential elevation when added to hNaV1.6-expressing HEK293 cells 
(Figure 2.1 A-F). P. schlechteri was the most potent activator, followed by P. transvaalicus 
(Figure 2.1 A and E). The scorpion toxins that exhibited the least potent agonist activity were 
H. gentili and P. granulatus (Figure 2.1 C and B). Four out of the six scorpion toxins also 
exhibited potentiation of veratridine-induced membrane potential elevation in hNaV1.6-
expressing HEK293 cells (Figure 2.1 G).  
 
In comparison, only 2 samples out of the 18 spider venoms tested potentiated veratridine-
induced membrane potential elevations in hNaV1.6. Macrothele gigas and Poecilotheria 
fasciata were the spider species that exhibited hNaV1.6 potentiation, amplifying membrane 
potential elevations by 45% and 46% respectively compared to control cells. All other spider 
crude venoms examined exhibited inhibitory activity and reduced veratridine-induced 
membrane potential elevation in hNaV1.6-expressing HEK293 cells. This observation 
suggests a possible difference between the effects of scorpion venoms, particularly those in 
the Parabuthus genus, to that of tarantula spider venoms on hNaV1.6 channels, with the 
scorpion venoms from the Parabuthus genus more likely to exhibit hNaV1.6 agonistic 
behaviour than tarantula spider venoms (Figure 2.1 G, for potentiation or inhibitory traces 
from all venoms see Appendix 3.1).  
 
Haplopelma hainanum, a species of tarantula spiders, was found to have marked inhibitory 
activity. The addition of crude H. hainanum venom in hNaV1.6-expressing HEK293 cells 
inhibited 85% of veratridine-induced membrane potential elevation compared to control 
responses (Figure 2.1 G, grey bar; Figure 2.2 A). One other species exhibited greater 
reduction in hNaV1.6 membrane potential elevations than H. hainanum venom. The sample 
was the venom from Euathlus species, and veratridine-induced membrane potential increases 
were reduced by 91% in cells exposed to the venom sample (Figure 2.2 B). However, since 
only microgram amounts of venom were available for Euathlus species, Haplopelma 
hainanum venom was chosen for further investigation. 
 
54 
 
 
 
55 
 
 
Figure 2.1 Differential actions of scorpion and spider venoms in hNaV1.6-expressing 
HEK293 cells 
The addition of scorpion and spider venoms into wells containing hNaV1.6-expressing 
HEK293 cells resulted in different membrane potential changes. Out of the 6 scorpion toxins 
examined, 4 sample were from the Parabuthus genus. All 6 samples of scorpion toxins were 
found to exhibit spontaneous activation, and 4 samples potentiated veratridine-induced 
membrane potential increase in hNaV1.6 channels. A-F) All 6 scorpion venoms examined 
exhibited agonistic behaviour, spontaneously elevating membrane potential in hNaV1.6-
expressing HEK293 cells immediately after addition. Venom from P. schlechteri was the 
most potent activator, followed by venom from P. transvaalicus. Traces were normalised to 
baseline fluorescence readings before the first addition. The X axis indicates time (in 
seconds) after the first addition. G) Effect of crude venoms on veratridine-induced NaV1.6 
responses. Four out of the six scorpion crude venoms (the first six species listed in panel G) 
exhibited potentiation of veratridine-induced membrane potential responses. In comparison, 
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only 2 spider venoms potentiated veratridine-induced membrane potential responses. The 
potentiating spider venoms were from Macrothele gigas and Poecilotheria fasciata. The 
spider crude venom with the most inhibitory activity was the sample from Euathlus species.  
Following the addition of venom from Euathlus species, 91% of veratridine-induced 
membrane potential elevation compared to control responses was inhibited in the cells. 
Addition of venoms from H. hainanum resulted in inhibiting 85% of the control response 
from the cells. The H. hainanum sample was coloured in grey in panel G. Traces were 
normalised to baseline fluorescence readings before the second addition. All responses were 
normalised to Area Under Curve values in positive-control wells, with 1:1000 BSA dissolved 
in PSS as the first addition and veratridine (100 µM) as the second addition. The dotted line 
at 100% indicates the positive-control response. 
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Figure 2.2 Haplopelma hainanum and Euathlus venoms elicited a large inhibition in 
veratridine-induced hNaV1.6 activity 
Crude venom or the control solution was used as the first addition, with veratridine (100 µM) 
used as the second addition. A) Crude H. hainanum venom reduced veratridine-induced 
membrane potential increase by 85% compared to control cells. B) Crude Euathlus venom 
reduced veratridine-induced membrane potential increase by 91% compared to control cells. 
All traces were normalised to baseline fluorescence readings before the second addition. All 
percentages were calculated as Area Under Curve values compared to responses by positive-
control wells. Control solution (1:1000 BSA dissolved in PSS) was added as the first addition 
and veratridine (100 µM) was added as the second addition in positive-control cells. All 
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traces were normalised to baseline fluorescence readings before the second addition. The X 
axis indicates time (in seconds) after the first addition. 
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2.4.2 H. hainanum fractionation and the biological activity of fractions 
Crude H. hainanum venom (1 mg) was fractionated using a C18 HPLC column, and the 
HPLC trace was matched against the biological activity of the fractions in hNaV1.6-
expressing HEK293 cells (Figure 2.3 A). A total of 70 fractions were tested. An equivalent of 
50 µg of crude venom were used in cell experiments. Fraction 24 was found to have the 
inhibitory effect towards veratridine-induced membrane potential increases. Fraction 24 
reduced 87% of the veratridine-induced response (measured as Area Under Curve) compared 
to positive-control cells (Figure 2.3 B). 
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Figure 2.3 Biological activity of H. hainanum fractions on hNaV1.6 channels 
A) The HPLC absorbance and the HPLC solvent B concentration over time were plotted on 
the same graph. The peak that eluted at minute 22 was associated with potent inhibitory 
activity in hNaV1.6-expressing HEK293 cells. The peak eluted at 13% B concentration on the 
HPLC column. The blue line indicates HPLC absorbance values, measured in milli Arbitrary 
Units (mAU) at the left Y axis. The red dotted line indicates the concentration of Solvent B 
up to a maximum of 100% at the right Y axis. B) Sample trace of the inhibitory effect of H. 
hainanum venom Fraction 24 when applied to hNaV1.6-expressing HEK293 cells. Fraction 
24 reduced veratradine-induced activation by 87% compared to that observed in control 
wells. Reconstituted venom fraction or control solution were used as the first addition, and 
veratridine (100 µM) was used as the second addition. All percentages were calculated as 
61 
 
Area Under Curve values compared to responses by positive-control wells. Control solution 
(1:1000 BSA dissolved in PSS) was added as the first addition and veratridine (100 µM) was 
added as the second addition in positive-control cells. All traces were normalised to baseline 
fluorescence readings before the second addition. The X axis indicates time (in seconds) after 
the first addition. 
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2.4.3 Fraction 24 of H. hainanum crude venom was dominated by a monoisotopic oxidised 
mass of 3604.062 Daltons 
Matrix-assisted laser desorption/ionisation (MALDI) was conducted on H. hainanum venom 
Fraction 24. Fraction 24 was found to contain a dominant peak with a monoisotopic mass of 
3605.062 Da, which fell into the range of potential spider-venom derived polypeptide 
mass
214
. Due to the ionisation process involved in the MALDI procedure that results in 
charged peptides, the monoisotopic oxidised mass of the peptide would be one Dalton lower 
than that observed in MALDI, making the actual monoisotopic oxidised mass of the peptide 
3604.062 Da.  
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Figure 2.4 Fraction 24 from H. hainanum crude venom fractionation was dominated by 
a peak with an observed mass of 3605.062 Da, corresponding to a monoisotopic oxidised 
mass of 3604.062 Da, likely associated with the known TTX-s NaV inhibitor 
Hainantoxin-I  
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MALDI examination of Fraction 24 from the H. hainanum venom fractionation. A) MALDI 
analysis of Fraction 24 from the H. hainanum venom fractionation showed the fraction 
contains a dominant peak of 3605.062 Da. The left Y axis indicates the percentage of 
compounds present in the sample, normalised to the maximum level of the compound that is 
most abundant in the sample. The X axis was measured as mass (Da) divided by electrical 
charge (z). B) The ionisation process during MALDI adds one Dalton to the original mass of 
the peptide, resulting in an increase of one Dalton in the observed mass, corresponding to a 
monoisotopic oxidised mass of 3604.062 Da for the peptide. The left Y axis indicates the 
percentage of compounds present in the sample, normalised to the maximum level of the 
compound that is most abundant in the sample. The X axis was measured as mass (Da) 
divided by electrical charge (z). 
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Mass comparison with other known venom peptides was conducted using the ArachnoServer 
Database
217
. The observed monoisotopic oxidised mass in H. hainanaum (3604.062 Daltons) 
was found to be only 1.6 Dalton lower than the monoisotopic oxidised mass of Hainantoxin-I 
(3605.620 Daltons), a toxin with known inhibition of TTX-s NaV channels
218
 already 
characterised from the venom of H. hainanum. Due to the likelihood of having purified this 
known peptide from H. hainanum venom, I decided to investigate to the activity of crude 
venoms in the hNaV1.8 isoform as well and explore for potential NaV1.8 modulators. 
 
2.4.4 Screening of crude spider and scorpion venoms on CHO cells expressing hNaV1.8 
channels 
The same species of scorpion and tarantula spider crude venoms previously covered in 
Section 2.4.2 were tested in cell-based high-throughput assays via the FLIPR
TETRA
 system, 
using CHO cells expressing hNaV1.8 and the β3 subunit. Deltamethrin (150 µM) was used as 
the second addition. 
 
H. gentili was the only scorpion venom that exhibited agonistic activity when applied to 
hNaV1.8-expressing CHO cells (Figure 2.5 A-F). The five other scorpion crude venoms tested 
exhibited a reduction in membrane potential when added into the cells, in contrast to the 
agonistic activity observed towards hNaV1.6. Potentiation of deltamethrin-induced membrane 
potential elevation was also absent for all scorpion venoms (Figure 2.5 G), which indicate a 
distinct difference between the actions of the tested scorpion venoms on hNaV1.6 and 
hNaV1.8. 
 
None of the 18 spider crude venoms tested exhibited excitatory properties towards hNaV1.8, 
and all exhibited inhibitory activity (Figure 2.5 G, for traces from all venoms see Appendix 
3.2). Poecilotheria metallica crude venom was found to exhibit the most potent inhibitory 
activity towards hNaV1.8-expressing CHO cells, with 97% inhibition of deltamethrin-induced 
membrane potential elevation compared to control wells (Figure 2.5 G, grey bar; Figure 2.6 
A). Two other species that exhibited potent inhibitory activity comparable to P. metallica was 
Poecilotheria ornata and Poecilotheria regalis. Cells affected by P. ornata and P. regalis 
venoms reduced  membrane potential elevation by 97% and 94% respectively (Figure 2.6 B-
C). P. metallica crude venom exhibited the most potent inhibitory activity (equal potency to 
P. ornata), however it was evident that P. ornata did not completely inhibit deltamethrin-
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induced response and a small peak was still observed following deltamethrin addition (Figure 
2.6 B). Venom from P. metallica was therefore chosen as a source of potential hNaV1.8 
inhibitory peptides for further investigation. 
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Figure 2.5 Effect of scorpion and spider venoms in hNaV1.8-expressing CHO cells 
None of the samples tested exhibited potentiation of hNaV1.8 responses. A-F) In contrast to 
the excitatory effect of scorpion crude venoms observed in hNaV1.6 channels, the scorpion 
venom samples did not exhibit excitatory effects towards the hNaV1.8 isoform. Only the 
venom from H. gentili exhibited agonistic activity when added to the cells. All other scorpion 
venom samples exhibited a reduction in membrane potential when added. Traces were 
normalised to baseline fluorescence readings before the first addition. The X axis indicates 
time (in seconds) after the first addition. G) Effect of crude venoms on deltamethrin-induced 
NaV1.8 responses. All venom samples tested exhibited inhibitory activity towards 
deltamethrin-induced membrane potential elevation of the hNaV1.8 channel. The samples 
with the highest inhibitory activity were venoms from Poecilotheria metallica, Poecilotheria 
ornata, and Poecilotheria regalis. P. metallica venom value was coloured grey in panel G 
and was chosen for further studies. Traces were normalised to baseline fluorescence readings 
before the second addition. All responses were normalised to Area Under Curve values in 
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positive-control wells, with 1:1000 BSA dissolved in PSS as the first addition and 
deltamethrin (150 µM) as the second addition. The dotted line at 100% indicates the positive-
control response. 
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Figure 2.6 Venoms from Poecilotheria metallica, Poecilotheria ornata, and Poecilotheria 
regalis exhibited the highest inhibitory effects in CHO cells expressing hNaV1.8 channels 
Crude venom or the control solution was added into the cells as the first addition. 
Deltamethrin, a known NaV1.8 activator, was added as the second addition. A) Crude P. 
metallica venom reduced deltamethrin-induced membrane potential increase in hNaV1.8-
expressing CHO cells by 97%. B) Crude P. ornata venom reduced deltamethrin-induced 
membrane potential increase in hNaV1.8-expressing CHO cells by 97%. C) Crude P. regalis 
venom reduced deltamethrin-induced membrane potential increase in hNaV1.8-expressing 
CHO cells by 94%. All percentages were calculated as Area Under Curve values compared to 
responses by positive-control wells. Control solution (1:1000 BSA dissolved in PSS) was 
added as the first addition and deltamethrin (150 µM) was added as the second addition in 
positive-control cells. All traces were normalised to baseline fluorescence readings before the 
second addition. The X axis indicates time (in seconds) after the first addition. 
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2.4.5 P. metallica venom fractionation and the biological activity of fractions 
Crude P. metallica venom (1 mg) was fractionated using a C18 HPLC column, and the 
biological activity of the resultant fractions were tested on hNaV1.8-expressing CHO cells. 
An equivalent of 50 µg of crude venom were used in cell experiments. Fraction 40 was 
observed to exhibit inhibition of deltamethrin-induced hNaV1.8 activation. This fraction 
elutes at 35% Solvent B concentration and is associated with a peak in the chromatogram 
(Figure 2.7 A). Cells incubated with Fraction 40 exhibited a reduction in response, inhibiting 
deltamethrin-induced activation by 68% (measured as Area Under Curve) compared to 
positive-control cells (Figure 2.7 B). 
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Figure 2.7 Biological activity of P. metallica fractions 
Inhibitory activity of deltamethrin-induced hNaV1.8 activation was found in Fraction 40 of 
the P. metallica venom. A) The HPLC absorbance and the HPLC Solvent B concentration 
were plotted with each other. The most potent inhibitory activity towards deltamethrin-
induced activation in hNaV1.8-expressing CHO cells was found in Fraction 40, which was 
associated with a peak in the chromatogram as indicated by the black arrow. This fraction 
eluted at 35% Solvent B concentration. The blue line indicates HPLC absorbance values, 
measured in milli Arbitrary Units (mAU) at the left Y axis. The red dotted line indicates the 
concentration of Solvent B up to a maximum of 100% at the right Y axis. B) Sample trace of 
the inhibitory effect of Fraction 40 from P. metallica venom when applied to hNaV1.8-
expressing CHO cells in membrane potential assays. The fraction inhibited deltamethrin-
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induced activation by 68% compared to membrane potential changes observed in control 
wells. Reconstituted venom fraction or control solution was used as the first addition, and 
deltamethrin was used as the second addition. All percentages were calculated as Area Under 
Curve values compared to responses by positive-control wells. Control solution (1:1000 BSA 
dissolved in PSS) was added as the first addition and deltamethrin (150 µM) was added as the 
second addition in positive-control cells. All traces were normalised to baseline fluorescence 
readings before the second addition. The X axis indicates time (in seconds) after the first 
addition. 
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2.4.6 Fraction 40 of P. metallica venom is dominated by a single mass of 3910.171 Da 
Fraction 40 was analysed for the presence of peptide masses using MALDI. Fraction 40 
presented with a dominant peak with a mass of 3911.171 Da (Figure 2.8 A and B). A smaller 
peak with a mass of 1955.992 Dalton was also observed in the sample (Figure 2.8 C). As the 
MALDI assay detects the mass of the peptide as mass divided by electric charge, the 
1955.992 Dalton peak would be a double-charged variant of the dominant peak. Indeed, the 
mass of the smaller peaks within the single-charged peak with 3911.171 Da increased 
stepwise by one Dalton per peak, due to the increase in the number of deuterium atoms by 
one per peak. In contrast, the mass of the smaller peaks within the peak with 1955.992 Da 
increased stepwise by 0.5 Dalton per peak, consistent with a doubly charged ion. The 
monoisotopic oxidised mass of the peptide observed is therefore 3910.171 Da. 
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Figure 2.8 Fraction 40 was dominated by a peak with a monoisotopic oxidised mass of 
3910.171 Da 
MALDI analysis of Fraction 40 from P. metallica was conducted. A) MALDI analysis of 
Fraction 40 was dominated by a peak of 3911.171 Da. A smaller peak with half the intensity 
of the dominant peak, and with a mass that is half of the mass seen for the dominant peak, 
was also found in the sample. The left Y axis indicates the percentage of compounds present 
in the sample, normalised to the maximum level of the compound that is most abundant in the 
sample. The X axis was measured as mass (Da) divided by electrical charge (z). B) Increased 
zoom on the peak at 3911.171 Da show stepwise increase of mass by one Dalton per peak for 
the smaller peaks. The ionisation process of MALDI adds one Dalton to the original mass of 
the peptide, indicating the true monoisotopic oxidised mass of the peptide to be 3910.171 Da. 
The left Y axis indicates the percentage of compounds present in the sample, normalised to 
the maximum level of the compound that is most abundant in the sample. The X axis was 
measured as mass (Da) divided by electrical charge (z). C) Increased zoom on the peak at 
1955.992 Da show stepwise increase of mass by 0.5 Dalton per peak for the smaller peaks, 
indicating that while the number of deuterium increases by one per peak, the peptide has a 
charge of two and is a double-charged variant of the dominant mass. The left Y axis indicates 
the percentage of compounds present in the sample, normalised to the maximum level of the 
compound that is most abundant in the sample. The X axis was measured as mass (Da) 
divided by electrical charge (z). 
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2.4.7 A novel peptide, Pme1a, was isolated in P. metallica venom 
Fraction 40 from the P. metallica venom was subjected to Edman sequencing to elucidate the 
sequence of the peptide present in the fraction. A novel peptide, named Pme1a, was found to 
be present in the fraction.  
 
The complete sequence for the peptide was finalised using tandem mass spectrometry 
(MS/MS). The novel peptide was successfully recovered in sufficient amounts following 
MS/MS. It was isolated with high purity (>90%) and was named Pme1a. The mass of Pme1a 
is determined to be 3910.268 Da, confirming that the mass observed in the Fraction 40 in the 
MALDI analyses was indeed that of Pme1a.  
 
Sequence comparison was conducted using the ArachnoServer Database
217
 and the sequence 
of Pme1a was found to be related to the vanillotoxin family (Figure 2.9 A). The vanillotoxin 
with the highest similarity to Pme1a is vanillotoxin 2 (80% similarity), followed by 
vanillotoxin 1 (72% similarity). Both vanillotoxins have known agonistic activity towards 
TRPV1 channels
219
, and produce inflammatory pain when injected into wild type mice. The 
sequence of Pme1a is also similar to jingzhaotoxins, a family of tarantula spiders peptides 
with known inhibitory activity towards NaV and KV channels
220, 221
. However, the 
jingzhaotoxins found to be similar to Pme1a were not characterised pharmacologically and 
their functions and molecular targets remain unknown (72% similarity with jingzhaotoxin-37; 
66% similarity with jingzhaotoxin-36; 66% similarity with jingzhaotoxin-29). The isolated 
peptide was tested using MALDI to check for peptide mass, and showed the same single-
charged and double-charged peaks that were observed in Fraction 40 (Figure 2.9 B). 
Increased zoom into the MALDI data indicate the mass of the peptide to be 3910.298 (Figure 
2.9 C) and confirms the purified peptide to be that of the mass found in Fraction 40. 
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Figure 2.9 Isolation and sequencing of Pme1a 
One novel peptide was isolated from Fraction 40 of the P. metallica venom. The peptide was 
named Pme1a. A) The structural similarity of Pme1a to known peptides was compared using 
BLAST analysis. Pme1a was found to be most similar to vanillotoxin 2 and vanillotoxin 1, 
two peptides with known TRPV1 agonistic activity, followed by three uncharacterised 
venoms from the jingzhaotoxin family. Cysteine residues are aligned within red boxes. 
Hydrophobic amino acid residues are highlighted in yellow. Positively charged amino acid 
residues are highlighted in fuchsia. Negatively charged amino acid residues are highlighted in 
green. B) MALDI analysis of the purified and sequenced peptide. The sample exhibited the 
same peaks as that observed in Fraction 40, with a main peak exhibiting 3911.298 Da and a 
double-charged peak with 1957.113 Da. The left Y axis indicates the percentage of 
compounds present in the sample, normalised to the maximum level of the compound that is 
most abundant in the sample. The X axis was measured as mass (Da) divided by electrical 
charge (z). C) Increased zoom on the main peak show the monoisotopic mass of the peptide 
was 3911.298. The ionisation process of the MALDI method adds one Dalton to the original 
mass of the peptide, indicating the true monoisotopic oxidised mass of the peptide to be 
3910.298 Da. This is identical to the mass found in Fraction 40. The left Y axis indicates the 
percentage of compounds present in the sample, normalised to the maximum level of the 
compound that is most abundant in the sample. The X axis was measured as mass (Da) 
divided by electrical charge (z).  
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2.4.8 Pme1a was found to inhibit NaV1.8 with an IC50 of 3 µM 
The concentration-response curve between the concentration of purified (> 90%) Pme1a 
added to hNaV1.8-expressing CHO cells and the membrane potential elevation response was 
established to determine the potency of Pme1a. Cells were incubated with various 
concentrations of Pme1a, ranging from 10 µM to 100 nM (Figure 2.10 A). Pme1a effectively 
reduced membrane potential elevation elicited by deltamethrin (150 µM) throughout the 
range of concentrations tested. The IC50 of Pme1a for NaV1.8 was determined to be 3 µM. 
 
Representative traces of membrane potential assays following incubation with various 
concentrations of Pme1a indicate that the peptide reduced the membrane potential elevations 
elicited by deltamethrin in a concentration-dependent manner (Figure 2.10 B). The venom did 
not delay the initiation of deltamethrin-induced membrane potential elevations, suggesting 
Pme1a may not affect hNaV1.8 activation kinetics (Figure 2.10 B). 
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Figure 2.10 Purified Pme1a was found to inhibit NaV1.8 with an IC50 of 3 µM 
Purified Pme1a inhibited deltamethrin-induced membrane potential elevations in hNaV1.8-
expressing CHO cells in a concentration-dependent manner, with an IC50 of 3 µM. A) 
Purified Pme1a was tested in hNaV1.8-expressing CHO cells at concentrations between 10 
µM and 100 nM, and exhibited inhibitory activity throughout the range tested. The IC50 for 
NaV1.8 was determined to be 3 µM. Data was normalised to the average of maximum Area 
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Under Curve values from positive control wells. All points were from an average of at least 3 
individual experiments. Error bars were represented as ± SEM. B) Representative traces of 
deltamethrin-induced membrane potential changes following incubation with various 
concentrations of Pme1a. Increased Pme1a concentration is linked to a concentration-
dependent reduction of the Area Under Curve value elicited by deltamethrin. Increased 
Pme1a concentration did not delay the time taken to initiate deltamethrin-induced membrane 
potential responses of hNaV1.8-expressing CHO cells. Each trace was representative of at 
least 9 wells over at least 3 individual experiments. Reconstituted peptide or control solution 
was used as the first addition, and deltamethrin was used as the second addition. Control 
solution (1:1000 BSA dissolved in PSS) was added as the first addition and deltamethrin (150 
µM) was added as the second addition in positive-control cells. All traces were normalised to 
baseline fluorescence readings before the second addition. The X axis indicates time (in 
seconds) after the first addition. 
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2.4.9 Pme1a exhibits agonistic activity towards TRPV1 and induces nociceptive behaviours 
in mild-type mice 
Pme1a was tested on TRPV1-expressing HEK293 cells following the discovery that Pme1a 
shares sequence similarities with vanillotoxins, a group of peptides with known agonistic 
activity towards the TRPV1 channel (Figure 2.11 A). Consistent with the structural 
similarities observed between Pme1a and vanillotoxins, Pme1a was found to exhibit TRPV1 
agonist activity at 30 µM. While Pme1a possesses low potency as a TRPV1 agonist, it is not 
a selective NaV1.8 inhibitor and exhibits off-target activity towards TRPV1. 
 
As the activation of TRPV1 by vanillotoxin is associated with spontaneous pain
219
, the 
physiological effects of Pme1a was therefore suspected to be nociceptive rather than anti-
nociceptive, contrary to what may be expected for a selective NaV1.8 inhibitor. Pme1a was 
injected locally into the hind paws of wild type C57BL/6 mice at the IC50 concentration (3 
µM) observed in membrane potential assays. Mice injected with Pme1a exhibited 
significantly more spontaneous nociceptive behaviours such as licking and lifting of the 
injected hind paw, and the effect of Pme1a peripheral administration was nociceptive instead 
of analgesic (Figure 2.11 B).  
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Figure 2.11 Pme1a has TRPV1 agonist activity and elicits nociceptive behaviours in 
mice 
Pme1a was tested in TRPV1-expressing HEK293 cells and in wild-type animals. A) Pme1a 
was tested in TRPV1-expressing HEK293 cells and elicited calcium influx responses at 30 
µM. The known TRPV1 agonist, capsaicin, was used as the positive control. All data points 
were normalised to baseline Area Under Curve values in negative control wells. All data 
points were the mean values from at least 3 experiments. Error bars are shown as ± SEM. B) 
Peripheral injection of Pme1a into the hind paws of mice elicited significantly more 
nocifensive spontaneous responses, such as flicking and licking of the injected paw, 
compared to control animals injected with the control solution. Each animal was observed for 
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10 minutes following the injection of Pme1a or control solution, and all nocifensive 
responses during the observation period was recorded. Pme1a was freeze-dried and 
reconstituted in PSS with 1:1000 BSA. Control solution injected into the control cohort 
consisted of PSS with 1:1000 BSA. All animal groups were allocated with n = 3. * P-value < 
0.05. Error bars are shown as ± SEM. 
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2.5 Discussion 
This chapter describes activity-guided isolation of a novel peptide from the crude venom of 
the tarantula spider species Poecilotheria metallica. The novel peptide, named Pme1a, 
exhibits hNaV1.8-inhibitory activity and activates TRPV1. Pme1a is a 35-amino-acid long 
peptide with 6 cysteine residues, and is the first peptide to be isolated from the venom of 
Poecilotheria metallica. Compared to A-803467, the small molecule currently used 
experimentally to inhibit NaV1.8, Pme1a exhibits weak potency as a NaV1.8 inhibitor (IC50 = 
3 µM). Surprisingly, instead of exhibiting structural similarities with other NaV-inhibitory 
spider peptides, the structure of Pme1a was related closely to vanillotoxins, a class of spider 
peptides associated with TRPV1 channel opening, leading to my examination of Pme1a in 
TRPV1 channels. 
 
Vanillotoxins, a class of toxins isolated from the tarantula Psalmopoeus cambridgei, was 
discovered via screening of spider and scorpion toxins for agonistic activity towards the 
capsaicin-sensitive TPRV1 channel
219
. Three vanillotoxins (VaTx) with varying potencies as 
TRPV1 agonists were discovered within the crude venom of P. cambridgei. Out of the three 
vanillotoxins, VaTx3 was the most potent TRPV1 activator (EC50 = 0.45 ± 0.04 µM), 
followed by VaTx2 (EC50 = 1.35 ± 0.15 µM) and VaTx1 (EC50 = 9.9 ± 0.97 µM). All 
vanillotoxins belong to the inhibitory cysteine knot (ICK) family of peptides, which includes 
spider toxins as well as scorpion, cone snail, and fungal toxins
222
. Many ICK proteins exhibit 
some form of protein inhibition, such as plant protease inhibitors and various cone snail and 
spider peptides
222-224
. On a three-dimensional scale, the ICK motif consists of three anti-
parallel β-sheets held together via a highly stable cysteine knot222, which is constructed with 
two disulphide bonds forming a ring and connected vertically by a third disulphide bond
223
. 
The ICK motif was first described due to the discovery of this three-dimensional cysteine 
structure in growth factors
225
. Its presence in spider and scorpion venoms have now become a 
classification distinct from the cysteine knots in animal, plant, or fungal proteins
222
. ICK 
toxins are now recognised as common inhibitors and activators of cationic channels, and are 
found in many spider and scorpion venom peptides. 
 
The two-dimensional structure of peptides that exhibit the ICK motif also contain properties 
that apply to vanillotoxins as well as Pme1a. A typical spider toxin with the ICK motif 
contains 30 to 40 amino acids and at least 6 cysteine residues
224
. The two-dimensional 
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sequence for such toxins are observed to follow a pattern with various numbers of other 
amino acids interspersed between the six cysteine residues, arranged in the following 
configuration: CX(3~7)CX(3~8)CX(0~7)CX(1~4)CX(4~13)C
223
. Both the vanillotoxins and 
Pme1a fit into this molecular arrangement. In particular, vanillotoxins exhibit a hyper-
variable β-loop protruding out of the cysteine loop, which is observed two-dimensionally as 
the six amino acid residues between C5 and C6
219
. Pme1a, VaTx1, and VaTx2 are identical at 
five of the six residues between C5 and C6 (Figure 2.10 A)
219
. However, VaTx3, the 
vanillotoxin that is most potent as a TRPV1 channel agonist, exhibited significant deviations 
from the amino acids present in this section compared to the other two vanillotoxins
219
. This 
section is considered to be crucial in the effect of vanillotoxins on TRPV1
219
, which could 
explain the differences in potency between VaTx3 and the other two vanillotoxins, rendering 
VaTx1 and VaTx2 less potent TRPV1 agonists. The similarities observed in this section 
between Pme1a and the vanillotoxins could be the reason behind the off-target activity of 
Pme1a at TRPV1. It is however unknown whether vanillotoxins affect the NaV1.8 channel, as 
the toxins have not been tested for activity in NaV isoforms. 
 
Injection of vanillotoxins into the hind paws of wild-type mice elicited nociceptive 
behaviours such as licking and flinching of the foot, much like that observed after injection of 
capsaicin, a known potent TRPV1 activator
219
. However, apart from agonistic activities at 
TRPV1 channels, vanillotoxins also exhibit inhibitory activities towards the KV2.1 
channel
219
, which is responsible for inhibitory repolarisations in sensory neurons. 
Interestingly, the inhibitory activity of vanillotoxin at KV2.1 channels is inversely related to 
the potency of individual vanillotoxins as TRPV1 agonists. VaTx1, the least potent TRPV1 
activator, was the most potent inhibitor of KV2.1, with VaTx1 exhibiting similar EC50 values 
for TRPV1 activation (EC50 = 9.9 ± 0.97 µM) and KV2.1 inhibition (IC50 = 7.4 ± 1.9 µM). 
VaTx2, the second-most potent TRPV1 activator, inhibited KV2.1 at IC50 values seven-fold 
higher than its EC50 value for TRPV1. The most potent TRPV1 activator from the family, 
VaTx3, exhibited very little KV2.1 inhibition even at concentrations 100-fold higher than its 
EC50 as a TRPV1 activator
219
. Pme1a exhibits high structural similarity with VaTx1 and 
VaTx2, but low similarities with VaTx3. Therefore, while it is possible that the nociceptive 
effects of Pme1a observed in animals is from TRPV1 activation, it is also plausible that 
Pme1a exhibits inhibitory activities in KV channels, a dual function that may also apply to 
vanillotoxins. This possibility is further supported by the observation that Pme1a only 
activated TRPV1 in transfected cells at a concentration of 30 µM or higher, yet the injection 
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of 3 µM of Pme1a locally into mice elicited significant increase in nocifensive behaviours. 
Further examinations into the selectivity of Pme1a in other ion channel families would be 
needed before the peptide can be considered a potential pharmacological tool. 
 
Pme1a also may display off-target activity in NaV channels other than NaV1.8. While 
vanillotoxins have not been examined for their efficacy in NaV channels, crude venom from 
P. metallica was observed to exhibit inhibitory effects when added to hNaV1.6-expressing 
HEK293 cells (Figure 2.1 G). It is therefore probable that Pme1a also exhibits inhibitory 
effects towards hNaV1.6. Future studies should be conducted to investigate the activity of 
Pme1a in other NaV isoforms, however time and material constrictions during the candidature 
did not permit the completion of such experiments. 
 
The tarantula spider species, Haplopelma hainanum, produced the venom in which I found 
potent hNaV1.6 inhibition and is the source of a family of venom peptides, named 
hainantoxins. The spider species H. hainanum, firstly described as Selenocosmia hainana, 
yielded 5 characterised hainantoxins and more than 190 venom peptides sequences
226
. All 
five characterised hainantoxins are known to inhibit select NaV isoforms, and exhibit the ICK 
motif seen in Pme1a and vanillotoxins
218
. While all members of the hainantoxin family have 
been characterised on NaV1.1, NaV1.2, NaV1.4, NaV1.5, and NaV1.7 channels, there have 
been limited exploration to the effect of the toxins in other NaV isoforms and other ion 
channels families. Hainantoxin-I, initially described as an inhibitor of NaV channels, was 
discovered to be ineffective in CaV channels and activates calcium-activated potassium (KCA) 
channels
218, 227
. Meanwhile hainantoxin-II, a toxin known to cause paralysis and death when 
injected into cockroaches and mice, has not been pharmacologically characterised and its 
neuronal target remains unknown
228
. Hainantoxin-V, the hainantoxin discovered most 
recently, has also not been characterised in detail, and is simply known to inhibit TTX-s NaV 
channels without altering the channels' activation kinetics
229
.  
 
More information is available for hainantoxin-III and hainantoxin-IV, the other two members 
of the family. However, a complete analysis of their effects in NaV channels, let alone in 
other ion channel families, has not been conducted. Hainantoxin-III is a potent TTX-s NaV 
inhibitor (IC50 = 1.1 nM)
230
 with no effect in TTX-r NaV channels
231
. The toxin 
preferentially inhibits rat NaV1.7 and also inhibits NaV1.1, 1.2, and 1.3 to a smaller degree. 
However, its efficacy at NaV1.6 was not examined
230
. Similarly, hainantoxin-IV was found to 
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inhibit TTX-s rat NaV isoforms
231
 and was shown to inhibit NaV1.1, 1.2, and 1.7, while 
having no effect over NaV1.4 and 1.5
232
. The efficacy of hainantoxin-IV in other TTX-s rat 
NaV isoforms, such as NaV1.3 and NaV1.6, were not tested. The binding site and the binding 
surface of hainantoxins is also poorly defined, with some suggesting hainantoxin-I may bind 
to binding site 1 on NaV channels
233
, while evidence based on kinetics changes following 
exposure to hainantoxin-IV indicate binding via other sites that regulate inactivation 
kinetics
232
. More characterisation would need to be conducted regarding hainantoxins before 
the properties and molecular targets of this family can be defined. 
 
Future studies concerning Pme1a would also need to be carried out before a full 
understanding of the novel peptide’s properties can be reached. It would be of interest to 
investigate the effect of Pme1a on other NaV isoforms, and also to examine whether it affects 
activation or inactivation kinetics of NaV1.8. Given the similarities between the structure of 
Pme1a and that of vanillotoxins, and the known activity of vanillotoxins at KV channels, it 
would also be insightful to explore the effect of Pme1a in KV channel isoforms to fully 
comprehend the physiological effects of this novel peptide. 
 
2.6 Conclusions 
Spider venoms offer a treasure of unexplored neurotoxins, many of which have the potential 
to become powerful tools in pharmacological studies as ion channel inhibitors. This chapter 
presents an exploration into spider venoms in search of potential NaV1.6 and NaV1.8 selective 
inhibitors, as the existing options are either not selective or do not corroborate well with 
knockout or gene mutation data. While a novel spider peptide, named Pme1a, was 
successfully isolated with promising inhibitory activity towards NaV1.8, sequence homology 
with known activators of the TRPV1 channel indicated off-target activity. Injection of Pme1a 
into wild-type mice resulted in nocifensive rather than analgesic behaviour, highlighting the 
time-consuming and unpredictable nature of isolating novel peptides from crude venoms in 
search of NaV modulators. I therefore investigated other models that can be used to better 
study the role of NaV1.6 and NaV1.8 channels in sensory neurons, such as in vitro cell models 
that have been employed commonly as a substitute for native in vivo DRG sensory neurons. 
To better assess the appropriateness of these models as tools to investigate peripheral neurons 
expressing NaV isoforms, I conducted bioinformatics analysis of three common in vitro cell 
lines derived from DRG neurons, to be presented in the next chapter. 
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Chapter 3 - Neuronal cell lines as model dorsal root ganglion 
neurons: a transcriptomic comparison 
 
3.1 Foreword 
Specific channel modulators, discovered through activity-guided purification and isolation, 
are good tools to study the contribution of specific ion channels in the pain mechanism of 
various conditions, and may lead towards the development of new analgesics. However, 
Chapter 2 described the unexpected difficulty of that approach due to off-target activity. One 
of the alternative tools to investigate the roles of NaV1.6 and NaV1.8 in nociceptive neurons 
and to screen for selective modulators would be to use in vitro DRG neuron-derived cell 
models, which have been used for research in lieu of native DRG neurons. A remaining 
challenge is that the gene expression of the cell lines have not been thoroughly classified and 
have not been compared to known subtypes of in vivo DRG neurons. I therefore examined the 
expression profile of three common in vitro cell lines, that of SH-SY5Y, F-11, and ND7/23 
cells. A bioinformatics analysis was conducted, as well as comparison between the 
transcriptome of these cell lines with native sensory neuron subtypes, particularly regarding 
markers known to be expressed in specific neuronal subtypes. I set out to explore how 
appropriate these cell lines would be as tools to study the function of various sensory neuron 
subtypes, and whether they could be used to profile and discover novel modulators of NaV1.6 
and NaV1.8. 
 
Data presented in this chapter have been published in Molecular Pain
234
. Compared to the 
publication, the contents have been modified and adopted to fit the flow and format of the 
thesis. 
 
I would like to thank Dr. Gregory J Baillie from the Institute for Molecular Bioscience 
Sequencing Facility for his assistance with bioinformatics sequencing and alignment.  
 
3.2 Introduction 
As outlined in Chapter 1, Section 1.2.1, utilising bioinformatics methods to associate specific 
DRG neuron functional subclasses with unique cellular markers and expression profiles is an 
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increasingly common research method. It is generally accepted that many specific proteins do 
indeed denote specific functional neuron subclasses, with examples including the transient 
receptor potential vanilloid 1channels (TRPV1) serving as an indication of capsaicin-and-
heat-sensitive DRG neurons
48, 235
, or the CaV isoform CaV3.3 working as a selective marker 
for C-low-threshold mechanosensitive receptors (C-LTMR)
115
. Further studies have divided 
neurons present in whole DRGs into as many as 17 different subclasses based on combined 
expression and electrophysiological data
36
, illustrating the molecular differences between 
neurons with varied sensitivity to different stimuli, and the need to separate desired DRG 
subclasses when investigating the effect of compounds in peripheral neurons. 
 
However, while primary DRG neurons are used extensively to study the pharmacological 
mechanisms involved in sensory neuron functions such as pain and itch, this approach has 
several drawbacks. The isolation and culture of DRG neurons is time-consuming, highly 
technical, and requires the use of animals. Importantly, not all neurons survive this process
236
. 
Removal of DRG neurons from the in vivo environment and axotomy of the peripheral 
processes also lead to adaptive changes such as down-regulation of the potassium channel 
subunit KV9.1, over-expression of the nerve growth factor receptor tropomyosin receptor 
kinase A (TrkA), and increased neuronal excitability
237-240
 . In addition, as DRG neurons are 
heterogeneous, only a subset of cells is likely to express the target of interest, and a 
substantial proportion of cultured cells include non-neuronal cell types such as fibroblasts and 
glial cells. 
 
Accordingly, researchers have turned to DRG-derived immortal cell lines as substitutes for 
intact DRG neurons when investigating endogenous receptors. Common candidates are the 
DRG-hybridoma cell lines F-11 and ND7/23, which were derived from embryonic or 
neonatal rat DRG neurons by fusion with the mouse neuroblastoma cell line N18Tg2
241, 242
 
and display neuron-like properties including excitable membranes and sensory neuronal cell 
surface markers. Similarly, it was shown that the neuroblastoma cell line SH-SY5Y, which is 
commonly used as a model of adrenergic or dopaminergic neurons, exhibits traits of 
peripheral sensory neurons such as functional expression of the sensory neuron-specific 
sodium channel isoform NaV1.7
243
.  However, although these cell lines are often considered 
suitable models to study mechanisms of nociceptor activation, and individual investigations 
of specific protein families have been conducted
243-245
, a systematic analysis of the expression 
profile of these cell lines in comparison with DRG neurons is lacking. 
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Therefore, RNA-Seq analysis with particular emphasis on ion channel and G protein-coupled 
receptor (GPCR) expression in DRG neuron-derived cell lines including the human 
neuroblastoma cells SH-SY5Y
246, 247
, the mouse neuroblastoma/rat embryonic DRG neuron 
hybrid cell line F-11
242
, and the mouse neuroblastoma/rat neonatal DRG neuron hybrid cell 
line ND7/23
241
, was conducted and presented in this chapter. Data from cell lines were 
compared to RNA-Seq analysis conducted on whole murine DRGs. Functional expression of 
select targets was confirmed by Ca
2+
 imaging. 
 
3.3 Materials and Methods 
3.3.1. Materials 
All materials were obtained from Sigma-Aldrich (Castle Hill, New South Wales, Australia) 
unless otherwise stated. Oxytocin and vasopressin were a kind gift from Professor Paul 
Alewood (Institute for Molecular Bioscience, University of Queensland). Capsaicin stock 
solution was prepared in ethanol and stored at -80 ˚C. Maximum final ethanol concentration 
from capsaicin stock did not exceed 0.001%. Menthol, AITC (allyl isothiocyanate), 
vasopressin, and oxytoxin stock solutions were prepared in DPBS (Dulbecco’s Phosphate 
Buffered Saline, Life Technologies, Mulgrave, Victoria, Australia; for composition see 
Appendix 2.5) and stored at -4 ˚C. Calcium 4 No-Wash dye stock solution was reconstituted 
using 10 mL of PSS (for PSS composition see Appendix 2.1) per vial of powder, and stored 
at -20 ˚C for up to 3 months. 
 
3.3.2 Animals 
Male wild-type C57BL/6 mice age 6-8 weeks and weighing 20 - 23 grams were used in the 
study. Ethical approval for experiments involving animal tissues was obtained from the 
University of Queensland animal ethics committee under the ethics approval number 
TRI/IMB/091/14/NHMRC. Experiments were conducted in accordance with the Animal Care 
and Protection Regulation Queensland (2012), the Australian Code of Practice for the Care 
and Use of Animals for Scientific Purposes, 8
th
 edition (2013) and the International 
Association for the Study of Pain Guidelines for the Use of Animals in Research.  
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All animals were housed in groups of 2-4 per cage in a stable environment under 12 hour 
light-dark cycles and had access to standard rodent chow and water ad libitum. A red 
polycarbonate Mouse House (Tecniplast, Italy) and shredded paper nesting material were 
supplied for enrichment. All animals were obtained from University of Queensland 
Biological Resources (Brisbane, Australia).  
 
3.3.3 Cell culture 
Human neuroblastoma SH-SY5Y cells (The European Collection of Cell Cultures) were 
grown in RPMI (Roswell Park Memorial Institute medium, Life Technologies, Mulgrave, 
Victoria, Australia; for composition see Appendix 2.8) with 15% FBS and 2 mM L-
glutamine.  
 
Mouse neuroblastoma/rat embryonic DRG neuron hybrid F-11 cells (The European 
Collection of Cell Cultures) were grown in Ham’s F12 media (Life Technologies, Mulgrave, 
Victoria, Australia; for composition see Appendix 2.3) with 10% FBS and 2% hypoxanthine-
aminopterin-thymidine (HAT) media supplement (50x) Hybri-Max
TM
 (for composition see 
Appendix 2.9). 
 
Mouse neuroblastoma/rat DRG neuron hybrid ND7/23 cells (The European Collection of 
Cell Cultures) were grown in DMEM (Life Technologies, Mulgrave, Victoria, Australia; for 
composition see Appendix 2.4) with 10% FBS, 2 mM L-glutamine, pyridoxine, and 110 
mg/ml sodium pyruvate. 
 
All three cell lines were incubated at 37°C and in 95% O2/5% CO2 air mixture. SH-SY5Y 
and ND7/23 cells were passaged every 3-5 days at a 1:5 dilution ratio or when approximately 
90% confluent. F-12 cells were passaged every 2-3 days at a 1:5 dilution ratio or when 
approximately 80% confluent. All cells were seeded in T75 cm
2
 Corning® (Corning, MA, 
USA) cell culture flasks. In order to passage cells, the cells were briefly removed from 
incubation and maintained in room temperature and growth media was removed from the 
flask. At least 5 mL/75 cm
2
 of DPBS was added into the flask to briefly wash the cells. The 
DPBS was then removed from the flask. 0 25% trypsin/EDTA (Life Technologies, Mulgrave, 
Victoria, Australia; for composition see Appendix 2.6) was then added at a concentration of 1 
mL/75 cm
2
, and the cells were dislodged by gently tapping the sides of the flask. The 
95 
 
dislodged cell suspension was diluted with a further 9 mL of the appropriate growth media 
(as mentioned above) and passaged according to aforementioned ratios in a new T75 cm
2
 
flask using new growth media. 
 
3.3.4 DRG extraction and dissociation 
Mice were sedated via inhalation of 50% O2/50% CO2 gas inhalation and euthanised via 
asphyxiation using 100% CO2, followed by cervical dislocation. The spine was immediately 
removed using surgical equipment, the dorsal side of the vertebra bones removed, and the 
tissue immersed in ice-cold DMEM. The spinal cord was then removed, and thoracic and 
lumbar DRGs (T6-L6 inclusive) were dissected with forceps under a dissection microscope 
and placed in fresh DMEM within a 35mm-diameter petri dish (Nunclon
TM
 Delta treated, 
Nunc, Denmark), followed by trimming of excess myelin. Dissected DRGs were then placed 
into fresh DMEM with 1 mg/mL collagenase and 0.5 mg/mL protease, and incubated at 37°C 
with 95% O2/5% CO2 for 45 minutes within a 15 mL conical centrifuge tube (Falcon
TM
, 
Corning, MA, USA) to allow for dissociation. Following incubation, the cell suspension was 
centrifuged at 20,000 rpm (revolutions per minute) for 3 minutes, and excess DMEM was 
removed. The cell pellet was then washed in approximately 2 mL of DPBS, centrifuged 
briefly, and excess DPBS was removed. Cell samples derived from the whole DRGs of 2 
mice were pooled together for RNA extraction. 
 
3.3.5 Cell dissociation and preparation 
Cells were brought up from frozen stocks and allowed to recover for at least 3-5 passages. 
RNA was extracted from SH-SY5Y cells at passage 29, from F-11 cells at passage 9, and 
from ND7/23 cells at passage 28. All cell lines were allowed to reach ~90% confluence in a 
T75 cm
2
 flask before harvesting. Cells were initially dissociated as described in Section 3.3.3 
with DPBS and 0.25% trypsin/EDTA. The dislodged cell suspension was diluted with a 
further 9 mL of the appropriate growth media, removed from the flask, and centrifuged at 
14,000 rpm for 5 minutes to form a pellet. Excess media was removed and the cell pellet was 
left intact for RNA extraction 
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3.3.6 RNA extraction 
RNA was extracted using the RNeasy Mini Kit (Qiagen, Melbourne, Australia) according to 
the manufacturer’s instructions, including on-column DNase digestion. Briefly, 600 µL of 
Buffer RLT (with 1% β-mercaptoethanol) were added to the cells, and the mixture was 
vortexed to disrupt the tissue and homogenise the lysate. The lysate was then centrifuged at 
full speed for 3 minutes and the supernatant removed, with an equivalent volume of 70% 
ethanol in Milli-Q water. Up to 700 µL of the mixture was centrifuged in a RNeasy spin 
column for 15 seconds at 8000 x g, and the flow-through was discarded. Samples in excess of 
700 µL were centrifuged in the same RNeasy spin column until all of the lysate have been 
centrifuged. Buffer RW1 (350 µL; Qiagen, Melbourne, Australia) was then added to the 
RNeasy spin column and centrifuged for 15 seconds at 8000 x g, and the flow-through was 
discarded. DNase I stock solution (Qiagen, Melbourne, Australia; for composition see 
Appendix 2.10) was added (10 µL) to 70 µL Buffer RDD (Qiagen, Melbourne, Australia) in a 
separate PCR tube (Corning, MA, USA). The two solutions were mixed by reverting the tube 
and centrifuged briefly, and the entirety of the mixture was applied to the RNeasy spin 
column membrane and left to incubate in room temperature for 15 minutes. At the end of the 
incubation, a further 350 µL of Buffer RW1 was added to the RNeasy spin column and 
centrifuged for 15 seconds at 8000 x g, and the flow-through was discarded. To wash the 
column, 500 µL of Buffer RPE (pre-diluted with 4 equivalent volumes of 100% ethanol; 
Qiagen, Melbourne, Australia) was added to the RNeasy spin column and centrifuged for 15 
seconds at 8000 x g, and the flow-through was discarded. This was followed by a further 
wash step with the addition of 500 µL of Buffer RPE (pre-diluted with 4 equivalent volumes 
of 100% ethanol) to the RNeasy spin column and centrifuged for 2 minutes at 8000 x g, and 
the flow-through was discarded. The RNeasy spin column was then removed from the 
collection tube and placed into a new 2 mL collection tube. 50 µL of RNAse-free water 
(Qiagen, Melbourne, Australia) was added to the column, and the column was centrifuged for 
1 minute at 8000 x g. The concentration of RNA in the final flow-through was determined 
using a NanoDrop Spectrophotometer (ND-1000, NanoDrop, DE, USA), with RNAse-free 
water as the negative control. 
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3.3.7 RNA-Seq and bioinformatics analysis 
Library construction and bioinformatics analysis were conducted by AGRF (the Australian 
Genome Research Facility, Melbourne, Australia), which determined the RNA Integrity 
Number (RIN) was above 8.5 for all samples. RNA-Seq was conducted on an Illumina Hiseq-
2000 machine as a 100-nucleotide single-end run, and primary .fastq data was generated with 
the CASAVA 1.8.2 pipeline (Illumina, CA, USA). Reads were screened for the presence of 
any adaptor or overrepresented sequences, ambiguous characters were clipped where 
required, and sequence bias was corrected. Alignment was performed with Tophat with 
default analysis parameters in single-end mode. The number of mismatches were restricted to 
no more than 2 bases. Reads from SH-SY5Y cells were mapped against the human genome 
(hg19), DRG reads were mapped against the mouse genome (mm9), and F-11 and ND7/23 
reads were mapped twice, against both the mouse genome (mm9) and rat genome (rn5). 
Transcripts assembly was performed by Cufflinks with the RABT (reference annotation-
based assembly) option
248
 using the UCSC (University of California, Santa Cruz) annotation, 
and multi-reads correction was used. Gene counts were then compiled using the HTSeq 
software
249
.  
 
3.3.8 Accession number and gene ontology (GO) analysis 
Raw bioinformatics data in the form of .fastq files and count tables generated with HTSeq are 
both available at the Gene Expression Omnibus database under the accession number 
GSE75811. Gene ontology (GO) analysis was conducted with the PANTHER database
250
 
with the Gene List Analysis tool
251
. Genes with >100 reads in each sample were compiled 
and submitted to Gene List Analysis and analysed according to Biological Processes (BP) 
terms. Genes from whole DRGs were assigned according to the Mus musculus genome, the 
SH-SY5Y sample was assigned to the Homo sapiens genome, and F-11 and ND7/23 samples 
were assigned to both Mus musculus and Rattus norvegicus genomes each. 
 
3.3.9 Transfection 
HEK293 cells (American Type Culture Collection, VA, USA) were routinely maintained in 
DMEM containing 10% FBS and 2 mM L-glutamine. Cells were split every 3-6 days in a 
ratio of 1:5 using 0.25% trypsin/EDTA. Cells were seeded on T75 cm
2
 (Nunc, Denmark) 
tissue culture flasks 24 hours prior to transfection and transfected with the plasmid DNA of 
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rat TRPV1 (D. Julius, Department of Physiology, University of California, Berkeley, CA, 
USA), mouse TRPA1 (A. Patapoutian, The Scripps Research Institute, La Jolla, CA, USA), 
rat TRPM8 (K. Zimmermann, Department of Anesthesiology, Friedrich-Alexander-
University, Erlangen-Nuremberg, Erlangen, Germany), human AVPR1B (arginine 
vasopressin receptor 1B; OriGene Technologies, MD, USA), or human oxytocin receptor 
(OriGene Technologies, MD, USA) using Lipofectamine
TM
 2000 (Thermo Fisher Scientific, 
MA, USA) according to the manufacturer's instructions. Twenty-four hours after transfection, 
cells were seeded on 384-well black-walled imaging plates (Corning, MA, USA) and used for 
Ca
2+
 experiments 24 hours after plating.  
 
3.3.10 Fluorescent Ca
2+ 
assays 
Cells were prepared as previously reported
243
. Briefly, SH-SY5Y, F-11, and ND7/23 cells 
were seeded onto 384-well black-walled imaging plates (Corning, MA, USA) at a density of 
30 000 - 50 000 cells per well 48 hour prior to calcium imaging experiments and incubated at 
37°C with 95% O2/5% CO2. SH-SY5Y cells were placed onto uncoated plates (Corning, Cat 
No #3542), while F-11 and ND7/23 cells were placed onto CellBIND® (Corning, Cat no 
#3683) plates. Transfected HEK293 cells were plated 24 hours prior to calcium imaging 
assays as previously stated. Cells were seeded to ensure ~90% confluency on the day of the 
experiment.  
 
Calcium 4 No-Wash dye (Corning, MA, USA) was diluted 1:10 in PSS from stock solution, 
and was loaded into cells 30 minutes prior to imaging. The plates with loaded dye were 
incubated at 37 ˚C with 95% O2/5% CO2. Ca
2+
 responses were measured using a FLIPR
TETRA
 
(Molecular Devices, CA, USA) fluorescent plate reader with excitation at 470-495 nM and 
emission at 515-575 nM. Camera gain and intensity were adjusted for each plate to yield a 
minimum of 1000-1500 arbitrary fluorescence units (AFU) baseline fluorescence. Only one 
addition was used. Prior to addition of agonists (capsaicin, menthol, AITC, vasopressin, or 
oxytocin), 10 baseline fluorescence readings were taken, followed by fluorescent readings 
every 0.5 seconds for 300 reads. 
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3.3.11 Data analysis 
Unless stated otherwise, all data are presented as mean ± standard error of the mean (SEM). 
Statistical significance was determined using an unpaired, two-tailed Student’s t-test unless 
otherwise stated, with statistical significance defined as P-value < 0.05. 
 
For heatmap generation, data was compiled into .csv format and heatmaps were created in 
RStudios with R version 3.2.2 with the gplots, pheatmap, and RColorBrewer libraries. 
 
GO term charts were generated using the online PANTHER database. 
 
Pie graphs were generated using default pie graph parameters within Microsoft Excel®.  
 
FLIPR
TETRA 
Ca
2+
 response data was analysed using Screenworks 3.2 (Molecular Devices, 
CA, USA), and were plotted and its statistical parameters determined using GraphPad 
Prism
TM
 (Version 6.00).  
 
To establish dose-response curves, the maximum response in fluorescence over the baseline 
after the addition of the agonist was fitted to a 4-parameter Hill equation with variable slope 
using GraphPad Prism
TM
 (Version 6.00). 
 
Sample sizes of each experiment are detailed in the figure legends of the corresponding 
figure. 
 
3.4 Results 
3.4.1 TUBA1A was selected to normalise reads 
As data normalisation relies upon housekeeping genes expressed in similar levels across all 
samples, I examined the expression of various housekeeping genes due to the recognised 
issue of differential expression levels for standard housekeeping genes
252
 and found TUBA1A 
to be one of the only candidates expressed at a similar global level (0.02-0.08% of all aligned 
reads) across all samples in my data. In contrast, other popular housekeeping genes 
commonly used in data normalisation, such as GAPDH and β-actin, were not expressed with 
similar intensity across all my samples. For instance, 64 reads aligned to GAPDH in the DRG 
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sample, while 12,475 reads aligned to GAPDH in the SH-SY5Y sample. I thus normalised all 
reads to the highly-expressed α-tubulin gene, with the intensities of gene expression 
presented as normalised gene ratios.  
 
3.4.2 F-11 and ND7/23 cells were aligned against mouse and rat genomes 
The two hybrid cell lines examined, F-11 and ND7/23, are known to contain both rat and 
mouse chromosomes (F-11)
242
 and to express rat surface markers after fusion with mouse 
neuroblastoma cells (ND7/23)
241
. It was not clear which genes are transcribed from the rat 
genome and which are from the mouse genome in these cell lines. It was therefore decided to 
align F-11 and ND7/23 reads twice, once against the mouse genome and once against the rat. 
I found that qualitatively, expression profiles largely mirrored each other between mouse and 
rat alignments in these two cell lines, varying predominantly in intensity.  
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Figure 3.1 Neuronal markers and gene ontology analysis on RNA samples 
The SH-SY5Y, F-11, and ND7/23 cell lines do not fit into existing categories of peripheral 
neurons, yet gene ontology analysis demonstrates the cell lines' transcriptomes retain similar 
ratios of enriched biological processes compared to whole DRGs. A) Expression of markers 
commonly used to identify specific peripheral neuron sub-populations, microglia, and non-
neuronal cells in SH-SY5Y, F-11, and ND7/23 cell lines. The majority of the genes exhibited 
very low expression levels across all samples. B) Gene ontology analysis of whole DRGs. C) 
Gene ontology analysis of SH-SY5Y cells. D) Gene ontology analysis of F-11 cells (aligned 
to the mouse genome). E) Gene ontology analysis of F-11 cells (aligned to the rat genome). 
F) Gene ontology analysis of ND7/23 cells (aligned to the mouse genome). G) Gene ontology 
analysis of ND7/23 cells (aligned to the rat genome). 
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3.4.3 Cell lines do not share expression profiles with known DRG neuron subclasses 
Cell line expression data was initially analysed against a wide range of known markers for 
specific neuronal types (Figure 3.1 A). Some of these include the peptidergic nociceptor 
marker TrkA (NTRK1), the mechanosensor marker PIEZO2/FAM38B, the myelinated 
neuronal marker CNTNAP2 (contactin associated protein-like 2), and unmyelinated C-LTMR 
marker CaV3.2 (CACNA1H)
115
. Out of the 43 neuronal markers investigated (B2M and VIM 
are non-neuronal markers), transcripts of 9 markers were found in all cell lines. These 9 
genes included the nociceptor markers NaV1.9 (SCN11A) and ASIC1, both of which are 
mentioned in Chapter 1; TLX3, a transcription factor that regulates the expression of several 
sensory channels and receptors implicated in sensing pain, itch and temperature
253
; PLXNC1, 
a marker for unmyelinated nonpeptidergic nociceptors and thermosensors; RET, a marker for 
myelinated and unmyelinated neurons
32
; the C-LTMR marker TH
254
; RUNX3, a transcription 
factor that regulates the development of proprioceptive DRG neurons
255
; the unmyelinated C-
fibre marker peripherin (PRPH); and LDHB, a marker of myelinated neurons
32
 (Figure 3.1 
A). However, the co-expression of some of these markers in individual cell lines was 
surprising given their expression profiles do not overlap significantly in subtypes of DRG 
neurons. Specifically, some markers are known to be selectively expressed in unmyelinated 
C-fibre neurons (such as PRPH and TH) while others are indicative of myelinated A-fibres 
(such as LDHB) and would thus not be expected to be present together in a single sensory 
neuron type. Many sensory neuron genes were also absent across all cell line samples, 
including nociceptive markers such as TRPV1
54
, TRPA1
256
, CGRP
21
, and NaV1.8 (SCN10A); 
mechanoreceptor markers such as PIEZO2
257
 and VGLUT3/SLC17A8 
258
; and markers for 
neurons responsible for itch such as par2 (F2RL1)
259
. This suggests that while the cell lines 
are known to express receptors found on DRG neurons, they do not mimic the entire 
repertoire of proteins expressed by functional in vivo DRG neuron classes. 
 
3.4.4 SH-SY5Y cells express conflicting molecular markers for multiple DRG neuron 
subtypes 
In SH-SY5Y cells, the most enriched marker was RET, the glial cell line-derived 
neurotrophic factor (GDNF) receptor tyrosine kinase, which was consistent with previous 
reports that these cells respond to GDNF with increased neurite outgrowth
260, 261
. SH-SY5Y 
cells expressed markers of A-fibres, including LDHB, CNTNAP2, and neurofilament heavy 
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polypeptide (NEFH). However, TrkA (NTRK1), a C-fibre marker, was also expressed, while 
the A-fibre marker TrkC (NTRK3) was completely absent. SH-SY5Y also lacked the 
nociceptor markers TRPV1, MAS-Related GPR Member D (MRGPRD), the peptidergic 
neuron markers CGRP, substance P (TAC1), the itch receptor marker somatostatin (SST), the 
mechanoreceptor marker TAFA4/FAM19A4, and the proprioceptor marker parvalbumin 
(PVALB). Overall, SH-SY5Y cells expressed a range of genes associated with different 
subtypes of sensory neurons and could not be classified according to known DRG neuron 
subclasses, including those defined by Usoskin et al.
32
, Li et al.
36
, or simpler categorisation 
based on expression of established markers relating to functional aspects, such as CGRP, IB4 
and NF200. Although further classification of sensory neurons was recently reported by Li et 
al.
36
, DRG classification criteria based on transcriptional markers remain relatively broad and 
as yet do not unambiguously encompass the possible 17 or more different fibre types that 
have been proposed based on responsiveness to mechanical and thermal stimuli as well as 
conduction velocity and rate of adaptation
29
. Thus, while these cells express genes - as well 
as their respective protein products
243, 244
 - known to be involved in key sensory neuron 
functions, they should not be regarded as a model for DRG neurons. 
 
3.4.5 F-11 and ND7/23 cells also express molecular markers for multiple DRG neuron 
subtypes 
F-11 and ND7/23 cells were both created from a fusion of mouse neuroblastoma cells and rat 
embryonic or neonatal DRG neurons, respectively
241, 242
. Accordingly, the expression profile 
of neuronal markers was similar in both cell lines, and included a number of markers for A-
fibre mechanosensors and proprioceptors, including LDHB, NEFH and TrkC (Figure 3.1 A). 
As with SH-SY5Y cells, markers for C-fibres were also present in both cell lines, including 
P2RX3, a purinergic ion channel expressed in C-fibre non-peptidergic neurons; plexin C1 
(PLXNC1), TH, PRPH, RET, and CaV3.3 (CACNA1I). ND7/23 cells expressed comparatively 
higher levels of TLX3, SCN11A, TrkC, and TrkA than F-11 cells, while ASIC1, PLXNC1, TH, 
PRPH, NEFH, CNTNAP2, LDHB, CACNA1H, and CACNA1I had reduced expression in 
ND7/23 cells compared with F-11 cells. TrkB was expressed at very low levels in both cell 
lines. The C-fibre marker TrkA was enriched approximately 20-fold in ND7/23 cells 
compared with F-11 cells, while TH was elevated approximately 10-fold in F-11 cells 
compared to ND7/23 cells. Such findings established that, similar to SH-SY5Y cells, both F-
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11 and ND7/23 cells expressed a range of cellular markers that are usually found in distinct 
sensory neuron subtypes and a specific neuronal origin can thus not be definitely assigned.  
 
3.4.6 Whole DRGs and cell lines expressed similar proportions of reads towards gene 
ontology terms 
All samples showed a similar distribution of genes expressed according to Biological 
Processes (BP) terms following global gene ontology (GO) analysis. The BP term with the 
most genes associated to it was ‘metabolic process’ across all samples, followed by the terms 
‘cellular process’ and ‘biological regulation’. Fourteen different BP terms were found to be 
present in all samples, with whole DRGs being the only sample that contained one extra term, 
that of ‘rhythmic process’ (Figure 3.1 B-G). The proportions of reads aligned to each BP term 
were not significantly different between each sample, indicating that while the cell lines do 
not exhibit expression profiles that fit the profile of endogenous DRG neurons, the cell lines 
maintain the physiological proportion of transcripts for various cellular functions. F-11 and 
ND7/23 samples both exhibited reduced numbers of genes associated with each BP term 
when analysed against the rat genome, however the distribution of associations across 
different terms remains very similar across the mouse and rat genomes for both samples.  
 
3.4.7 Whole DRGs expressed significantly more CaV, KV, and NaV reads than the cell lines 
The expression of ion channels in whole DRGs and the three cell lines were analysed next. 
The expression of ion channels and GPCRs with putative therapeutic importance was 
assessed based on classification obtained from IUPHAR 
(http://www.guidetopharmacology.org). 
 
There were 261 ion channel genes detected in whole DRGs (≥ 1 read aligned to the gene), 
217 in SH-SY5Y cells, 223 in F-11 (mouse), 201 in F-11 (rat), 214 in ND7/23 (mouse), and 
189 genes in ND7/23 (rat). Twenty-one families of ion channels were expressed by all 
samples, including several considered as therapeutic targets for pain such as ASIC receptors, 
GABAA receptors, and voltage-gated sodium, potassium, and calcium channels (Figure 3.2 
A). Whole DRGs had the highest number of ion channel transcripts among the samples, with 
494,237 reads aligned to ion channel genes. The level of ion channel expression was also at 
least three times higher in whole DRGs (1.42% of total aligned reads) than in the cell lines 
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examined. 0.53% of total aligned reads in SH-SY5Y cells consisted of ion channel reads, 
while ion channel reads made up 0.43% of total aligned reads in F-11 (mouse), 0.48% of total 
aligned reads in F-11 (rat), 0.42% of total aligned reads in ND7/23 (mouse), and 0.45% of 
total aligned reads in ND7/23 (rat). 58 ion channels were found to be uniquely expressed in 
whole DRGs, while 8 uniquely expressed ion channel genes were found in SH-SY5Y, 3 in F-
11, and 4 in ND7/23 (Table 3.1). 
 
The most striking difference in the distribution of ion channel transcripts between DRGs and 
cell lines lies in the percentage of voltage-gated sodium, potassium, and calcium channels. 
Together, NaV, KV, and CaV consisted of 59% of all reads aligned to ion channels in whole 
DRG, a trend that was reflected in the three cell lines. NaV, KV, and CaV constituted 43% of 
all ion channel transcripts in SH-SY5Y cells, 40% in F-11 cells (mouse and rat), 35% in 
ND7/23 cells (mouse), and 38% in ND7/23 cells (rat) counts. However, much of the CaV 
expression in the cell lines was contributed by CaV auxiliary units rather than the channel-
forming CaV α units, and this was especially true for SH-SY5Y cells. SH-SY5Y cells also 
abundantly expressed cholinergic nicotinic receptors, amounting to 27% of all ion channel 
transcripts. In contrast, cholinergic nicotinic receptors consisted of 15% or less ion channel 
transcripts in all other samples (whole DRG 2%, F-11 mouse 3%, F-11 rat 2%, ND7/23 
mouse 14%, and ND7/23 rat 11%) (Figure 3.2 B-G). 
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Figure 3.2 Whole DRGs and cell lines have unique expression patterns of ion channels 
families 
Sections of the pie chart without an annotated percentage constituted ≤ 0.5% of total ion 
channel expression in the sample. A) Compilation of the ion channel genes with the highest 
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expression levels for each sample. B) Distribution of ion channel expression in whole DRGs. 
C) Distribution of ion channel expression in SH-SY5Y cells. D) Distribution of ion channel 
expression in ND7/23 cells (aligned to the rat genome). E) Distribution of ion channel 
expression in ND7/23 cells (aligned to the mouse genome). F) Distribution of ion channel 
expression in F-11 cells (aligned to the rat genome). G) Distribution of ion channel 
expression in F-11 cells (aligned to the mouse genome). 
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 Whole DRGs SH-SY5Y F-11 ND7/23 
Uniquely 
expressed 
ion 
channels 
 ANO1 
AQP4 
ASIC2 
CACNA1D 
CACNA1E 
CACNA2D3 
CHRNA6 
CHRNB3 
GABRA1 
GABRA2 
GABRA3 
GABRA5 
GABRB2 
GABRG1 
GABRG2 
GABRG3 
GJB1 
GJC3 
GJD2 
GRIA1 
GRID2 
GRIK1 
GRIK4 
GRIN3A 
HCN1 
HVCN1 
KCNA1 
KCNA2 
KCNB2 
KCNC2 
KCND3 
KCNG2 
AQP10 
AQP3 
CHRND 
GABRQ 
GJC2 
KCNJ8 
KCNQ1 
SCNN1D 
 
 
 
 
CATSPER2 
GJB3 
MCOLN3 
 
 
 
KCNK6 
KCNN3 
SCNN1A 
TRPM5 
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KCNG4 
KCNH5 
KCNJ16 
KCNJ3 
KCNJ9 
KCNK10 
KCNK13 
KCNK18 
KCNK4 
KCNQ3 
KCNS1 
KCNU1 
KCNV1 
NALCN 
P2RX5 
RYR3 
SCN10A 
SCN1A 
SCN4A 
SCN2B 
TRPA1 
TRPC4 
TRPC6 
TRPM3 
TRPM8 
TRPV1 
 
Uniquely 
expressed 
GPCRs 
ADRA1D 
ADRA2A 
ADRB2 
AGTR1B 
CCKAR 
CHRM2 
CYSLTR2 
APLNR 
GPR63 
GPR98 
HTR2B 
LTB4R1 
NPFFR2 
PTGER2 
GPBAR1 AGTR2 
DRD2 
DRD4 
GIPR 
GPR20 
GPR4 
HRH3 
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DARC 
ELTD1 
GABBR2 
GALR1 
GPR126 
GPR139 
GPR149 
GPR179 
GPR26 
GPR35 
GPR37L1 
GPR61 
GPR75 
GPR83 
GRM4 
GRM8 
HCRTR1 
HCRTR2 
HRH1 
HTR1A 
HTR1B 
HTR1D 
HTR1F 
HTR2A 
HTR4 
HTR5A 
HTR7 
LPAR5 
MCHR1 
MRGPRD 
MRGPRX1 
NPY1R 
OPRK1 
PTH2R 
 
 
SSTR5 
TAS1R2 
VIPR2 
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OXTR 
P2RY1 
P2RY12 
PTGDR 
PTGER3 
S1PR1 
 
Table 3.1 Ion channels and GPCRs uniquely expressed in whole DRGs and cell lines 
Comparison of ion channels and GPCRs detected in whole DRGs and cell lines reveals that 
large number of genes are absent from the cell lines. A gene is considered to be uniquely 
expressed if >100 reads are detected only in one sample. 
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3.4.8 Analysis of ion channels with the highest expression in each sample 
A compilation of the 30 ion channels with the highest expression in each sample revealed 
significant differences as well as similarities between the cell lines and compared with whole 
DRGs (Figure 3.2 A). The ion channels with the highest expression in whole DRGs were 
NaV1.8 (SCN10A), KV1.1 (KCNA1), and the NaV β4 subunit (SCN4B). Other ion channels 
highly expressed in whole DRGs, but expressed at very low levels in the cell lines, included 
NaV1.9, aquaporin 1, the NaV β1 subunit, KV4.1 (KCND1), and glycine receptor β unit 
(GLRB). In addition, transcripts for NaV1.1 (SCN1A), ionotropic glutamate receptor 1 
(GRIK1), and KV4.3 (KCND3) were found at lower levels in DRGs but were virtually absent 
in the three cell lines. Transcripts for SCN8A (NaV1.6) and SCN9A (NaV1.7), channels 
responsible for signal transduction and known to have important roles in pain, were present in 
all cell lines as well as being highly expressed in whole DRGs. F-11 and ND7/23 cells in 
particular expressed NaV1.6 and NaV1.7 at higher levels than SH-SY5Y cells, with F-11 cells 
expressing more NaV1.6 than ND7/23, and ND7/23 cells expressing more NaV1.7 than F-11 
cells.  
 
The nicotinic cholinergic receptor α3 (CHRNA3) was the ion channel with the highest 
expression in SH-SY5Y and ND7/253 cells, but few transcripts were found in whole DRGs 
and F-11 cells. The second-most enriched ion channel in SH-SY5Y cells, the CaVα2δ subunit 
2 (CACNA2D2), also had very little expression in the other samples. Other ion channels 
highly expressed in SH-SY5Y cells included CaV auxiliary units such as CACNG4 and 
CACNA2D1, and voltage-gated chloride channels such as CLCN3 (Figure 3.2 A). 
 
While the overall gene expression profiles of F-11 and ND7/23 cells were similar, there was 
notable disparity within ion channel expression. F-11 cells expressed a large amount of 
transcripts for KV11.1 (KCNH2, otherwise known as hERG) and 5-HT receptor 3a (HTR3A), 
genes that were expressed at much lower level in ND7/23 cells (Figure 3.2 A). In contrast, 
CHRNA3 was the most highly expressed ion channel transcript in ND7/23 cells, but was only 
expressed at low levels in F-11 cells. Apart from these exceptions, many ion channel genes 
where expressed at similar levels in F-11 and ND7/23 cells. Several of these, including ion 
channels with recognised roles in nociception such as ASIC1, CaV3.2 (CACNA1H), and 
KV7.2 (KCNQ2), were highly expressed in F-11 and ND7/23 cells as well as in whole DRGs 
and SH-SY5Y cells (Figure 3.2 A). Similarly, P2RX3, CaV3.3 (CACNA1I), TRPV2, and 
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CaV2.2 (CACNA1B) were enriched in F-11 and ND7/23 cells to a lesser extent compared with 
DRGs and SH-SY5Y cells. For all of these ion channels, transcript numbers were higher in F-
11 cells compared with ND7/23 cells. In contrast, TRPM2, CLCN2, KCNK3, CLCN5, GRIA2, 
TPCN1, KCNC3, KCNC1, and KCNT1 were expressed at higher levels in ND7/23 cells than 
F-11 cells.  
 
3.4.9 The GPCR genes with the highest expression in whole DRGs are GABAB receptor genes 
Many GPCRs initiate intracellular changes after activation from external chemicals, making 
this family of receptors ideal pharmacological targets. A number of GPCRs are already 
established analgesic targets, such as the opioid receptors, while others have recognised roles 
in inflammation and nociception, such as bradykinin and protease-activated receptors
262-264
. 
 
A total of 300 different GPCR genes from the IUPHAR list were expressed in whole DRGs, 
218 genes in SH-SY5Y cells, 215 in F-11 (mouse), 188 in F-11 (rat), 225 in ND7/23 (mouse), 
and 187 in ND7/23 cells (rat) (Figure 3.3 A-G). Whole DRGs contained the most GPCR 
transcripts, with 185,707 reads aligned to GPCR genes accounting for 0.54% of all aligned 
reads. SH-SY5Y cells had the second-most abundant GPCR expression (0.38% of all aligned 
reads), followed by ND7/23 mouse (0.35%), ND7/23 rat (0.33%), and F-11 rat and mouse 
(both 0.26%). Similar to the trend seen for ion channels, whole DRGs had both the highest 
GPCR expression level and the highest number of uniquely expressed GPCRs, with 46 
GPCRs uniquely expressed in whole DRGs. SH-SY5Y cells expressed 8 unique GPCRs, F-
11 cells expressed 1, and ND7/23 cells expressed 10 (Table 3.1).  
 
Forty-five families of GPCRs were expressed by all four samples. Amongst these, the 
adhesion class GPCR family had the highest expression levels in all samples, constituting 
42% of all GPCR transcripts from SH-SY5Y cells, 35% in ND7/23 cells (rat), 32% in F-11 
cells (rat), 29.5% in ND7/23 (mouse), 28.3% in F-11 (mouse), and 17% in whole DRGs.  
 
The GPCR family with the second highest expression in whole DRGs were the GABAB 
receptors GABBR1 and GABBR2 (16% of all GPCR reads), a trend that was not observed in 
the cell lines where GABAB receptors only consisted of 3% of GPCR reads in F-11 and 
ND7/23 (rat), and 2% in ND7/23 (mouse) and SH-SY5Y cells. However, expression of 
approximately equivalent transcript numbers for both the R1 and R2 subunit of the GABAB 
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receptor was only observed in DRG neurons, suggesting that functional GABAB receptors do 
not form in the neuronal cell lines (Figure 3.3 B). 
 
Other GPCRs with high expression in whole DRGs include sphingosine-1-phosphate receptor 
3 (S1PR3) and the orphan GPCRs GPR158 and GPR56. These genes, together with the 
prostaglandin F receptor (PTGFR), par3 (F2RL2), 5-HT receptor 1D (HTR1D), prostaglandin 
E receptor 3 (PTGER3), and adenosine A1 receptor (ADORA1), were expressed at very low 
levels in neuronal cell lines. Two exceptions in this group include the orphan GPCRs with 
unknown function, GPR137 and GPR153, which were expressed in all samples (Figure 3.3 
A). 
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Figure 3.3 Whole DRGs and cell lines have unique expression patterns of GPCRs 
Sections of the pie chart without an annotated percentage constituted ≤ 0.5% of total ion 
channel expression in the sample. A) Compilation of the GPCR genes with the highest 
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expression levels for each sample. B) Distribution of GPCR expression in whole DRGs. C) 
Distribution of GPCR expression in SH-SY5Y cells. D) Distribution of GPCR expression in 
ND7/23 cells (aligned to the rat genome). E) Distribution of GPCR expression in ND7/23 
cells (aligned to the mouse genome). F) Distribution of GPCR expression in F-11 cells 
(aligned to the rat genome). G) Distribution of GPCR expression in F-11 cells (aligned to the 
mouse genome). 
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3.4.10 GPCR genes enriched in cell lines 
The GPCR with the highest level of expression in SH-SY5Y cells was latrophilin 2 (LPHN2). 
Latrophilin 2 is an adhesion GPCR that plays a role in exocytosis and is closely related to 
latrophilin 1 (LPHN1), the receptor for latrotoxin, the active peptide in black widow spider 
venom
265
. Interestingly, latrophilin 1 was the GPCR with the highest expression in F-11 cells 
and the second highest expressed in ND7/23 cells, and was also present in whole DRGs. 
Many genes enriched in SH-SY5Y cells, such as smoothened (SMO) and par1 (F2R), were 
also expressed in other samples. However, a small group of genes, including the muscarinic 
acetylcholine receptor M3 (CHRM3) and prostaglandin E2 receptor (PTGER2), were 
enriched in SH-SY5Y cells but largely absent in other samples (Figure 3.3). 
 
In F-11 cells, the prostaglandin I2 receptor (PTGIR), par1 (F2R), and LPHN1 were the most 
highly expressed GPCRs. In ND7/23 cells the GPCRs with the highest expression were the 
cannabinoid receptor 1 (CNR1), LPHN1, and pituitary adenylate cyclase-activating 
polypeptide type I receptor (ADCYAP1R1). The majority of GPCR genes were expressed at 
similar levels in F-11 and ND7/23 cells. GPCRs enriched in F-11 and ND7/23 tend to be 
expressed at very low levels in whole DRGs, whereas a group of GPCRs highly expressed in 
DRGs, including CELSR3 and BAI2, were enriched in SH-SY5Y cells. Of note, GPR123 and 
PTGER4 were enriched exclusively in F-11 cells, and CD97 and FZD2 were enriched only in 
ND7/23 cells. When aligned to the mouse genome, the top 30 GPCRs expressed for F-11 and 
ND7/23 cells resembled each other very closely. Interestingly, F-11 cells expressed mouse 
but not rat transcripts of PTGIR, while the same was the case for ADCYAP1R in ND7/23 cells 
(Figure 3.3 A).  
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Figure 3.4 Calcium response to oxytocin and vasopressin addition in DRG neurons and 
cell lines 
Functional oxytocin receptors are expressed in SH-SY5Y cells, but not in F-11 or ND7/23 
cells. Functional vasopressin receptors are absent from all three cell lines. This confirms the 
findings regarding oxytocin and vasopressin receptors in the transcriptome. A) Calcium 
influx responses of SH-SY5Y, F-11, and ND7/23 cell lines upon exposure to oxytocin. B) 
Calcium response of HEK293 cells transfected with oxytocin receptor (OXTR) upon 
exposure to oxytocin. C) Calcium influx responses of SH-SY5Y, F-11, and ND7/23 cell lines 
upon exposure to vasopressin. D) Calcium response of HEK293 cells transfected with the 
vasopressin V1B receptor (AVPR1B) upon exposure to vasopressin. 
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3.4.11 Functional vasopressin receptors were absent from all cell lines, while the oxytocin 
receptor was present in SH-SY5Y cells and absent in the other cell lines 
Both arginine vasopressin receptors and oxytocin receptors, while not traditionally 
considered important targets in pain pathways and are not previously thought to be present in 
peripheral DRG neurons, are now observed to have an emerging functional role in pain. The 
vasopressin receptor has been linked to strain-dependent pain sensitivity to formalin and 
capsaicin
266
 and oxytocin activation ameliorates visceral pain in particular
267
.  
 
Consistent with a specific role of these GPCRs in pain, both vasopressin receptor 1B and 
vasopressin receptor 2 were expressed at very low level or absent in DRGs. In contrast, all 
three cell lines expressed oxytocin receptors, but vasopressin receptor 1A and 1B were 
absent. Functional Ca
2+
 imaging via the FLIPR
TETRA
 was therefore used to verify these 
findings. Transcriptomic data indicated the oxytocin receptor was expressed in SH-SY5Y 
cells, absent in F-11 cells, and only aligned to three reads in ND7/23 cells. Accordingly, only 
SH-SY5Y responded to oxytocin at concentrations that elicit Ca
2+
 responses in HEK293 cells 
transfected with the oxytocin receptor, confirming the presence of functional oxytocin 
receptors in SH-SY5Y cells and its absence in F-11 and ND7/23 cells (Figure 3.4 A-B). 
Moreover, consistent with transcriptomic results, vasopressin did not elicit an increase in 
intracellular Ca
2+
 in any of the cell lines tested, albeit robust Ca
2+
 responses were elicited in 
HEK293 cells transiently transfected with arginine vasopressin receptor 1B (Figure 3.4 C-D). 
 
3.4.12 CaV expression in the cell lines is consistent with previous experimental data 
The expression profile of CaV transcripts in SH-SY5Y cells was entirely consistent with that 
previously reported
245
, with CaV2.1, CaV2.3, CaV3.2, and CaV1.1 being completely absent in 
SH-SY5Y cells. CaV3.1 had the largest number of reads in SH-SY5Y cells, followed by 
CaV2.2 and CaV1.3. SH-SY5Y cells also expressed several CaV auxilliary units at high levels, 
a trend that was also observed in F-11 and ND7/23 cell lines. In contrast, the order of 
expression of CaV alpha units in DRGs was observed as CaV2.2 > CaV2.1 > CaV3.2 > CaV1.2 
> CaV3.3 > CaV1.3 > CaV2.3 > CaV3.1 > CaV1.1 > CaV1.4, with all alpha isoforms being 
present (for detailed data see Appendix 3.3). This was mirrored by the F-11 and the ND7/23 
cells, both of which expressed all CaV isoforms with a similar pattern. F-11 and ND7/23 
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expressed most CaV3.2 out of all CaV alpha subunits, closely followed by CaV2.2, CaV1.2, 
and CaV3.3.  
 
3.4.13 KV11.1 was the KV isoform with the highest expression in all cell lines, and all cell 
lines lacked KV1.1 
The expression of KCNQ2 and KCNQ3, which are the genes encoding the KV7.2 and KV7.3 
isoforms, was consistent with previous results indicating the presence of this channel in 
DRGs
18
, F-11 cells
268
, and SH-SY5Y cells
269
. KCNQ3, however, was absent in ND7/23 cells. 
KV1.1, a key KV channel regulating excitability in DRG neurons, was found to be virtually 
absent in all cell lines, whereas the KV11 subtype family was expressed most abundantly 
(55.06% of all KV transcripts in SH-SY5Y, 58.56% in F-11, and 38.30% in ND7/23), and 
KV1 family expression was at least 30-fold lower in all cell line samples compared to whole 
DRGs. KV11.1 (KCNH2), commonly known as the human ether-a-go-go-related gene 
(hERG), was the most abundant KV subtype channel in all three cell line samples. These 
findings are consistent with previous studies reporting absence of KV1.1, and endogenous 
expression of hERG, in these cell lines
270-272
.  
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Figure 3.5 Calcium responses to TRP activators for cell lines and transfected HEK293 
cells 
Calcium responses to the application of selective TRP activators for cell lines and HEK293 
cells transiently expressing TRPA1, TRPM8, or TRPV1. None of the cell lines responded to 
AITC, menthol, or capsaicin, confirming the absence of TRPA1, TRPM8, and TRPV1 
expression in the three cell lines examined. (A) Calcium responses of the cell lines to AITC. 
(B) Calcium responses of HEK293 cells transiently expressing rat TRPA1 channels to AITC. 
(C) Calcium responses of the cell lines to menthol. (D) Calcium responses of HEK293 cells 
transiently expressing rat TRPM8 channels to menthol. (E) Calcium responses of the cell 
lines to capsaicin. (F) Calcium responses of HEK293 cells transiently expressing rat TRPV1 
channels to capsaicin. 
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3.4.14 Very low amounts of TRPA1, TRPM8, and TRPV1 were expressed in all cell lines 
The expression profile of TRP channel transcripts was similar across all cell lines. TRPA1 
and TRPV1, the TRP channels receptive to the noxious stimuli mustard oil and capsaicin 
respectively, were largely missing from the three cell lines. Very small amounts of TRPV1 
were present in the three cell lines and TRPA1 was completely absent. TRPM8, the menthol 
and cold receptor, was also expressed at very low levels in all cell lines.  
 
The recently-identified cold-sensitive channel TRPC5
273
 was revealed to be present in whole 
DRGs and in ND7/523 cells, with very low expression in SH-SY5Y and F-11 cells. TRPM3, 
another novel channel suggested to be a potential nociceptor and thermoceptor
274
, was 
present in whole DRGs, F-11 cells, and ND7/23 cells, with very low expression levels in SH-
SY5Y cells (for detailed data see Appendix 3.3).  
 
These findings were confirmed with fluorescent intracellular calcium measurements after the 
application of selective TRP channel agonists (Figure 3.5). The TRPA1 activator, AITC, did 
not elicit a response from any of the cell lines despite activating transfected HEK293 cells 
transiently expressing rat TRPA1 at the same concentrations (Figure 3.5 A-B). The 
application of the TRPM8 agonist menthol also elicited minimal responses from all of the 
three cell lines, while robust Ca
2+
 responses were observed in transfected HEK293 cells 
(Figure 3.5 C-D). Similarly, capsaicin, known to activate rat, mouse, and human TRPV1
50, 275, 
276
, elicited no responses in the cell lines, but robustly activated TRPV1-transfected HEK293 
cells (Figure 3.5 E-F). The relatively lack of expression of these key thermosensitive TRP 
channels suggests that none of the three cell line examined should be used as model 
nociceptive or thermosensitive neurons.   
 
3.5 Discussion 
Immortalised neuronal cell lines as models of primary sensory neurons represent a 
comfortable compromise for the investigation of the neuropharmacological mechanisms 
underlying pain. These neuroblastoma-derived cell lines often express molecular targets 
consistent with those found in sensory neurons, bypassing the need for excision and primary 
culture of tissue while – presumably – retaining endogenous protein expression profiles. 
Indeed, one advantage of using immortalised neuronal cell lines over heterologously 
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transfected cells is the co-expression of relevant auxiliary subunits as well as interacting 
proteins, and the constellation of channels and receptors that would form the 'signallosome' in 
a native neuron, providing a more holistic insight to nociceptive pharmacology and 
signalling. However, these properties are often based on assumptions about the gene 
expression profile of such cell lines, and the lack of comprehensive analyses of receptor 
expression in these cell lines limits their applicability.  
 
Sensory neurons are a heterogeneous group of neurons with distinct functional 
characteristics. Since cell lines can be considered monoclonal and originate from a single cell 
colony, the absence of genes enriched in specific subgroups of neurons could be expected – it 
is plausible that the gene expression profile of ND7/23 and F-11 cells would resemble only 
one subset of the many different types of sensory neurons. Indeed, both ND7/23 and F-11 
cells are often considered a model for small nociceptive neurons that give rise to 
unmyelinated C-fibres. However, the precise type of sensory neuron that these cell lines may 
have arisen from, or that they most closely resemble, is difficult to assess currently, not least 
because the precise number of individual neuronal subtypes found in DRG are unclear. Based 
on functional characteristics of the fibres innervating target organs including skin, at least 16 
subclasses of purely sensory neurons should exist
29
. In recent years, significant efforts have 
been made towards identifying the gene expression profile of these individual neuronal 
classes, as it is becoming increasingly clear that it is the constellation of ion channels, 
GPCRs, auxiliary subunits and interacting proteins expressed in a given neuron that defines 
its functional properties. For example, cold sensitivity in trigeminal neurons is defined by co-
expression of KV1.1/1.2 channels with TRPM8
61
, while in sensory neurons innervating the 
skin a similar functional relationship was observed between TRPM8 and KV7.2/7.3 
channels
18
. There is also existing evidence towards the presence of multiple neuron types 
within F-11 cell lines
277
, indicating that while neuron-derived cell lines are supposedly clones 
of the parent cell, a myriad of neuronal subtypes exists within one population.  
 
This chapter thus set out to assess the gene expression profile of the model sensory neuron 
cell lines ND7/23 and F-11 as well as the neuroblastoma cell line SH-SY5Y, which has 
previously been reported to express genes and ion channels normally restricted to peripheral 
sensory neurons such as NaV1.7
244
. Moreover, if any of the cell lines are found to resemble 
specific classes of peripheral sensory neurons with known expression of NaV1.6 or NaV1.8, 
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the cell lines could be used as in vitro models for high-throughput investigation of 
compounds that may modulate the two NaV isoforms.  
 
When compared with the gene expression profile of whole DRGs, I found the expression of 
many individual genes known to be expressed in, or play an important role in the function of, 
sensory neurons. These include RET, TH, PRPH, and LDHB. At the same time, many sensory 
neuron-enriched genes were also absent from the cell lines, such as TRPV1 and SCN10A. As 
an assessment of markers between PNS and CNS, the absence of central nervous system 
microglial markers such as CCL4 and GPR183
278
 in the neuronal cell lines was expected, 
given that all three cell lines derive from peripheral neurons.  
 
Based on a comprehensive study assessing the gene expression profiles of sensory neurons 
using single-cell RNA sequencing, Usoskin et al.
32
 defined four basic PNS sensory neuron 
subtypes, characterised by expression of TAC1, NTRK1 and CALCA (peptidergic cluster); 
MRGPRD and P2RX3 (non-peptidergic cluster); TH (tyrosine hydroxylase containing 
cluster); NEFH and PVALB (neurofilament-containing cluster); as well as eleven subgroups 
by correlating both old and novel markers to physiological function in peripheral nerves. Li et 
al.
36
 also examined the types of neurons present in DRGs in a separate study, and classified 
mouse DRG neurons into 10 main types and 14 subordinate subtypes based on molecular 
markers, functional annotations and transcriptional patterns. The resulting clusters matched 
the classification by Usoskin et al. to some extent, but also introduced additional 
transcriptional markers defining subgroups of sensory neurons. Importantly, the gene 
expression profile of F-11, ND7/23 and SH-SY5Y cells resembled none of these 
classifications closely, with all cell lines expressing markers from several different clusters, 
as well as markers of non-neuronal cells including B2M and VIM
32
. Indeed, F-11 cells 
expressed high levels of P2RX3, TH and NEFH, thus simultaneously incorporating markers 
of non-peptidergic, tyrosine hydroxylase-containing, and neurofilament-expressing neurons 
based on the classification proposed by Usoskin et al.
32
. ND7/23 cells also expressed high 
levels of the peptidergic neuron marker NTRK1, the non-peptidergic marker P2RX3, TH, and 
the neurofilament-expressing marker NEFH. The cell lines also expressed markers that 
belong to separate clusters based on the classifications by Li et al.
36
, including black (TH), 
turquoise (P2RX3, NTRK1) and blue (NEFH)
36
.  
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Similar discrepancies were also observed when comparing the gene expression profile of the 
cell lines to the transcriptome of neurons expressing NaV1.8, which are typically considered 
nociceptive and express high levels of ANO3, TRPA1 and CHRNA6
131
, none of which were 
present in the immortalised neuronal cell lines examined. These discrepancies are perhaps 
less surprising given none of the cell lines expressed more than one read of NaV1.8 transcripts 
in the entire sample. Indeed, my results showed that allocation of neuronal cell lines to any 
single meaningful subtype of sensory neuron is hardly possible, as they expressed a mixture 
of cellular markers that are typically found in non-overlapping cell populations, including 
markers for myelinated neurons as well as for unmyelinated neurons. Some examples include 
the presence of TrkA, TrkB, and TrkC in all cell line samples, suggesting a mixed heritage of 
the cell lines. Thermo-sensitive proteins responsible for temperature sensing such as TRPV1, 
TRPA1, and TRPM8 were all virtually absent in the cell lines, making them unlikely to have 
been derived from thermosensors. The complete lack of PIEZO2 also indicate the cell lines 
are not to be used to investigate stretch- and mechano-sensitive neurons in their native 
state
279
. Other subclasses I can rule out are subsets of pruriceptors due to the lack of par2 and 
somatostatin in the cell lines.  
 
Despite the discrepancies in cellular markers, global GO analysis of all samples according to 
BP terms revealed similar functional distribution of genes between all samples, suggesting 
that these neuronal cell lines maintain broad functional similarities with DRG neurons 
regardless of the poor fit into the existing framework of neuron classification. It is possible 
that while gene markers are not expressed in the cell lines, other genes with similar roles are 
expressed instead through compensatory mechanisms to maintain functional similarity with 
in vivo peripheral neurons. 
 
While the chapter assessed gene expression profiles in undifferentiated ND7/23, F-11 and 
SH-SY5Y cells, all three cell lines have the capacity and plasticity to develop into mature, 
terminally differentiated neurons upon exposure to various reagents such as retinoic acid or 
forskolin
269, 280
. These agents can be used to drive the cells towards various phenotypes away 
from their native form. This is certainly observed in SH-SY5Y cells, which can express 
different receptors based on the method used to induce differentiation (for a brief review 
see
281
). It is thus possible that differentiated cell lines may resemble certain neuronal subtypes 
more closely, and a transcriptomic analysis on differentiated cells could provide additional 
insight into processes involved in neuronal maturation.  
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A drawback of transcriptomic studies lies in difficulties reconciling gene expression with 
expression of functional proteins. However, the presence of N-methyl-D-aspartate receptors 
(GRIN1), HCN2 channels, NaV1.7 (SCN9A), CaV2.2 and opioid receptors in all cell lines 
have been confirmed, consistent with previous findings
243, 244
. I have additionally confirmed 
the observed pattern of expression in the cell lines for selected targets using a 
pharmacological approach where sufficiently selective agonists were readily available.  
 
3.6 Conclusions 
This chapter presents the first comprehensive transcriptomic analysis of the gene expression 
profile in F-11 and ND7/23 cell lines in comparison with whole mouse DRGs and the human 
neuroblastoma-derived cell line SH-SY5Y. I found that all cell lines expressed a multitude of 
receptors and ion channels with relevance to nociceptive signalling. However, although the 
cell lines investigated express molecular targets found in native DRGs, they are not 
representative of specific subclasses of peripheral sensory neurons and do not fit into existing 
peripheral neuron categories. Therefore, despite being derived from DRG neurons, these in 
vitro cell models do not represent native DRG neuron subtypes such as nociceptors, making it 
difficult to use these cells to investigate for potential modulators of NaV1.6 and NaV1.8 
channels, or to investigate nociceptors in general. The next chapter therefore turns to an 
animal model of a NaV1.7-independent pain modality, that of burn-induced pain, to study the 
role of selective NaV isoforms in animal pain pathways and to discern other potential novel 
therapeutic targets and clinically effective new drugs for burn-induced pain. 
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Chapter 4 – Behavioural and pharmacological analysis of a burn-
induced pain model in mice 
 
4.1 Foreword 
Using bioactive compounds to isolate modulators of the NaV1.6 and NaV1.8 isoforms, as well 
as using neuron-derived in vitro cell models to simulate the effect of modulators in 
nociceptive neurons, have been covered in chapters 2 and 3 of this thesis. However, both 
methods have challenges and issues that the previous chapters have brought to light. Using 
bioactive venoms to screen for selective modulators resulted in a lead peptide, but one that 
has off-target activity. This concern was only revealed after extensive chemical purification 
and the identification of the amino acid sequence, making the method time-consuming and 
with a high rate of failure. At the same time, chapter 3 analysed the transcriptome profile of 
three common in vitro cell lines and found none of them to be representative of native DRG 
neuron subtypes, and are not appropriate as tools to investigate NaV-expressing nociceptors. I 
therefore utilised an animal model instead in this chapter, capitalising on the clinical 
relevance of animal models of pain and using known channel modulators to study the role of 
selective NaV channels in burn-induced pain, a condition that is known to be only partially 
affected by the absence of NaV1.7. 
 
Some data presented in this chapter have been accepted for publication by Molecular Pain
282
. 
The content has been edited and additional data has been included to fit the structure of a 
thesis chapter. 
 
4.2 Introduction 
Burn injury is one of the most common injuries around the world, causing an estimated 
265,000 deaths annually world-wide and necessitating medical treatment of nearly 11 million 
people in 2004
4
. Out of the three potential causes of a thermal burn - scald, flame, and contact 
burns - burns from a flame is consistently responsible for approximately 40% of all cases 
across patients of all ages, with the exception of young children under 5 years of age, who 
primarily suffer from contact burns
283
. Electric and chemical burns, two non-thermal causes 
of burn injuries, only make up less than 10% of all burn incidences when combined. Pain is 
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present in most patients following a burn injury, particularly as the patient recovers and scar 
tissue develops. Burn pain is a complex symptom consisting of multiple components, 
including spontaneous or non-evoked pain as well as hypersensitivity to mechanical and 
thermal stimuli that can transition from an acute, self-limiting nociceptive response to chronic 
pain with neuropathic components
284
. 
 
Procedural pain, which is pain associated with surgical interventions including debridement, 
grafting, and dressing changes, is short-lasting but severe in comparison to background 
pain
285
, and often requires additional intensive analgesic treatment in addition to the patient's 
existing regimen. Pain intensity can also fluctuate unpredictably over time and requires 
constant dose monitoring. The degree of pain appears to be independent of existing analgesic 
dose and burn severity
286
. Moreover, pain can last long after the burn injury has healed, and 
evidence of chronic pain with neuropathic features has been observed in patients irrespective 
of burn intensity
287
, making pain a difficult-to-manage and a frequently undertreated 
consequence of burn injury. 
 
While opioids remain a central approach for analgesia, especially in the acute phase
5
, 
concerns remain regarding opioid dependence, withdrawal, and side effects in burn patients. 
In addition, the fluid and unpredictable nature of burn pain results in frequent dose 
adjustments and pain control that is often unsatisfactory. Accordingly, adjuvant analgesics 
such as antidepressants, anticonvulsants, and non-steroidal anti-inflammatory drugs are used 
extensively in burn pain
288
, but often with conflicting results
289, 290
. 
 
Burn-induced pain is one of the conditions that do not fully respond to NaV1.7 inhibition. 
While burn-induced thermal allodynia was completely alleviated in NaV1.7 knockout mice, 
mechanical allodynia was not affected by NaV1.7 gene knockout, suggesting molecular 
mechanisms amongst neuropathic pain symptoms differ in a modality-dependent manner 
even if these symptoms are induced by the same injury. The efficacy of selective NaV isoform 
inhibition in abolishing mechanical allodynia was then examined using venom-derived NaV 
inhibitors, and NaV1.6 inhibition was shown to be the only treatment that significantly 
modulated mechanical allodynia. The burn-induced pain model also successfully replicated 
the efficacy of NaV1.7 inhibition in burn-induced thermal allodynia. Examination of NaV1.6 
expression in affected DRG neurons, however, indicate NaV1.6 expression was not changed 
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following the burn injury, prompting an in-depth bioinformatic analysis of injured DRG 
neurons, to be described in Chapter 5. 
 
4.3 Materials and Methods 
4.3.1 Materials 
All materials were obtained from Sigma-Aldrich (Castle Hill, New South Wales, Australia) 
unless otherwise stated. Meloxicam was obtained from Abcam (Melbourne, Victoria, 
Australia). Oxycodone was obtained from Mundipharma Pty Ltd (Sydney, New South Wales, 
Australia). The µ-conotoxins GIIIA and TIIIA were synthesised by Boc chemistry using 
methods described previously
291
 by Mr. Zoltan Dekan (Institute for Molecular Biosciences, 
University of Queensland), who also synthesised Pnc1. 
 
4.3.2 Animals 
Male wild-type C57BL/6 mice age 6 - 8 weeks and weighing 20 - 23 grams were used in the 
study. Ethical approval for experiments involving live animals was obtained from the 
University of Queensland animal ethics committee under the ethics approval number 
PHARM/074/13/RAMACIOTTI. Experiments were conducted in accordance with the 
Animal Care and Protection Regulation Queensland (2012), the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes, 8th edition (2013) and the 
International Association for the Study of Pain Guidelines for the Use of Animals in 
Research. 
 
All animals were housed in groups of 2 - 4 per cage in a stable environment under 12-hour 
light-dark cycles and had access to standard rodent chow and water ad libitum. A red 
polycarbonate Mouse House (Tecniplast, Italy) and shredded paper nesting material were 
supplied for enrichment. All animals were obtained from University of Queensland 
Biological Resources (Brisbane, Australia). 
 
Sample sizes of each experiment are detailed in the figure legends of the corresponding 
figure. 
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4.3.3 Induction of burn injury 
To induce a mild burn injury, the plantar skin of the left hind paw of mice was applied with 
firm pressure to a Peltier plate (Hot/Cold Plate, Ugo Basile, Comerio, Italy) set at 52.5 °C for 
25 seconds under 3% isoflurane anaesthesia. A pair of tweezers, with the tips wrapped in 
tissue paper, was used to press the plantar portion of the paw onto the Peltier plate. Sham 
control animals underwent the same procedure with the plate set at 22 °C (room temperature). 
Behavioural assessment was performed at the time points indicated and the same animals 
were used for each of the behavioural tests. 
 
4.3.4 Mechanical allodynia testing 
Mechanical allodynia was assessed using electronic von Frey (MouseMet Electronic von 
Frey, TopCat Metrology, United Kingdom). All measurements were conducted by a blinded 
observer unaware of treatments. Mice were habituated in the von Frey apparatus for at least 
10 minutes prior to testing. The von Frey filament was placed against the plantar skin of the 
hind paw and the pressure increased at a rate of 1 gram per second through rotation of the 
device. The MouseMet Software automatically recorded the force at which paw withdrawal 
occurred. The paw withdrawal force (PWF) was determined by the average of three tests, 
separated by at least 2 minutes. 
 
4.3.5 Thermal allodynia testing 
Thermal allodynia was assessed using the Hargreaves Test (Plantar Analgesia Meter, IITC, 
CA, USA) for model establishment and clinical drug treatment, and the thermal threshold 
probe (MouseMet Thermal, TopCat Metrology, United Kingdom)
292
 for selective NaV 
inhibitors. All measurements were conducted by a blinded observer unaware of treatments. 
 
For the Hargreaves Test, mice were habituated in the Hargreaves apparatus in individual 
polyvinyl boxes (10 x 10 x 10 cm) placed on glass heated to 25 °C for at least 30 minutes 
prior to testing. A radiant light heat source (50 °C) was focused on the plantar skin of the 
hind paw, and the latency to a withdrawal response was recorded. The mean time to 
withdrawal was determined from the average of three tests, separated by at least 2 minutes. A 
cut-off time of 20 seconds was used to avoid tissue damage. 
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For the thermal threshold probe, mice were tested according to methods described 
previously
292
. Briefly, mice were habituated in individual mouse runs for at least 5 min prior 
to testing. The thermal probe (MouseMet Thermal, TopCat Metrology, United Kingdom) was 
lightly placed against the plantar surface of the mouse paw and initiated heating of the probe 
while in contact with the mouse’s paw. The probe was preheated to ~37 °C before coming in 
contact with the paw, then once in contact heats at a rate of 2.5 °C per second, with a cut-off 
set at 60 ˚C to prevent tissue damage. Removal of the probe from the paw terminates heating 
and displays the withdrawal temperature. The temperature that elicited a paw withdrawal, 
known as the paw withdrawal temperature (PWT), was determined by a single test. 
 
4.3.6 Paw thickness 
Paw thickness was measured along the distal-proximal axis at the metatarsal level using a 
digital vernier caliper (Kincrome, Queensland, Australia) whilst the mouse was under 3% 
isoflurane anaesthesia. The paw thickness of the left (ipsilateral) paw was normalised to the 
value of the contralateral paw for each animal. 
 
4.3.7 Gait Analysis 
Gait analysis was assessed using the CatWalk XT analysis system (Noldus Information 
Technology, The Netherlands) as previously described
293
. Mice were placed individually at 
one end of the elevated glass walkway and allowed to walk freely to the other end until three 
successful runs were recorded. Mice received no prior training. Runs that took longer than 10 
seconds or with a speed variance > 90% were deemed unsuccessful and discarded. The green 
intensity of the walkway background was set at 0.10 and camera gain at 20.00. Recordings 
were analysed using the CatWalk XT software with the parameters described in Appendix 
3.4. 
 
4.3.8 Drug Treatment 
The analgesic efficacy of clinical compounds was assessed 3 days after the induction of burn 
injury or the sham procedure. All compounds were administered by intraperitoneal injection 
(i.p) with a drug concentration of 10 µL/g using a 30-gauge needle. Animals were 
randomised to receive either meloxicam (5 mg/kg) once daily, gabapentin (100 mg/kg) three 
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times daily, amitriptyline (3 mg/kg) once daily, or matched vehicle control, with the first dose 
administered at the time of the burn injury. Oxycodone (1, 3, and 10 mg/kg) was 
administered once only on the day of testing. All compounds were diluted in DPBS 
(Dulbecco’s Phosphate Buffered Saline, Life Technologies, Mulgrave, Victoria, Australia; 
for composition see Appendix 2.5), except meloxicam, which was diluted in DPBS with 10% 
dimethyl sulfoxide (DMSO). Behavioural assessment was performed at least 30 minutes after 
the final dose of all compounds by an investigator unaware of the treatments received by each 
individual animal. 
 
4.3.9 Motor Assessment 
Motor performance was assessed 3 days after the induction of burn injury or the sham 
procedure using the Parallel Rod Floor Apparatus with ANY-Maze Software (Stoelting Co., 
Wood Dale, USA). A single dose of oxycodone (10 mg/kg), gabapentin (100 mg/kg), or 
amitriptyline (3 mg/kg) was administered by i.p injection 30 minutes prior to motor 
assessment. Animals were placed in the Parallel Rod Floor Apparatus, and the ANY-Maze 
software recorded the distance travelled and number of foot slips over a 1-minute period. The 
ataxia index was calculated as the ratio of the total number of foot slips to the total distance 
(in metres) travelled. 
 
4.3.10 Analgesic efficacy of selective NaV inhibitors 
Experiments were conducted 3 days after the induction of burn injury or the sham procedure. 
All compounds were administered by shallow intraplantar injection (i.pl) into the left hind 
paw of mice under 3% isoflurane anaesthesia (for location see Appendix 3.5). Tetrodotoxin 
(TTX; Cayman Chemical, MI, USA) was diluted in DPBS. TIIIA, GIIIA, and Pnc1a were 
reconstituted in PSS with 1:1000 BSA (Alfa Aesar, MA, USA; Cat# J65966). ICA-121431 
and A-803467 were diluted in DPBS with 10% DMSO. Behavioural assessment was 
performed at least 5 minutes after the dose by an investigator unaware of the treatments 
received by each individual animal. All i.pl injections had a volume of 10 µL. 
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4.3.11 PDL-coating of coverslips for cell culture 
PDL (Poly D-lysine) powder was reconstituted with sterile Milli-Q water at a concentration 
of 200 µg/mL and separated into aliquots. Round coverslips (Thermo Fisher Scientific, 
Victoria, Australia) were sterilised via autoclave and were placed into sterile 24-well tissue 
culture plates (Nunclon
TM
 Delta treated, Nunc, Denmark), with one round coverslip 
occupying one well. Each coverslip had 40 µL of the PDL solution placed on the centre and 
was left in a sterile environment for 60 minutes to coat the coverslip surface with PDL to 
facilitate better cell adhesion. The PDL solution was removed from the coverslip at the end of 
the 60-minute incubation. 
 
4.3.12 Cell culture 
HEK293 cells stably expressing human NaV1.1 (hNaV1.1) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM (Minimum 
Essential Media; for composition see Appendix 2.2) with 10% FBS (foetal bovine serum, 
Life Technologies, Mulgrave, Victoria, Australia) and 2 mM L-glutamine (GlutaMax
TM
, Life 
Technologies, Mulgrave, Victoria, Australia). To maintain selective pressure for NaV 
expression, this culture media was supplemented with blasticidin (2 µg/mL; Life 
Technologies, Mulgrave, Victoria, Australia) and geneticin (300 µg/mL; Life Technologies, 
Mulgrave, Victoria, Australia). 
 
HEK293 cells stably expressing human NaV1.2 (hNaV1.2) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 
2 mM L-glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with blasticidin (4 µg/mL) and geneticin (600 µg/mL). Cells were seeded in 
T75 cm
2
 Corning® (Corning, MA, USA) cell culture flasks with CellBIND® surface. 
 
HEK293 cells stably expressing human NaV1.3 (hNaV1.3) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 
2 mM L-glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with blasticidin (2 µg/mL) and geneticin (600 µg/mL). 
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HEK293 cells stably expressing human NaV1.4 (hNaV1.4) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 
2 mM L-glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with blasticidin (2 µg/mL), geneticin (600 µg/mL), and zeocin (500 µg/mL; 
Life Technologies, Mulgrave, Victoria, Australia). Cells were seeded in T75 cm
2
 Corning® 
(Corning, MA, USA) cell culture flasks with CellBIND® surface. 
 
HEK293 cells stably expressing human NaV1.5 (hNaV1.5) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 
2 mM L-glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with blasticidin (2 µg/mL) and geneticin (600 µg/mL). Cells were seeded in 
T75 cm
2
 Corning® (Corning, MA, USA) cell culture flasks with CellBIND® surface. 
 
HEK293 cells stably expressing human NaV1.6 (hNaV1.6) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 
2 mM L-glutamine. 
 
HEK293 cells stably expressing human NaV1.7 (hNaV1.7) ion channels were obtained from 
Scottish Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 
2 mM L-glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with blasticidin (4 µg/mL) and geneticin (600 µg/mL). 
 
HEK293 cells stably expressing human NaV1.8 (hNaV1.8) were obtained from Scottish 
Biomedical (SB cells, Glasgow, UK). Cells were grown in MEM with 10% FBS and 2 mM 
L-glutamine. To maintain selective pressure for NaV expression, this culture media was 
supplemented with blasticidin (2 µg/mL) and geneticin (600 µg/mL). Cells were seeded in 
T75 cm
2
 Corning® (Corning, MA, USA) cell culture flasks with CellBIND® surface. 
 
All cells were incubated at 37°C and 95% O2/5% CO2. Cells were passaged every 3-5 days at 
a 1:5 dilution ratio or when approximately 90% confluent. All cells were seeded in T75 cm
2
 
Corning® (Corning, MA, USA) cell culture flasks unless previously stated. In order to 
passage cells, the cells were briefly removed from incubation and maintained in room 
temperature and had growth media removed from the flask. At least 5 mL/75 cm
2
 of DPBS 
was added into the flask to briefly wash the cells and was then removed from the flask. 
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0.25% Trypsin/EDTA (0.25% trypsin/ethylenediaminetetraacetic acid in Hank’s Balanced 
Salt Solution, Life Technologies, Mulgrave, Victoria, Australia; for composition see 
Appendix 2.6) was then added at a concentration of 1 mL/75 cm
2
, and the cells were 
dislodged by gently tapping the sides of the flask. The dislodged cell suspension were diluted 
with a further 9 mL of the appropriate growth media (as mentioned above) and passaged in 
1:10 dilution ratio in a new T75 cm
2
 flask and using new growth media. 
 
4.3.13 Immunofluorescence antibody validation 
HEK293 cells stably expressing human NaV (hNaV) isoforms hNaV1.1-1.8 were grown in 
conditions as described in Section 4.3.12. Following passaging of the cells, ~100 µL of the 
cell suspension was placed into the wells of the 24-well tissue culture plate with PDL-coated 
coverslips within them. Approximately 500 µL of the appropriate culture media was then 
added into individual wells. The 24-well tissue culture plate was then incubated at 37 °C and 
95% O2/5% CO2 for 24 hours. 
 
After 24 hours, media was removed from the 24-well plate and the coverslips were washed 
with 500 µL of fresh DPBS for 5 times. The cells growing on the coverslip were fixed for 
immunofluorescence for 10 minutes using 100 µL of 4% formaldehyde (Thermo Fisher 
Scientific, Victoria, Australia) diluted in DPBS, followed by washing with 500 µL of fresh 
DPBS for 5 times. The cells were further blocked using 3% donkey serum, 3% BSA, and 
0.1% Triton
TM
 X-100 dissolved in DPBS for 10 minutes, followed by washing with 500 µL 
of fresh DPBS for 5 times. 
 
Two primary antibodies for NaV1.6, produced by Abcam (Abcam, Melbourne, Victoria, 
Australia; rabbit anti-mouse antibody, Cat #: ab65166) and Alomone (Alomone, Jerusalem, 
Israel; rabbit anti-mouse antibody, Cat #: ASC-009), were reconstituted in sterile Milli-Q 
water as per manufacturers’ instructions. Both antibodies were diluted 1:300 in the blocking 
solution and 100 µL of the diluted solution were placed on the coverslips and incubated at 4 
°C overnight. The solution was removed at the end of the incubation and the coverslips were 
washed with 500 µL of fresh DPBS for 5 times. 
 
The fluorescent secondary antibody (Abcam, Melbourne, Victoria, Australia; Donkey Anti-
Rabbit IgG Alexa Fluor® 488, Cat #: ab150073) were then diluted 1:1000 in the blocking 
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solution and 100 µL of the diluted solution were placed on the coverslips and incubated at 4 
°C overnight. The solution was removed at the end of the incubation and the coverslips were 
washed with 500 µL of fresh DPBS for 5 times. 
 
DAPI (4',6-diamidino-2-phenylindole) was then diluted 1:1000 in DPBS and sufficient 
amounts of the diluted solution were placed on the coverslips for 5 minutes. The solution was 
removed at the end of the incubation and the coverslips were washed with 500 µL of fresh 
DPBS for 5 times. 
 
The glass coverslips were carefully removed from the 24-well plate using tweezers, and were 
mounted on glass slides (Superfrost, Menzel-Glaser, Thermo Fisher Scientific, Queensland, 
Australia) using 10 µL of fluorescent mounting media (Dako, Sydney, New South Wales, 
Australia) per coverslip, and kept at 4 °C for a minimum of 2 hours to allow the mounting 
media to set. 
 
The slides were then imaged with an Olympus BX-51 upright fluorescent microscope 
(Olympus, NY, USA), equipped with an Olympus DP-71 12Mp colour camera (Olympus, 
NY, USA) and an Exfo Xcite 120 lamp (Excelitas, MA, USA). Images were taken using the 
DP Capture software (Olympus, NY, USA) when examined through the GFP-4050A filter 
using the 100x/1.4 Plan Apo Oil lens (Nikon Instruments, NY, USA) with immersion oil 
(Carl Zeiss Immersol
TM
 Immersion Oil, Carl Zeiss, New South Wales, Australia). 
 
4.3.14 DRG neuron immunofluorescence experiments 
At 3 days after the burn injury or the sham procedure, mice were sedated via inhalation of 
50% O2/50% CO2 gas inhalation and euthanised via asphyxiation using 100% CO2, followed 
by cervical dislocation. The spine was immediately removed using surgical equipment, the 
dorsal side of the vertebra bones removed, and the tissue immersed in ice-cold DMEM. The 
spinal cord was then removed, and lumbar DRGs (L3-L5 inclusive) were dissected with 
forceps under a dissection microscope and placed in fresh DPBS within a 33mm-diameter 
petri dish (Nunclon
TM
 Delta treated, Nunc, Denmark), followed by trimming of excess 
myelin. At least 3 mice were sacrificed per separate sample in the control and burn cohorts. 
 
138 
 
DRGs were then placed into 4% formaldehyde diluted in DPBS for 15 minutes, then rinsed in 
fresh DPBS. The DRGs were then placed for 1 hour into 10% sucrose (Chem-supply, South 
Australia, Australia) dissolved in DPBS, followed by immersion into 20% sucrose solution 
for approximately 6 hours, then immersion into 30% sucrose solution overnight. 
 
Individual DRGs were then placed separately on parafilm (Labtek, Queensland, Australia) 
with one drop of Tissue-Tek® O.C.T. media (ProSciTech, Queensland, Australia) on top of 
each DRG. The DRG blocks were then transferred to a Leica cryostat (Leica CM3050 S, 
Leica Biosystems, New South Wales, Australia) and cut at a thickness of 14 µM per slice 
with object temperature and chamber temperature both set at -20 °C. Slices were transferred 
to positively-charged glass slides (Superfrost Plus, Menzel-Glaser, Thermo Fisher Scientific, 
Queensland, Australia) and left in room temperature for approximately 30 minutes to dry. 
 
A fluid-resistant barrier was drawn using a PAP-Pen (Aqua hold pap pen, ProSciTech, 
Queensland, Australia) around each sample on the glass slide. The samples were then 
blocked using 3% donkey serum, 3% BSA, and 0.1% Triton
TM
 X-100 dissolved in DPBS for 
10 minutes, followed by washing with 500 µL of fresh DPBS for 5 times. 
 
Primary antibody for NaV1.6 (Abcam, Melbourne, Victoria, Australia; rabbit anti-mouse 
antibody, Cat #: ab65166) was reconstituted in sterile Milli-Q water as per manufacturers’ 
instructions. The antibody was diluted 1:300 in the blocking solution and 25 µL of the diluted 
solution were placed on the sample. Each sample were then covered with coverslips and 
incubated at 4 °C overnight. Coverslips were then carefully taken off the sample and the 
solution removed at the end of the incubation, and the slides were washed with 500 µL of 
fresh DPBS for 5 times. 
 
The fluorescent secondary antibody (Abcam, Melbourne, Victoria, Australia; Donkey Anti-
Rabbit IgG Alexa Fluor® 488, Cat #: ab150073) were then diluted 1:1000 in the blocking 
solution and 25 µL of the diluted solution were placed on the sample. Each sample were then 
covered with coverslips and incubated at 4 °C overnight. Coverslips were then carefully taken 
off the sample and the solution removed at the end of the incubation, and the slides were 
washed with 500 µL of fresh DPBS for 5 times. 
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Samples were mounted using 10 µL of fluorescent mounting media (Dako, Sydney, New 
South Wales, Australia) per sample. Individual coverslips were placed carefully over each 
sample and kept at 4 °C for a minimum of 2 hours to allow the mounting media to set. 
 
The slides were then imaged with an Olympus BX-51 upright fluorescent microscope 
(Olympus, NY, USA), equipped with an Olympus DP-71 12Mp colour camera (Olympus, 
NY, USA) and an Exfo Xcite 120 lamp (Excelitas, MA, USA). Images were taken using the 
DP Capture software (Olympus, NY, USA) when examined through the GFP-4050A filter 
using the 20x/0.75 Plan Apo lens (Nikon Instruments, NY, USA). 
 
4.3.15 Data Analysis 
Data were plotted and analysed by GraphPad Prism, version 6.00. Statistical significance was 
defined as P-value < 0.05 and was determined by unpaired t-test assuming equal variance. 
Data is expressed as the mean ± standard error of the mean (SEM). CatWalk data was 
extracted from the CatWalk XT software (Noldus, The Netherlands) and plotted in GraphPad 
Prism. Relative optical density calculation and composite immunofluorescence image 
compilation were done using ImageJ (Public Domain software, obtained from 
imagej.nih.gov). Figures were assembled using Adobe Illustrator® C56, version 16.0.3. 
 
4.4 Results 
4.4.1 Mice in the burn injury model exhibited robust mechanical allodynia, thermal 
allodynia, and inflammation of the injured paw 
A peripheral mild burn injury was produced in wild-type male C57BL/6 mice based on 
methods used in a previous mouse model
187
 and in rat models
294-296
. Exposure of the left hind 
paw in mice to a metal surface set at a temperature of 52.5°C for 25 seconds resulted in a 
first-degree or superficial burn (for detailed location see Appendix 3.5), as evidenced by the 
immediate development of localised redness and swelling, without the presence of blisters. 
Mild spontanous pain was present immediately after burn injury (9.8 ± 2.7 pain behaviours / 
5 minutes) and persisted for up to 6 hours, precluding behavioural assessment of mechanical 
and thermal allodynia. Once spontanous pain subsided, a significant reduction in mechanial 
and thermal thresholds was observed compared to sham control animals, which was observed 
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within 6 hours of the burn injury and persisted for at least 4 days post burn injury (Figure 4.1 
A-B). Inflammation, as evidenced by a statistically significant increase in the thickness of the 
affected paw of mice compared to the mice's contralateral paw, developed rapidly, peaking 
immediately after the burn injury (Paw thickness 6 hours: 156 ± 5 %), and persiststed for at 
least 4 days (Figure 4.1 C). 
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Figure 4.1 Establishment of a mouse model of burn-induced pain after a unilateral hind 
paw mild heat injury 
Model establishment measurements for the mouse burn-induced pain model. A) Time course 
of the development of mechanical allodynia assessed using the electronic von Frey apparatus. 
B) Time course of the development of thermal allodynia assessed using the Hargreaves 
method. C) Time course of development of inflammation, as measured by paw thickness 
normalised to the contralateral paw. Statistical significance was determined using t-test, * P-
value < 0.05 compared to sham control. All data are represented as mean ± SEM; n = 3 for 
sham control group and n = 18 for burn group. 
 
 
 
142 
 
4.4.2 Gait abnormalities following the injury were examined holistically using the CatWalk 
apparatus 
While gait analysis has previously been utilised to quantify pain-related behaviours in other 
rodent models of inflammatory and neuropathic pain
297, 298
, gait abnormalities have not 
previously been assessed in rodent models of burn injury. Here, the chapter provides for the 
first time a detailed characterisation of gait analysis following a unilateral burn-injury in mice 
using the CatWalk XT. All paw pressure parameters (mean intensity, mean intensity of the 15 
most intense pixels, max intensity) were significantly reduced in the ipsilateral hind paw 
compared to the contralateral hind paw (Figure 4.2 A-C), signifying a difference in weight 
bearing between the hind paws. Paw print area parameters (print area, max contact area) were 
minimally affected, perhaps confounded by the presence of swelling in the ipsilateral hind 
paw (Figure 4.2 D-E). Some differences in dynamic paw parameters (stand, swing, duty 
cycle) were detected in the first 24 hours, but lost statistical significance after 48 hours 
(Figure 4.2 F-H). Interlimb coordination, as measured by the regularity index, remained 
unchanged from sham controls, indicating that burn-injured mice followed a normal step 
sequence (Figure 4.2 I). As the paw pressure parameter ‘mean intensity of the 15 most 
intense pixels’ (Figure 4.2 B) was the most sensitive parameter to detect differences between 
ipsilateral and contralateral hind paws in burn-injured mice, this parameter was used to assess 
the effects of clinical compounds on weight bearing behaviour. Descriptions of all assessed 
measurements can be found in Appendix 3.4. 
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Figure 4.2 Characterisation of gait abnormalities in a unilateral mouse model of burn 
injury using selected parameters from the CatWalk XT 
Time course of changes in (A-C) paw pressure, (D, E) paw print area, and (F-H) dynamic 
paw parameters in the ipsilateral and contralateral hind paw in burn injured animals. (I) No 
changes in interlimb coordination as measured by the regularity index were detected between 
burn and sham controls. Statistical significance was determined using t-test. * P-value < 0.05 
compared to contralateral paw or sham control as indicated. All data is presented as mean ± 
SEM with 5-10 mice per group. 
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4.4.3 Analgesic efficacy of clinically used analgesics in the mouse model 
To further characterise the model, the analgesic efficacy of a range of clinically used 
compounds were assessed in the model, as systematic assessment of clinically used 
analgesics has not previously been reported in burn-induced pain. Oxycodone (3 and 10 
mg/kg), meloxicam, and gabapentin all significantly alleviated mechanical allodynia 
compared to vehicle control, however PWF was not returned to baseline values (PWF: 
oxycodone (3 mg/kg), 2.1 ± 0.4 g; oxycodone (10 mg/kg), 2.5 ± 0.5 g; meloxicam (5 mg/kg), 
2.2 ± 0.4 g; gabapentin (100 mg/kg), 2.7 ± 0.3 g; vehicle control, 1.1 ± 0.5 g; P-value < 0.05; 
Figure 4.3 A), while amitriptyline and oxycodone (1 mg/kg) had no significant effect. Both 
oxycodone (10 mg/kg) and amitriptyline abolished thermal allodynia, significantly increasing 
the time of withdrawal to a radiant light stimulus compared to vehicle control (time to 
withdrawal: oxycodone (10 mg/kg), 12.1 ± 3.5 seconds; amitriptyline (3 mg/kg), 15.3 ± 2.0 
seconds; vehicle control, 6.7 ± 1.1 seconds; * P-value < 0.05; Figure 4.3 B), while 
meloxicam, gabapentin and oxycodone at doses less than 3 mg/kg had no significant effect. 
Weight bearing on the ipsilateral hind paw was significantly increased by oxycodone (10 
mg/kg) and amitriptyline (ratio to control: oxycodone (10 mg/kg), 1.27 ± 5 %; amitriptyline 
(3 mg/kg), 1.18 ± 7 %; vehicle control, 0.99 ± 6 %; * P-value < 0.05; Figure 4.3 C), but not 
by meloxicam, gabapentin or doses of oxycodone less than 3 mg/kg. The observed anti-
allodynic effects of oxycodone and amitriptyline were not due to motor impairment, as only 
gabapentin (100 mg/kg) significantly increased the ataxia index compared with vehicle 
control (ataxia index: vehicle control, 2.8 ± 0.4; gabapentin, 9.6 ± 0.9. * P-value < 0.05; 
Figure 4.3 D). 
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Figure 4.3 Activity of clinically used analgesic compounds in the burn-induced pain 
mouse model 
The analgesic efficacy of drugs clinically used to treat burn pain was examined in the mouse 
burn-induced pain model. A) Oxycodone (3 and 10 mg/kg), meloxicam, gabapentin, and 
amitriptyline partially but significantly alleviated mechanical allodynia as assessed by 
electronic von Frey. B) Only oxycodone (10 mg/kg) and amitriptyline significantly reversed 
thermal allodynia assessed by the Hargreaves method. C) Oxycodone (10 mg/kg) and 
amitriptyline led to a significant increase in weight bearing of the ipsilateral hind paw, as 
detected by the ‘Mean Intensity of the 15 most intense pixels’ parameter using the Catwalk 
XT. D) Only gabapentin (100 mg/kg) had a significant effect on motor impairment, 
significantly increasing the ataxia index (calculated as the ratio of the total number of foot 
slips to the total metres travelled; all numbers are ratios and are therefore without units) 
compared to vehicle control. Statistical significance was determined using t-test. * P-value < 
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0.05 compared to vehicle control. Dotted lines represent the mean value from sham control 
mice that did not undergo the burn injury. All data are represented as mean ± SEM with 5-17 
mice per group. 
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4.4.4 Analgesic effect of selective NaV inhibitors in different burn-induced pain modalities 
The model was then used to ascertain the analgesic efficacy of various selective NaV 
inhibitors administered peripherally via i.pl injection (injection into the left paw; for exact 
location see Appendix 3.5), both to validate the previous finding that NaV1.7 affects burn-
induced thermal allodynia and to investigate the involvement of various NaV isoforms in 
burn-induced mechanical allodynia. Intraplantar injection was chosen over intraperitoneal 
injection due to a variety of factors, including limited availability of the compound (Pnc1a in 
particular) and systemic side effects following systemic administration of other compounds 
(such as TTX). Moreover, I sought to understand the effect of local NaV inhibition in neurons 
directly affected by the burn injury, as opposed to general inhibition of both affected and 
unaffected neurons. 
 
Thermal allodynia was examined with the thermal threshold probe instead of the Hargreave’s 
apparatus. The Hargreave’s apparatus required mice to be re-habituated in the cages 
following drug injection for an average of 1 hour. However, the rapid onset and offset of 
NaV-inhibitory effects of the peptides when administered i.pl (effects are observed to 
completely disappear at an average of 10-30 minutes following injections) makes it 
unpractical to test the effect of the peptides with the Hargreave’s apparatus, as the analgesic 
effect is likely to have disappeared after the re-habitation period and could not be assessed. 
  
Thermal allodynia was significantly alleviated with TTX (1 µM, i.pl), which conformed to 
the previous observation that the inhibition of NaV1.7, a TTX-s isoform, significantly 
diminished burn-induced thermal allodynia
187
 (Paw withdrawal temperature: TTX, 46.1 ± 1.4 
°C; vehicle control 43.3 ± 0.6 °C; * P-value < 0.05; Figure 4.4 A). The inhibition of TTX-
resistant NaV1.8 using A-803467 (10 µM, i.pl.) did not revert thermal allodynia (Paw 
withdrawal temperature: A-803467, 44.9 ± 0.8 °C; vehicle control, 43.3 ± 0.6 °C; Figure 4.4 
A). Injection of Pnc1a (1 µM, i.pl), a selective NaV1.7 peptide inhibitor extracted from the 
venom of Pamphobeteus nigricolor and characterised extensively in-house (data not shown), 
successfully alleviated thermal allodynia, which concurred with data obtained from NaV1.7-
knockout mice
187
 (Paw withdrawal temperature: Pnc1a, 47.3 ± 1.0 °C; vehicle control 43.3 ± 
0.6 °C; * P-value < 0.05; Figure 4.4 A). GIIIA (10 µM, i.pl), a venom peptide that is 
inhibitory for NaV1.1, NaV1.2, NaV1.4, and NaV1.6, did not significantly alter the symptoms 
of thermal allodynia, suggesting none of those NaV isoforms contribute substantially towards 
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the neuronal activity responsible for burn-induced thermal allodynia (Paw withdrawal 
temperature: GIIIA, 43.3 ± 1.2 °C; vehicle control, 43.3 ± 0.6 °C; Figure 4.4 A).  
 
Mechanical allodynia from burn injury was examined using the electrical von Frey system. 
TTX (1 µM, i.pl) was first tested to ascertain whether TTX-s or TTX-r NaV isoforms 
predominantly affect mechanical allodynia in burn injury. Since TTX significantly reverted 
symptoms of mechanical allodynia symptom (PWF: TTX, 2.2 ± 0.3 g; vehicle control, 1.2 ± 
0.1 g; * P-value < 0.05; Figure 4.4 B), TTX-s NaV isoforms were determined to play a major 
role in burn-induced mechanical allodynia. To confirm that TTX-r NaV isoforms do not 
contribute to burn-induced mechanical allodynia, A-803467 (10 µM, i.pl.) was used to inhibit 
NaV1.8 and was indeed found to be ineffective  (PWF: A-803467, 1.2 ± 0.2 g; vehicle 
control, 1.2 ± 0.1 g; Figure 4.4 B). Pnc1a (1 µM, i.pl.) was therefore tested due to the known 
efficacy of NaV1.7 inhibition in burn-induced thermal allodynia, and also to validate the 
observation in knockout mice that NaV1.7 gene knockout did not alleviate burn-induced 
mechanical allodynia. Pnc1a was not effective in modifying mechanical allodynia (PWF: 
Pnc1a, 0.8 ± 0.2 g; vehicle control, 1.2 ± 0.1 g; Figure 4.4 B), suggesting that NaV1.7 
inhibition does not contribute to TTX-s NaV isoform-mediated reversal in burn-induced 
mechanical allodynia. GIIIA (10 µM, i.pl.) was then tested to examine the efficacy of 
inhibiting NaV1.1, NaV1.2, NaV1.4, and NaV1.6, and significantly alleviated paw withdrawal 
threshold to levels comparable to TTX administration (PWF: GIIIA, 2.0 ± 0.3 g; TTX, 2.2 ± 
0.3 g; vehicle control, 1.2 ± 0.1 g; * P-value < 0.05; Figure 4.4 B). To better elucidate the 
contribution of various NaV isoforms inhibited by GIIIA, TIIIA (10 µM, i.pl.), a conotoxin 
with known inhibitory activity for NaV1.1, NaV1.2, and NaV1.4
212
, was administered and did 
not demonstrate a significant difference in PWF compared to vehicle control (PWF: TIIIA, 
1.0 ± 0.2 g; vehicle control, 1.2 ± 0.1 g; Figure 4.4 B). Thus, these results suggest that the 
inhibition of NaV1.6 in the periphery caused a significant reduction in burn-induced 
mechanical allodynia in the mouse model, but did not affect burn-induced thermal allodynia, 
and the opposite was observed for NaV1.7 inhibition. Lastly, weight bearing was not 
alleviated from the local administration of GIIIA or TTX, suggesting that while TTX-s NaV 
isoforms are vital in mediating mechanical and thermal allodynia, these channels were not 
effective in modulating weight bearing. 
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Figure 4.4 NaV1.6 inhibition alleviated burn-induced mechanical allodynia but was not 
effective in burn-induced thermal allodynia 
The analgesic effect of NaV inhibitors were used to examine the contribution of NaV channels 
in different modalities of burn-induced pain. Peripheral NaV1.6 inhibition significantly 
reduced mechanical allodynia and did not affect thermal allodynia, and the opposite was 
observed in peripheral NaV1.7 inhibition. A) Both TTX and Pnc1a significantly reverted 
mechanical allodynia as assessed by the electronic von Frey system. B) TTX and GIIIA 
significantly reversed thermal allodynia as measured by the thermal probe method. The 
involvement of NaV1.6 was determined by utilising TIIIA to inhibit other NaV isoforms 
(NaV1.1, NaV1.2, and NaV1.4) also affected by GIIIA. C) TTX-s NaV isoforms do not revert 
gait abnormalities of the injured mice as observed in the CatWalk. Statistical significance was 
determined using t-test. * P-value < 0.05 compared to vehicle control. Dotted lines represent 
the mean value from sham control mice that did not undergo the burn injury. All data are 
represented as mean ± SEM with 4-15 mice per group. 
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4.4.5 Validation of NaV1.6 antibodies for selectivity in immunofluorescence 
Since pharmacological characterisation of the model suggested the involvement of NaV1.6 in 
mechanical allodynia, immunofluorescence (IF) was used to examine NaV1.6 expression in 
DRG neurons following the burn injury. Two antibodies, manufactured by Abcam (category 
number: ab65166) and Alomone (category number: ASC-009), were validated in HEK293 
cells expressing hNaV1.1-1.8 (Figure 4.5) for immunofluorescence.  
 
The anti-NaV1.6 antibody produced by Abcam selectively labelled HEK293 cells expressing 
NaV1.6 over cells expressing NaV1.1-1.5, 1.7, and 1.8 (Figure 4.5 A). In comparison, the 
NaV1.6 antibody produced by Alomone exhibited significant labelling for HEK293 cells 
expressing NaV1.1-1.4 as well as cells expressing NaV1.6 (Figure 4.5 B), indicating a lack of 
NaV1.6 selectivity. The Abcam NaV1.6 antibody was therefore selected for 
immunofluorescence studies in native tissues for NaV1.6 expression changes following the 
burn injury. 
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Figure 4.5 Validation of commercially available NaV1.6 antibodies 
Two commercially available antibodies for NaV1.6, produced by Abcam (category number: 
ab65166) and Alomone (category number: ASC-009), were tested for NaV1.6 selectivity in 
HEK293 cells expressing NaV1.1-1.8. The antibody produced by Abcam exhibited more 
NaV1.6 selectivity than the Alomone antibody and was chosen to stain native tissues from the 
burn injury model. A) Selectivity of the Abcam NaV1.6 antibody in HEK293 cells expressing 
NaV1.1-1.8 channels. Marked fluorescence was observed only in HEK293 cells expressing 
NaV1.6. B) Selectivity of the Alomone NaV1.6 antibody in HEK293 cells expressing NaV1.1-
1.8 channels. Marked fluorescence was observed in cells expressing NaV1.1, 1.2, 1.3, and 1.6 
isoforms. Binding was also observed in cells expressing NaV1.4, 1.5, and 1.7 to a lesser 
degree. As the antibody exhibits binding to NaV isoforms other than NaV1.6, the antibody 
produced by Alomone was deemed to be inappropriate for use in future studies and the 
Abcam antibody was chosen to study the expression of NaV1.6 in native tissues. 
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4.4.6 The expression of NaV1.6 in DRG neurons affected by the burn injury 
Cryo-sections of DRGs extracted from sham control mice and mice with the burn injury were 
compared using IF staining, with the hypothesis that as NaV1.6 inhibition successfully 
alleviated burn-induced mechanical allodynia, NaV1.6 expression could have become up-
regulated in DRG neurons following the injury. However, IF studies did not indicate an 
observable difference in NaV1.6 expression in L3, L4, and L5 DRG neurons following the 
burn injury (Figure 4.6 A-B). Analysis of the relative optical density of the IF images 
between the sham cohort and the burn injury cohort showed no significant differences 
between the two groups (Relative Optical Density: Burn group, 1244 ± 84.9; Control group 
(Normal), 1421 ± 119.4; Figure 4.6 C. Images were representative of 6 control samples and 
13 burn injury samples over 2 separate experiments), indicating that the expression of NaV1.6 
in DRG neurons was not altered significantly despite the efficacy of NaV1.6 inhibition 3 days 
following the burn injury. 
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A Control sample 
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B Burn sample 
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Figure 4.6 Immunofluorescence imaging was used to examine the expression of NaV1.6 
in DRG neurons before and after the peripheral burn injury 
A) Representative image of control DRG slices from animals that did not undergo the burn 
injury (6 images from 2 separate experiments). B) Representative image of DRG slices at 3 
days following the burn injury, without the administration of any compounds to the animal 
(13 images from 2 separate experiments). C) Comparison of average relative optical density 
(ROD) of immunofluorescence images indicate no significant differential expression of 
NaV1.6 was detected in DRG neurons following the burn injury. Image analysis was 
conducted using Image J. Bar graph is presented as mean ± SEM.  
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4.5 Discussion 
This chapter established and characterised a mouse model of burn injury-induced pain using 
behavioural and pharmacological approaches. This model appears suitable for analgesic 
efficacy profiling of novel treatments that may provide improved management approaches for 
this under-treated and difficult-to-manage condition. In contrast to previously reported mouse 
models
187
, this model causes a superficial or first-degree burn, without the presence of 
blisters or broken skin, while still producing robust mechanical and thermal allodynia as well 
as detectable differences in weight bearing behaviour. 
 
Mechanical and thermal allodynia are both abnormal stimulus-induced sensations that may 
mimic elevated pain experienced by patients during procedures such as dressing changes
285
. 
However, stimulus-evoked allodynia may be poorly reflective of spontaneous or background 
pain and I thus evaluated the ability of the CatWalk XT system to detect burn-induced gait 
abnormalities as a surrogate for non-stimulus evoked pain. Consistent with previous studies, I 
found a good correlation between development of altered CatWalk XT parameters, 
specifically those relating to paw contact with the glass walkway, with mechanical and 
thermal allodynia detected by more traditional behavioural assessment. However, gait 
abnormalities were only alleviated by high dose oxycodone and amitriptyline, suggesting that 
these parameters are not simply a reflection of mechanical allodynia but represent a distinct 
pain modality. It is possible that this discrepancy arises from interference of local 
inflammation and paw swelling with normal gait. Accordingly, it is currently unclear whether 
analgesic effects detected using the CatWalk XT system can be translated more readily to 
clinical efficacy in human burn patients than effects detected using conventional tests such as 
the von Frey or Hargreaves apparatus. The often poor predictive power of conventional 
assessment of evoked nociceptive behaviours suggests that effects on gait should be assessed 
routinely, as these parameters may reflect clinically meaningful measures of pain and 
analgesia. 
 
Mild burn injuries affecting less than 10% of total body surface area represent the 
overwhelming majority of burn injuries in the clinical setting and account for approximately 
80% of all hospital or emergency service burn admissions
299
, making this model relevant to 
many patients. Clinically used analgesics and adjuvants known to have some efficacy in 
burn-induced pain, such as oxycodone and gabapentin
300, 301
, reduced mechanical and thermal 
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allodynia as well as gait abnormalities, supporting the translational validity of my model. 
Specifically, gabapentin and amitriptyline, two drugs used as chronic pain adjuvant 
treatments, were effective at alleviating mechanical and thermal allodynia respectively. 
However, both drugs were only partially anti-allodynic, consistent with effects seen in the 
clinic
290, 294, 302
.  
 
A small human study indicated the administration of a single 1200 mg dose of gabapentin 
effectively alleviated mechanical allodynia immediately following burn injuries
302
, but lacked 
efficacy in acute pain post-burn as an adjunct analgesic in a randomised control trial 
involving 53 patients
290
. Similarly, amitriptyline is widely used for management of chronic 
pain, and intraplantar administration of amitriptyline also produced thermal antihyheralgesia 
in a rat model of local mild burn
294
. My model identified both gabapentin and amitriptyline as 
potentially effective analgesic compounds in burn-induced pain, although systematic clinical 
trials assessing efficacy of adjuvants in human burn patients are lacking. 
 
Opioids form the mainstay of therapy for burn-induced pain, albeit the specific drug of choice 
varies. Oxycodone, a commonly used µ opioid receptor agonist, successfully reversed 
mechanical allodynia, thermal allodynia, as well as weight bearing parameters. Notably, burn 
injury-induced pain behaviours were relatively opioid-resistant compared with doses required 
to elicit analgesia in simple nociceptive models (1-2 mg/kg)
303, 304
. A requirement for higher 
opioid doses to achieve effective analgesia has also been noted for human burn patients
305
, 
suggesting that the pathophysiological mechanisms underpinning burn-injury induced pain 
incorporate elements that lead to decreased efficacy of opioids. This phenomenon can either 
lead to ineffective analgesia due the clinician’s unwillingness to prescribe beyond standard 
opioid doses, or place patients at higher risk of opioid adverse effects. 
 
As NaV1.7 knockout animals did not develop burn-induced thermal allodynia but exhibited 
robust burn-induced mechanical allodynia
187
, this chapter further explored the contribution of 
various NaV isoforms in burn-induced thermal and mechanical allodynia. TTX was examined 
first in thermal allodynia and was found to be effective, suggesting that TTX-s NaV isoforms 
are involved in burn-induced thermal allodynia. NaV1.8 inhibition subsequently demonstrated 
no effect on thermal allodynia, reiterating that TTX-s NaV channels are the mediators of the 
nociceptive signals in this modality. The finding also concurred with the previous finding that 
NaV1.8 and NaV1.9 knockout mice displayed no differences in burn-induced thermal 
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allodynia compared to wild-type mice
187
. The inhibitor used for NaV1.8, the small molecule 
A-803467, exhibits high potency for NaV1.8 (IC50 = 8 nM) with more than a-hundred-fold 
selectivity for NaV1.8 compared to NaV1.2, NaV1.3, and NaV1.7
210
, and is widely used in 
animal models and in electrophysiology for NaV1.8 inhibition
134, 174, 204
. NaV1.7 inhibition via 
Pnc1a i.pl injection resulted in the highest paw withdrawal temperature among all 
experimental cohorts tested, but NaV1.7 inhibition did not revert the paw withdrawal 
temperature to that observed in uninjured mice (dotted line, average of 49.6 °C, n = 15, 
Figure 4.4 A). In comparison, Shields et al.
187
 observed a complete reversal of thermal 
allodynia in NaV1.7 knockout animals 3 days after the injury. This discrepancy could be due 
to physiological differences between global gene knockout and local functional inhibition. 
Treatment with GIIIA, a peptide that inhibits NaV1.1, 1.2, and 1.6, did not alleviate thermal 
allodynia in the mice, indicating these isoforms are also unrelated to burn-induced thermal 
allodynia. 
 
The study conducted by Shields et al.
187
 showed that NaV1.7 knockout mice demonstrated no 
behavioural differences compared to control wild-type mice in burn-induced mechanical 
allodynia, suggesting a lack of NaV1.7 involvement in that pain modality. At the same time, 
the study conducted by Salas et al.
306
 found subcutaneous injections of TTX to successfully 
alleviate mechanical allodynia in rats with a peripheral burn injury. Such evidence would 
suggest TTX-s NaV isoforms apart from NaV1.7 are responsible for burn-induced mechanical 
allodynia. In my burn injury model, the peripheral administration of TTX was found to be 
effective in abolishing mechanical allodynia, confirming the contribution of TTX-s NaV 
isoforms. Further, the administration of the highly selective NaV1.7 inhibitor Pnc1a elicited 
no change in mechanical withdrawal thresholds in injured mice compared to control mice. I 
therefore confirmed that NaV1.7 does not affect burn-induced mechanical allodynia. TTX-r 
NaV isoforms were shown to be ineffective at reversing burn-induced mechanical allodynia, 
seen both in my model and in NaV1.8 and NaV1.9 knockout mice in the publication by 
Shields et al.
187
. 
 
The peripheral administration of GIIIA, however, restored mechanical pain threshold to 
levels comparable to that achieved by TTX. The conotoxin GIIIA inhibits NaV1.1, NaV1.2, 
NaV1.4, and NaV1.6
211
. In order to further dissect the contribution of different NaV isoforms 
in burn-induced mechanical allodynia, TIIIA was also administered in the mice model and 
was found to be ineffective towards mechanical allodynia. TIIIA inhibits NaV1.1, NaV1.2, 
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and NaV1.4
211, 212
. As NaV1.4 is a muscle NaV isoform not present in neurons, the discrepancy 
between the results for GIIIA and TIIIA implies that NaV1.6 plays a pivotal role in burn-
induced mechanical allodynia. Such findings make NaV1.6 a potential pharmacological target 
for burn-induced mechanical allodynia, further adding to the roles NaV1.6 already play in 
various NaV1.7-independent pain states
2, 133
. 
 
Examples of NaV1.6 contributing to NaV1.7-independent pain states include neuropathies 
caused by oxaliplatin and cisplatin
133
, two platinum-based chemotherapy drugs. For example, 
only GIIIA administration was successful at alleviating oxaliplatin-induced cold allodynia
2
, 
whereas selective inhibitors for all NaV isoforms as well as inhibitors of TRPA1, TRPV1, and 
TRPM8 all proved to have no efficacy. In particular, oxaliplatin-induced cold allodynia was 
reproduced by the combined administrations of the KV inhibitor 4-aminopyridine and the 
NaV1.6 activator Cn2
2, 202
. Cisplatin-induced mechanical allodynia in mice following 
peripheral administration of cisplatin was also only alleviated by GIIIA, with TIIIA being 
ineffective at affecting mice symptoms
133
. Both oxaliplatin and cisplatin-induced 
neuropathies are NaV1.7-independent pain conditions, much the same as burn-induced 
mechanical allodynia. 
  
The different mechanisms between burn-induced thermal and mechanical allodynia could be 
due to the involvement of different peripheral fibres. NaV1.7 is diffusely expressed in C-
fibres and in the nodes of Ranvier of a portion of Aδ-fibres within the sciatic nerve and dorsal 
root
171
, while NaV1.6 is expressed diffusely in C-fibres as well as in the nodes of Ranvier of 
all A-fibres
191. Aδ-fibres are known to conduct fast pain signals10 and allow for protective 
reflexes away from painful stimuli, and selective Aδ-fibre block in humans causes a loss in 
the perception of pain modality information, such as noxious heat or cold, and leaves subjects 
feeling only pain
10. Aδ-fibres are further divided into high-threshold and low-threshold heat 
sensors
8
, as well as various polymodal sensors
11, 12
. Different contributions of A and C-fibres 
towards mechanical and thermal allodynia have also been noted in other pain conditions. A-
fibre block in capsaicin-induced pain resulted in a 75% reduction of mechanical allodynia, 
but retained the burning sensation felt from capsaicin
22, 23
. At the same time, spinal nerve 
ligation in rats resulted in increased excitability of mechano-sensitive A-fibres, as well as an 
increase in the size of these fibres' receptive fields and maximum firing frequency
24
. Such 
findings have led towards the preposition that A-fibres contribute more towards mechanical 
allodynia, while C-fibres are responsible for thermal hyperalgesia. In light of this chapter's 
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findings, which indicate NaV1.7 mediates burn-induced thermal allodynia but not mechanical 
allodynia, these data align with the hypothesis that A-fibres contribute more towards burn-
induced mechanical allodynia and C-fibres play a greater role in burn-induced thermal 
allodynia.  
 
I therefore wanted to examine if the expression of NaV1.6 in DRG neurons of the mice with 
the burn injury was elevated. However, the expression of NaV1.6 in L3-L5 DRG neurons was 
not changed following the injury. While the overall expression of NaV1.6 was unchanged in 
DRG neuron somas, the presence of NaV1.6 along the sensory neuron axons could have been 
altered following the burn injury due to altered trafficking. There is certainly existing 
evidence that NaV1.6 distribution is changed along the axons in neuronal injury models
197, 199
, 
and future studies investigating the function and distribution of NaV channels in the axon 
would provide useful insight in selective NaV isoform trafficking in various pain conditions. 
 
At the same time, the quality of the commercially available NaV1.6 antibodies was also 
concerning, as seen in Figure 4.5. While the Abcam NaV1.6 antibody was superior to the 
NaV1.6 antibody produced by Alomone, the selectivity of the Abcam antibody remains 
mediocre. Additionally, more precise measurements to further investigate the expression 
levels of NaV1.6 such as RNA expression analysis and PCR (polymerase chain reaction) are 
also warranted to assess expression changes quantitatively. It also should not be overlooked 
that other proteins, not necessarily NaV channels, could be differentially expressed following 
the burn injury. I therefore decided to conduct a RNA sequence analysis on the ipsilateral 
DRGs of mice from the burn-induced pain model, to be described in the next chapter, and 
analyse in-depth the expression of genes following the injury. 
 
4.6 Conclusions 
This chapter describes a mouse model of burn-induced pain associated with mechanical 
allodynia, thermal allodynia, inflammation, and gait abnormalities, which all developed 
within a day of the thermal insult and lasted for at least four days. This chapter also presents, 
for the first time, indications that NaV1.6 is involved in mediating burn-induced mechanical 
allodynia, a condition previously established as being independent of NaV1.7 involvement. 
However, immunofluorescence analysis of affected DRG neurons indicate a lack of change in 
the expression of NaV1.6, and highlight the unreliability of available commercial NaV1.6 
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antibodies. Therefore, I conducted a RNA sequence (RNA-seq) transcriptomic analysis of 
L3-L5 ipsilateral DRGs to better investigate the changes in the landscape of gene expression 
following the burn injury, to be presented in the next chapter of this thesis. 
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Chapter 5 – Bioinformatic investigation of the mice burn injury 
model and identification of putative novel pharmacological 
targets for burn-induced pain 
 
5.1 Foreword 
The previous chapter described the successful establishment of a burn-induced pain model in 
mice, and how it was used to effectively evaluate the contribution of various NaV isoforms in 
different modalities of burn-induced pain. However, the subsequent attempt to analyse 
potential expression changes of NaV1.6 using immunofluorescence methods indicated a lack 
of NaV1.6 expression changes in ipsilateral DRG neurons following the burn injury, despite 
the efficacy of NaV1.6 inhibition in alleviating burn-induced mechanical allodynia. In order 
to quantitatively analyse all gene expression changes following the burn injury, I have 
conducted a RNA-seq analysis on the ipsilateral DRG neurons from the burn pain model, and 
to research whether known modulators of the protein products of genes differentially 
expressed may be used as putative therapeutic leads for analgesia. 
 
Some data presented in this chapter have been accepted for publication by Molecular Pain
282
. 
The content has been edited and additional data has been added to enhance the flow of the 
thesis. 
 
5.2 Introduction 
The development of rapid RNA sequencing techniques have revolutionised the field of 
neuropharmacology, with sequencing being employed increasingly frequently to discern 
changes in transcription following a nerve injury
307, 308
, genetic mutations that cause neuronal 
disorders
127
, or selective protein expression that could be related to functional neuron 
subclasses
32, 131, 309
. The expression changes exhibited by neurons during chronic pain 
conditions have been particularly exciting, as it can be hypothesised that an up-regulation of 
certain genes could indicate these genes are actively related to the establishment and 
maintenance of neuropathic pain, while the opposite can be hypothesised of genes down-
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regulated, presenting researchers with a novel way to examine the molecular causes of 
neuropathic pain. 
 
The burn-induced pain mouse model, described in Chapter 4, demonstrated that burn-induced 
allodynia was alleviated after local inhibition of NaV isoforms. While previous transcriptomic 
studies have examined burnt skin, muscle, and circulating leukocytes of burn patients
310-312
, 
there was no published transcriptomic analysis of murine DRG neurons affected by a burn 
injury. Bioinformatic analysis of skeletal muscle directly affected by a burn injury and 
muscle distant from the burn site have both been assessed in mice, revealing the differential 
expression of genes involved with inflammation, defence mechanisms, and chemokines
310
. 
Similarly, the transcriptome from circulating leukocytes following severe burn injuries in 
humans found that genes involved in innate immunity were significantly up-regulated
311
. In 
comparison, a study of chemical burn injury on the porcine skin indicated genes involved in 
cellular movement and signalling were differentially expressed, suggesting that various types 
of burn injuries affect different genes. 
 
This chapter thus present the first transcriptomic study of murine DRGs following a 
peripheral burn injury, utilising the burn-injury model established in Chapter 4. The data this 
chapter present give a view into the neuronal molecular changes in burn-induced pain, as well 
as pointing towards potential molecular targets that can be investigated to try to alleviate 
burn-related pain. Gene ontology was also analysed based on differentially expressed genes. 
Proglumide, a known inhibitor the of cholecystokinin B receptor, which was found to be up-
regulated at the gene level following the burn injury, was tested for analgesic efficacy in the 
mouse model. Cell models investigated in Chapter 3 were also re-evaluated to assess their 
appropriateness in testing novel targets found from the bioinformatic analysis of DRGs 
affected by the burn injury. 
 
5.3 Materials and Methods 
5.3.1 Chemicals 
All materials were obtained from Sigma-Aldrich (Castle Hill, New South Wales, Australia) 
unless otherwise stated. Oxycodone was obtained from Mundipharma Pty Ltd (Sydney, New 
South wales, Australia).  
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5.3.2 Animals 
Male wild-type C57BL/6 mice age 6 - 8 weeks and weighing 20 - 23 grams were used in the 
study. Ethical approval for experiments involving live animals and animal tissues was 
obtained from the University of Queensland animal ethics committee under the ethics 
approval number PHARM/074/13/RAMACIOTTI. Experiments were conducted in 
accordance with the Animal Care and Protection Regulation Queensland (2012), the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 8th 
edition (2013) and the International Association for the Study of Pain Guidelines for the Use 
of Animals in Research. 
 
All animals were housed in groups of 2 - 4 per cage in a stable environment under 12 hour 
light-dark cycles and had access to standard rodent chow and water ad libitum. A red 
polycarbonate Mouse House (Tecniplast, Italy) and shredded paper nesting material were 
supplied for enrichment. All animals were obtained from University of Queensland 
Biological Resources (Brisbane, Australia). 
 
Sample sizes of each experiment are detailed in the figure legends of the corresponding 
figure. 
 
5.3.3 Induction of burn injury 
The burn injury was induced with modifications from that described in Section 4.3.3, using 
temperature and burn durations according to a previous mouse model
187
. A pair of tweezers, 
with the tips wrapped in tissue paper, was used to press the plantar portion of the paw onto 
the Peltier plate. Sham control animals underwent the same procedure with the plate set at 22 
°C (room temperature). Behavioural assessment was performed at the time points indicated 
and the same animals were used for each of the behavioural tests. 
 
5.3.4 RNA extraction 
On the third day following burn or sham injury, animals were euthanised with carbon dioxide 
followed by cervical dislocation. The spine was immediately removed and the dorsal side of 
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the vertebra dissected to expose the spinal cord. The entire spine was then immersed in ice-
cold Dulbecco’s Modified Eagle’s Medium (DMEM). The spinal cord was then removed, and 
L3, L4, and L5 DRGs were extracted from the ipsilateral side of the injury with forceps. The 
DRGs were immediately placed into RNALater (Thermo Fisher Scientific, Scoresby, 
Victoria, Australia) and excess myelin was trimmed. DRGs were then cut into pieces in 
RNALater, and RNA was extracted using the RNeasy Mini Kit (Qiagen, Melbourne, 
Australia) according to manufacturer’s instructions (as stated in Section 3.3.6), including on-
column DNase digestion. Samples from 4 individual animals were pooled together for one 
biological replicate. Three biological control replicates and three burn injured biological 
replicates were analysed to ensure statistical significance. 
 
5.3.5 RNA-Seq  
Library construction and bioinformatics analysis were conducted by the Institute for 
Molecular Bioscience Sequencing Facility (The University of Queensland, Brisbane, 
Australia). RNA-Seq was conducted on the Illumina NextSeq 500 platform as 75-nucleotide 
single-end runs, with libraries prepared using TruSeq stranded total RNA library preparation. 
Reads were mapped using the STAR aligner (version star/2.3.0e)
313
 and samtools
314
. Reads 
were mapped to the Ensembl Mus musculus mm10 genome (version GRCm38). Count tables 
were generated using HTSeq_count from HTSeq package
249
, and differential expression 
analysed using the R (version 3.2.2) package DESeq2
315
. 
 
5.3.6 Bioinformatics analysis 
Plots were generated using the R packages gplots, ggplots2, and pheatmap. Differentially 
expressed genes from DESeq2 analysis were ranked by adjusted P-value. Genes with 
adjusted P-value < 0.05 were used for gene ontology (GO) analysis, which was conducted 
using Cytoscape 3.2.1
316
 with the ClueGO 2.1.7 plugin
317
. ClueGO was used with the 
following settings: Ontologies/Pathways used Mus musculus GO (Biological Processes, 
version from 30 April 2015). Evidence: all. GO tree internal 3-8 levels. GO term restrictions: 
3 minimum genes and 1% of genes. Network connectivity (Kappa score) = 0.4. STRING 
diagrams were generated using STRING v10
318
. Following alignment, count output from 
HTSeq was analysed using the DESeq2 statistical package.  
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5.3.7 Drug treatment 
The analgesic efficacy of compounds was assessed 3 days after the induction of burn injury 
or the sham procedure. All compounds were administered by intraperitoneal injection (i.p) 
with compound concentration of 10 µL/g using a 30-gauge needle. Animals were randomised 
to receive either proglumide (30 mg/kg) once daily or matched vehicle control, with the first 
dose administered at the time of the burn injury. Oxycodone (1 mg/kg) was administered 
once only on the day of testing. All compounds were diluted in DPBS (Life Technologies, 
Mulgrave, Victoria, Australia). Behavioural assessment was performed at least 30 minutes 
after the final dose of all compounds by an investigator unaware of the treatments received by 
each individual animal. 
 
5.3.8 Measurement of mechanical allodynia 
Mechanical allodynia was assessed as described in Section 4.3.4. 
 
5.3.9 Measurement of thermal allodynia 
Thermal allodynia was assessed as described in Section 4.3.5. Only the Hargreave’s 
apparatus was used for results presented in Chapter 5. 
 
5.3.10 Measurement of gait abnormalities 
Gait analysis was assessed using the CatWalk XT analysis system (Noldus Information 
Technology, The Netherlands) as described in Section 4.3.7. 
 
5.3.11 Motor Assessment 
Motor performance was assessed as described in Section 4.3.9. 
 
5.3.12 Heatmap generation 
Genes found to be differentially expressed in burn samples were analysed in the cell lines 
examined in Chapter 3. For heatmap generation, data was compiled into .csv format and 
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heatmaps were created in RStudios with R 3.2.2 with the gplots, pheatmap, and 
RColorBrewer libraries. 
 
5.4 Results 
5.4.1 All samples were aligned to the mouse genome  
All samples were uploaded and available for the public under the Gene Expression Omnibus 
accession number GSE75691. Data includes raw .fastq files and count tables produced with 
HTSeq as .txt files. 
 
The transcriptomic analysis of gene expression changes in whole DRGs was conducted using 
Illumina NextSeq 500 RNA-seq. A total of 4,302 billion reads, 72% of which were uniquely 
mapped to the Mus musculus genome, were generated from all samples. All samples were 
aligned with the mouse genome (mm10). Three separate samples were extracted from the 
control cohort and from mice with the burn injury. All RNA samples were extracted from L3, 
L4, and L5 whole DRGs.  
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 Control #1 Control #2 Control #3 Burn #1 Burn #2 Burn #3 
Total reads 60256073 
 
29770261 138943352 127060392 39879029 48647489 
Aligned 
reads 
46413203 
(77.03%) 
21967696 
(73.79%) 
107534778 
(77.39%) 
95718380 
(75.33%) 
28751886 
(72.10%) 
36988499 
(76.03%) 
Reads with 
no feature 
10196437 
(16.92%) 
4576618 
(15.37%) 
25087845 
(18.06%) 
25266646 
(19.89%) 
6585482 
(16.51%) 
6728193 
(13.83%) 
Ambiguous 
reads 
225655 
(0.37%) 
117170 
(0.39%) 
478791 
(0.34%) 
449063 
(0.35%) 
142839 
(0.36%) 
185837 
(0.38%) 
 
Table 5.1 Read numbers of RNA samples 
RNA samples were obtained from DRGs from burn-injured animals and control animals that 
underwent a sham procedure. The samples were aligned to the mouse genome (mm10). 
‘Total reads’ show the amount of reads in each alignment. 'Aligned reads' indicate the 
number of reads matched to one unique position in the genome. ‘Reads with no feature' 
indicate the number of reads that did not match to any position in the genome. 'Ambiguous 
reads' indicate the number of reads mapped to more than one position in the genome. All 
percentage values are based on the number of total reads. 
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5.4.2 Thirty genes were found to be differentially expressed in the burn injury model 
A total of 30 genes were differentially expressed at P-value < 0.05 in whole DRGs after the 
burn injury (Table 5.2, for full list see Appendix 3.6), with the level of gene expression 
ranging from at least log2FoldChange 0.46 (ANXA10) to 2.59 (ATF3). Six of these genes are 
associated with a known function in pain
319
. These genes include neuropeptides with a known 
role in nociceptive signalling (Table 5.2), specifically neuropeptide Y (NPY), neurotensin 
precursor (NTS), and galanin (GAL); as well as the gastrin and cholecystokinin receptor 
(CCKBR), the ionotropic N-Methyl D-Aspartate 2B receptor (GRIN2B), and glutamic acid 
decarboxylase 2 (GAD2). ATF3, the most up-regulated gene, codes for a protein associated 
with neuronal injury, supporting the hypothesis that at least some sensory projections are 
directly injured in the burn 
187
. 
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Gene log2FoldChange P-value Adjusted P-
value 
Role in Pain 
ATF3 2.59 4.12E-84 8.73E-80 unknown 
GPR151 2.00 1.05E-36 1.11E-32 unknown 
NPY 1.42 4.82E-20 3.41E-16 Known analgesic 
effect 
320
 
LIPN 1.20 1.53E-15 8.11E-12 unknown 
NTS 1.16 3.93E-15 1.66E-11 Involved in visceral 
nociception and 
stress-related 
analgesia 
321
 
ECEL1 1.17 2.26E-13 7.99E-10 unknown 
GAL 1.09 1.69E-12 5.12E-09 Knockout animals 
show reduced 
nociceptive 
behaviours 
322
 and 
chronic 
administration 
causes pain 
hypersensitivity 
323
 
CCKBR 1.05 3.72E-12 9.87E-09 Knockout animals 
show reduced 
sensitivity in 
neuropathic pain 
324
 
TMEM88B 1.03 1.15E-10 2.71E-07 unknown 
SEMA6A 0.83 4.64E-09 9.84E-06 unknown 
SEZ6L 0.88 1.61E-08 3.11E-05 unknown 
STAR 0.89 1.93E-08 3.40E-05 unknown 
FLRT3 0.67 4.25E-07 0.00069 unknown 
STMN4 0.62 7.42E-07 0.00112 unknown 
GRIN2B 0.77 9.27E-07 0.00130 Overexpression 
enhanced 
inflammatory pain 
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responses 
325
. 
Knockouts enhanced 
acute nociceptive 
responses 
326
 
PAPPA 0.55 9.84E-07 0.00130 unknown 
FST 0.66 1.43E-06 0.00178 unknown 
FGF3 0.64 2.66E-06 0.00314 unknown 
UCN 0.55 5.96E-06 0.00665 unknown 
SERPINB1A 0.50 9.75E-06 0.01034 unknown 
PLXNA4 0.46 1.80E-05 0.01738 unknown 
TUBB6 0.63 1.78E-05 0.01738 unknown 
GM5152 0.47 3.22E-05 0.02848 unknown 
MMP16 0.57 3.19E-05 0.02848 unknown 
GAD2 0.62 3.59E-05 0.03045 Knockout animals 
showed sensitised 
pain behaviours
327
 
CCL8 0.63 5.23E-05 0.03961 unknown 
GADD45A 0.48 5.02E-05 0.03961 unknown 
WFDC3 0.64 5.20E-05 0.03961 unknown 
SLC4A8 0.518428 5.72E-05 0.041841 unknown 
ANXA10 0.47941 7.05E-05 0.049852 unknown 
 
Table 5.2 Table of genes found to be differentially expressed in DRG neurons affected 
by a peripheral burn injury 
Differentially expressed genes are arranged according to adjusted P-value (in-build false 
discovery rate control in the DESeq2 package, using the Benjamini-Hockberg method). A 
gene is considered to be statistically significant if P-value < 0.05. 
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5.4.3 Volcano plot revealed all differentially expressed cells were up-regulated 
A volcano plot revealed significant up-, but no down-regulation of genes in comparison with 
control DRGs (Figure 5.1). It is interesting that ATF3, a cellular marker for inflammation and 
injury, was also previously found to be significantly up-regulated in another murine burn-
induced pain model
187
, which suggests the mechanism of DRG neuron injury may be similar 
across different peripheral burn injury models. 
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Figure 5.1 Volcano plot of differentially expressed genes in the burn samples 
Volcano plot comparing log2(fold change) to -log10(adjusted P-value) reveals the identity of 
differentially expressed genes. Genes with adjusted P-value < 0.05 are coloured red, and 
genes with the lowest P-value are annotated with gene names. All differentially expressed 
genes were found to be up-regulated. 
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5.4.4 No ion channels were found to be differentially expressed in DRG neurons following the 
burn injury 
The expression of ion channels was examined specifically in the transcriptome, especially as 
the inhibition of NaV isoforms alleviated symptoms of the burn-induced pain, as indicated in 
Chapter 4 and in existingliterature
187, 306
. However, it was revealed that no ion channels were 
differentially expressed in DRG neurons following the peripheral burn injury. A volcano plot 
comparing log2(fold change) to -log10(adjusted P-value) was constructed (Figure 5..2), with -
log10(adjusted P-value) = 0 indicating no change (P-value = 0.99). The cut-off for statistical 
significance is -log10(adjusted P-value) = 1.3, which indicates a P-value of 0.05. 
 
The volcano plot demonstrated that KCNN4, the gene encoding the calcium-activated 
potassium channels KCA3.1, was the ion channel with the smallest P-value in all ion channel 
genes. However the adjusted P-value for KCNN4 was only 0.069, which renders the down-
regulation observed to be non-statistically significant.  
 
The only other ion channel genes with P-values lower than 0.99 were GABRA5 (0.1136), 
KCNK16 (0.4112), and KCNQ3 (0.8737). GABRA5 encodes the γ-aminobutyric acid (GABA) 
A receptor, alpha 5, a subtype of inhibitory GABA receptors. KCNK16 encodes the 
background potassium channel TALK-1, otherwise known as K2p16.1. KCNQ3 encodes the 
potassium voltage-gated channel KV7.3, which is the molecular target of flupirtine and 
retigabine, two clinical drugs already used as adjuvants for neuropathic pain. However, the P-
value associated with all three genes were higher than 0.10, indicating a non-statistically 
significant change in expression.  
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Figure 5.2 Analysis of the expression changes of ion channels in DRGs following the 
burn injury 
The ion channel with the lowest adjusted P-value was KCNN4, followed by GABRA5, 
KCNK16, and KCNQ3. However, P-values for the expression changes of all genes fell above 
0.05, and were not statistically significant. Therefore, it can be concluded that none of the ion 
channel were found to be differentially expressed following the mild heat injury. 
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5.4.5 Gene ontology analysis of differentially expressed genes 
Gene Ontology (GO) analysis was conducted to further decipher the processes that were 
enhanced following the burn injury. Analysis of all 30 genes found to be differentially 
expressed identified ‘Behavioural Defense Response’, ‘Neuropeptide Signalling Pathway’, 
‘Axon Guidance’ and ‘Response to Extracellular Stimulus’ as the four main functional 
clusters of altered gene expression (Figure 5.3 A-B). Additional biological process terms 
found to be involved were glutamatergic synaptic transmission, associative learning, 
associative learning, and acid secretion (Figure 5.3 B). 
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Figure 5.3 Gene ontology analysis of genes differentially expressed in burn samples 
Functional categories were assigned to genes within Cytoscape according to the Biological 
Processes terms, version 30 April 2015. Visualisations were drawn with the Cytoscape plugin 
ClueGO. A) Genes were clustered into one main functional group and three smaller groups. 
Overview pie chart was representative of the number of gene ontology interactions in each 
functional group. B) GO Biological Processes pathway terms for the differentially expressed 
genes. Numbers after the bar indicate the number of genes associated with each term. The X-
axis indicates the percentage of associated genes for each term. Asterisks indicate the P-value 
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of the association after Bonferroni stepdown adjustment; * = P-value < 0.05, ** = P-value < 
0.01. 
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5.4.6 Network analysis of differentially expressed genes 
To gain additional insight into the molecular mechanisms contributing to altered neuronal 
function and pain after burn injury, I also conducted a network analysis with STRING 
(Version 10). Glutamatergic transmission and neuronal secretion formed distinctive networks 
and clusters (Figure 5.4), confirming the findings of GO analysis. GRIN2B and GAD2 were 
functionally linked to NPY, GAL, NTS, and CCKBR, consistent with the established roles of 
these genes in pain and nociception. A second functional cluster linked ATF3, ECEL1 and 
TUBB6. Several other genes significantly up-regulated after the burn injury could not be 
linked to functional networks, reflecting the poorly defined physiological roles of genes such 
as TMEM88B, SEZL6, LIPN, ANXA10, CCL8, and GPR151 in sensory neurons.  
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Figure 5.4 Network analysis of up-regulated genes in burn samples 
STRING diagram showing interactions between differentially expressed genes, generated 
with STRING version 10 and with the ‘More’ option (add 10 more gene partners) utilised 
once only. The diagram is presented in confidence view, and the thickness of edges 
connecting genes is determined by the strength of associations based on evidence. 
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5.4.7 Proglumide is effective in alleviating mechanical allodynia and synergistically increase 
the analgesic effect of opioids 
The cholecystokinin 2 receptor (CCKBR), a G protein-coupled receptor known as a pain 
target, was found to be up-regulated in the transcriptome following burn injury. I therefore 
assessed the analgesic effects of the cholecystokinin receptor (CCK) antagonist proglumide, 
which is already available in the clinic. Proglumide was tested alone and in combination with 
a sub-therapeutic dose of oxycodone (1 mg/kg) in the burn injury, as CCK receptor 
antagonists are known to augment the analgesic effects of opioids in humans
328, 329
. This 
could lead to solid clinical benefit due to the findings in Chapter 4 that oxycodone was not 
effective at alleviating burn-induced allodynia at standard doses in the mouse model, and a 
high dose is required for appropriate pain relief.  
 
Proglumide alone significantly alleviated mechanical allodynia compared to vehicle control, 
albeit only partial analgesia was achieved (PWF: proglumide (30 mg/kg), 2.3 ± 0.3 g; vehicle 
control, 1.2 ± 0.1 g; P-value < 0.05; Figure 5.5 A). Co-administration of proglumide with 
oxycodone significantly reversed mechanical allodynia further (PWF: proglumide (30 mg/kg) 
+ oxycodone (1 mg/kg), 2.3 ± 0.3 g), although the combination was not statistically 
significant compared to proglumide alone (P-value = 0.13). Proglumide had no significant 
effect on thermal allodynia, however in combination with oxycodone, the time to withdrawal 
in response to a radiant light heat source was significantly increased (time to withdrawal: 
proglumide (30 mg/kg) + oxycodone (1 mg/kg), 8.8 ± 2.1 s; vehicle control, 3.0 ± 0.5 s; P-
value < 0.05; Figure 5.5 B). Interestingly, neither proglumide alone nor proglumide in 
combination with oxycodone significantly increased weight bearing in the ipsilateral hind 
paw (ratio to control: proglumide (30 mg/kg), 1.09 ± 4 %; proglumide (30 mg/kg) + 
oxycodone (1 mg/kg), 1.07 ± 4 %; vehicle control, 1.00 ± 3 %; P-value > 0.05; Figure 5.5 C). 
Proglumide had no significant effect on the ataxia index compared to vehicle control (ataxia 
index: vehicle control, 3.3 ± 0.6; proglumide (30 mg/kg), 3.1 ± 1.0; P-value > 0.05; Figure 
5.5 D), indicating proglumide does not result in drowsiness or motor deficiencies. 
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Figure 5.5 Analgesic activity of the cholecystokinin receptor antagonist proglumide in 
burn-induced pain, both alone and in combination with a low dose opioid 
A) Both proglumide (30 mg/kg) administered on its own and proglumide (30 mg/kg) in 
combination with oxycodone (1 mg/kg) significantly alleviated burn-induced mechanical 
allodynia. B) Proglumide (30 mg/kg) alone had no significant effect on burn-induced thermal 
allodynia, however thermal allodynia was significantly reversed when administered in 
combination with oxycodone (1 mg/kg). C) Neither proglumide (30 mg/kg) alone nor 
proglumide (30 mg/kg) in combination with oxycodone (1 mg/kg) significantly improved 
weight bearing behaviour of the ipsilateral hind paw, as detected by the ‘Mean Intensity of 
the 15 most intense pixels’ parameter using the Catwalk XT. D) Proglumide (30 mg/kg) had 
no significant adverse effect on motor behaviour as assessed by the parallel rod floor test. 
Statistical significance was determined using t-test. * P-value < 0.05 compared to vehicle 
control. Dotted lines represent the mean value for the contralateral paw. All data are 
represented as mean ± SEM with 4-8 mice per group.  
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5.4.8 Assessment of the expression of genes differentially expressed in the burn model in in 
vitro cell lines examined in Chapter 3 
The in vitro cell lines examined in Chapter 3 were re-analysed in regard to the expression of 
the 30 genes found to be differentially expressed in the burn-injury model (Figure 5.6). The 
30 genes were examined with the hypothesis that if any genes are found to be expressed 
abundantly in the cell lines, the cell lines could be used as potential in vitro models for 
assessing inhibitors of these genes.  
 
Genes differentially expressed following the burn injury are expressed at low levels in 
physiologically normal DRGs, with the exception of ATF3 and PLXNA4, genes associated 
with transcription and cytoskeleton arrangement. NPY, PLXNA4, and TUBB6 are all 
expressed in the three cell lines investigated, with F-11 expressing an abundant amount of 
NPY and TUBB6. SEZ6L, ECEL1, and SLC4A8 were also expressed in F-11 and ND7/23 
cells. Interesting, GAL was expressed abundantly only in SH-SY5Y cells, and was largely 
absent in DRGs and the other cell lines. 
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Figure 5.6 Analysis of the expression of genes up-regulated in the burn injury in cell 
lines 
The expression of genes found to be differentially expressed in the burn samples were 
examined in whole DRG and the cell lines studied in Chapter 3. Normalised expression of 
each gene (normalised to TUBA1A) are shown in the middle of each cell. Genes 
differentially expressed following the burn injury are mostly expressed at low levels in 
physiologically normal DRGs. NPY, PLXNA4, and TUBB6 are expressed in all three cell 
lines. F-11 expressed large amounts of NPY. GAL was only expressed in large amounts in 
SH-SY5Y. TUBB6. SEZ6L, ECEL1, and SLC4A8 were expressed in F-11 and ND7/23 cells. 
 
188 
 
5.5 Discussion 
In this study, I have used RNA-seq analysis to explore gene expression changes that could 
provide insight into altered sensory neuron functions after a burn injury. Although 
transcriptomic analyses have been widely used to comprehensively analyse differential gene 
expression, global gene expression changes that occur in DRGs after a mild peripheral burn 
have not been previously explored. However, changes in expression of cytokines and 
inflammation-related genes that occur after burn injuries have been assessed in cultured 
keratocytes from burn patients
330
, and RNA from circulating leukocytes of patients critically 
injured in burn injuries have also been studied
311
. None of the differentially expressed genes 
identified in these studies overlapped with those identified in my DRG transcriptome, as 
expected based on the different tissue types studied. Consequently, gene ontology terms 
enriched in these other studies were also distinct from mine. However, compared with a study 
which analysed whole porcine skin following a bromine-induced chemical burn
312
, my GO 
analysis yielded similar pathways and biological functions. These included the terms 'axonal 
guidance' and 'cell signalling', suggesting convergent molecular changes in both burn models. 
While 'cancer' was a biological function highly enriched in the porcine skin, this was not the 
case in my study, possibly due to the nature of the bromine burn. Similar term enrichment 
was also found in a transcriptomic analysis of skeletal muscle both at the burn site and distant 
from the injury in mice
310
, which - similar to my findings - also identified the enriched terms 
'stress response' and 'defense response'.  
 
Overall, I detected 30 genes that were differentially up-regulated in DRGs following a first-
degree burn. The small number of genes is likely a reflection of the relatively mild injury 
induced. The biological processes enriched in my dataset exhibited an inflammatory and 
regenerative profile consistent with peripheral nerve injury and regeneration, as well as 
synaptic signalling and neuropeptide secretion indicative of functional sensitisation. Up-
regulation of genes associated with neuronal damage, including ATF3
331
, ECEL1
332
 and 
STAR
333
, support the view that at least some sensory projections are directly injured during 
the burn
187
. Interestingly, although NaV channels have previously been identified as crucial 
for burn-induced thermal allodynia at the behavioural level in Chapter 4 and in existing 
literature
187
, gene expression levels of all NaV isoforms were unchanged. This perhaps 
indicate NaV channels affect neuropathic pain through functional rather than transcriptomic 
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alterations, necessitating possible future live-cell functional studies to better understand the 
mechanism behind the involvement of NaV isoforms in burn injury.  
 
When the expression of all ion channels were analysed, none of the ion channels were found 
to be significantly altered in gene expression. The ion channel that had the highest statistical 
significance for expression change was the KCNN4 gene, a calcium-activated potassium 
channel known to be preferentially expressed in small diameter neurons
334
. The product of 
the KCNN4 gene, KCA3.1, also has a definite role in CNS inflammation, with its distribution 
and activity positively related to the presence of neuronal and microglial inflammation
335
. 
KCA3.1 inhibition speeds up motor recovery in mice models of spinal cord injury and protects 
neurons from death
336
, making the channel a putative pharmaceutical target for analgesia. 
However, the high P-value of contributed to KCNN4 expression changes (P-value = 0.069) 
makes this a doubtful find compared to the 30 significantly up-regulated genes the study did 
yield. Future studies could certainly be conducted to assess the contribution of the KCA3.1 
channel towards burn-induced pain, particularly as burn injury results in significant local 
inflammation that may be related to the known roles of KCA3.1 in inflammation. 
 
Potential pain-related genes identified from the 30 genes found to be significantly 
upregulated included NPY, NTS, and GAL. All three genes are well-known to be involved in 
nociceptive signalling pathways. Up-regulation of NPY has been consistently observed in 
inflammatory and neuropathic pain models and appears to play an important role in spinal 
nociceptive transmission, as well as recovery from hyperalgesia
337, 338
. NPY receptor 
inhibitions has also been reported to lead to reduction in pain behaviours, particularly in rats 
following intraplantar carrageenan injection
339
.  
 
In contrast, the role of GAL and NTS in pain is more complex, with both peptides reported to 
mediate pro-algesic as well as analgesic effects
340-342
. Galanin is required developmentally for 
the survival of small diameter, unmyelinated neurons
343
, which are commonly considered 
nociceptors
341
. Galanin knockout mice do not exhibit allodynia and hyperalgesia behaviours 
following neuronal injury
343
, which suggest galanin mediates nociceptive signals in the 
organism. At the same time, the excessive expression of galanin also reduces pain from 
partial sciatic nerve injury, making it likely that a 'nociceptive' range of galanin exists, 
outside of which analgesia may arise. With neurotensin, knockout mice paradoxically exhibit 
both a deficiency in nociception as well as a deficiency in stress-induced analgesia. It is 
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possible that NTS also exhibits a 'nociceptive' range of concentrations that allows for pain, 
and neurotensin levels outside of the concentration range would result in analgesia. 
 
Other major genes which are significantly up-regulated in the burn injury transcriptome 
include the ionotropic N-Methyl D-Aspartate (NMDA) 2B receptor (GRIN2B), the glutamic 
acid decarboxylase 2 (GAD2), and the gastrin and cholecystokinin receptor (CCKBR). 
NMDA receptors are widespread throughout the nervous system, with NMDA2B implicated 
in glutamate-mediated hyperalgesia
344
 as well as use-dependent spinal sensitisation and long-
term potentiation
345
. Ketamine, a non-selective NMDA receptor antagonist, has also been 
used in burn pain with some success
288, 294
. However, NMDA antagonists are often associated 
with hyper-excitability and excitatory CNS side effects.  
 
The enzyme glutamic acid decarboxylase (GAD) converts glutamate to the inhibitory 
neurotransmitter GABA and altered expression of GAD2, a subtype of GAD, is likely to 
result in dysregulation of inhibitory neuronal neurotransmission. Accordingly, epigenetic 
suppression of GAD2 expression in central pain pathways has been linked to the development 
of persistent pain
327
, while peripheral overexpression of GAD2 led to attenuation of 
neuropathic pain behaviours
346
.  
 
Up-regulation of the gene encoding the cholecystokinin 2 receptor (CCK-2 or the gene 
CCKBR), a gastrin and cholecystokin receptor, was particularly interesting in light of my 
observation that high opioid doses are required to elicit analgesia in the burn pain model. 
Overexpression of the CCK-2 receptor is known to be associated with enhanced nociception 
and neuropathic pain
324, 347
 and its activation interferes with opioid-induced analgesia
263, 348
. I 
thus investigated the analgesic and opioid-sparing effect of the CCK inhibitor proglumide on 
the basis that this compound is already in clinical use with standard doses, and any efficacy in 
the model could be directly translated to improved management of burn-induced pain in the 
clinic. Indeed, proglumide was efficacious in mechanical allodynia when administered as 
monotherapy, or together with oxycodone at opioid doses that did not produce analgesic 
effects (1 mg/kg). This corroborates with existing evidence that proglumide interacts 
synergistically with opioids to increase analgesic efficacy in other pain conditions
328, 329
. It is 
also interesting to note that co-administration with oxycodone did not statistically further 
increase PWF values compared to proglumide monotherapy, suggesting that proglumide 
itself could be a potent analgesic and more than an adjuvant drug in burn pain.  
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Co-administration of proglumide and oxycodone also alleviated burn-induced thermal 
allodynia, although proglumide alone had no significant effect on thermal withdrawal 
thresholds or gait, suggesting that CCK-2 receptor-mediated analgesia is modality-specific. 
Proglumide also did not induce any motor deficits in the animals, suggesting that 
cholecystokinin receptor antagonists do not cause drowsiness or CNS disturbances.  
 
Proglumide was selected to investigate the effect of CCK-2 inhibition as the compound is 
already a clinical drug with an established dose and safety profile. While proglumide is not an 
inhibitor of both CCK-1 and CCK-2 channels, it was chosen for the ease with which the 
finding can be translated into the clinic. Future studies with more selective CCK-2 
antagonists could be conducted to investigate the specific involvement of CCK-2, as well as 
becoming potential drug leads in drug discovery. 
 
While the in vitro cell lines were deemed as not representative of any of the known native 
DRG neuron subtypes, these cell lines nonetheless can serve as models to screen potential 
modulators of proteins that the cell lines do express. The presence of galanin in SH-SY5Y 
cells and the abundant expression of neuropeptide Y in F-11 cells indicate the two cell lines 
can be used as tools to screen for compounds that may interact with these two neuropeptides, 
stressing the need for better understanding of the strengths and weaknesses of individual in 
vitro models. Many of the genes up-regulated in the burn-injury transcriptome warrants 
further studies, as the majority of the genes transcribe proteins that researchers have little or 
no knowledge of, such as the orphan receptor GPR151, or were previously considered to be 
unrelated to pain or inflammation. Such findings open up more options for investigating 
putative drug targets for pain, and broaden the list of proteins that could contribute to the 
complex molecular changes in peripheral neurons following thermal injuries. 
 
5.6 Conclusions 
This chapter described the first transcriptomic analysis of DRG neurons affected by a 
peripheral burn injury, based on the mouse burn-induced pain model described in Chapter 4. 
Despite evidence that the inhibition of NaV isoforms reduced burn-induced allodynia 
behaviours in the mice, no ion channels were found to be differentially expressed in the 
neurons following the injury. Instead, 30 non-ion-channel genes were found to be 
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significantly up-regulated. The CCKBR gene was up-regulated in DRG neurons following the 
burn injury, an interesting find given the known role of CCK-2, the protein product of 
CCKBR, in opioid analgesia. Proglumide, an inhibitor of CCK receptors, was found to 
significantly alleviate mechanical allodynia in the burn injury model, offering a clinically 
relevant discovery towards more efficient analgesia in burn-induced pain in patients. Many of 
the genes found to be differentially expressed in the transcriptome have not previously been 
linked to pain or injury, offering a breadth of novel putative drug targets for burn-induced 
pain that awaits exploration in greater detail. 
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Chapter 6 - Overall Conclusions 
 
Pain remains an enigmatic condition with no clear answers for many patients in the clinic, 
even after the pivotal discovery that the loss of functional NaV1.7 channels causes human 
congenital insensitivity to pain
127
. While global NaV1.7 knockout in mice was shown to be 
non-responsive to a range of neuropathic pain conditions and demonstrated deficiencies in 
acute pain sensing
175
, it is now evident that NaV1.7 is not responsible for all that is painful
2, 
178, 186
, dashing the hopes that the NaV1.7 channel may be a panacea for all pain. The 
subsequent surging interest in the role of NaV channels in pain have revealed that other NaV 
isoforms, in particular NaV1.6 and NaV1.8, also play a major part in noxious sensing
2, 186, 197, 
198, 205, 207, 349, 350
, suggesting that further understanding of NaV1.6 and NaV1.8 may help us to 
decipher the pathophysiological mechanisms of pain. 
 
In this thesis, I set out in pursuit of better, more optimised tools and models that could be 
used to investigate the mechanistic roles of NaV1.6 and NaV1.8 in nociception. Due to the 
diffuse distribution of NaV channels in the CNS as well as in the PNS, an ideal NaV inhibitor 
with clinical potential should be one that is highly selective for the desired NaV isoform and 
does not cross the blood-brain barrier, avoiding significant CNS side effects. Peptides derived 
from spider venoms are historically known to yield highly potent and selective modulators of 
ion channels
188, 219, 351
. These peptides also have large molecular masses between 3 000 and 
10 000 Daltons
214
, which restrict distribution in vivo and often lead to an inability to penetrate 
into the CNS, making peptides good candidates as NaV inhibitors. However, peptide 
administration becomes complicated and inconvenient when central analgesic effects are 
needed. The best example would be the peptide-derived analgesic ziconotide, which requires 
administration as an intrathecal infusion to function as a centrally acting analgesic
112-114
. 
Moreover, as shown in this thesis, the rapid process of finding promising peptides from 
spider venoms cannot guarantee the selectivity of the compounds. Extensive off-target 
activity analysis is required for peptides discovered based on activity-guided isolation. For 
the compound Pme1a outlined in this thesis, off-target activity for TRPV1 was found after 
sequence identification. Structure-activity guided modification of the peptide sequence, a 
lengthy process involving the chemical synthesis of many analogues, would be required to 
eliminate the off-target activities. Lastly, peptides have inherent disadvantages when 
considered as clinical leads, such as extremely poor oral bioavailability and difficulties with 
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chemical synthesis, which pose limitations on the efficiency of extracting NaV channel 
modulators from crude spider venoms. 
 
An alternative means to rapidly assess potential NaV1.6 and NaV1.8 inhibitors would be to 
use cell models to examine the efficacy of possible modulators, which drove me to examine 
in vitro cell models commonly used in lieu of DRG neurons. The NaV α subunits do not 
function alone in the native neuron. The pore-forming NaV α subunit exists together with β 
subunits as well as second messenger pathways, all of which are often missing in cells 
transfected with only NaV α subunits. The absence of β subunits are known to alter the 
kinetics and voltage sensitivity of the channels, with single α subunits exhibiting slower 
kinetics than that observed in NaV channels on native neurons
148
, arguing that neuron-derived 
cell lines better resemble in vivo conditions due to the retention of intracellular second-
messenger pathways and auxiliary units. The three cell lines I examined in this thesis can be 
considered sufficient tools to study proteins that the cell lines do express, however they 
should not be used broadly as representatives of peripheral sensory neurons subclasses, as 
seen in the lack of resemblance in expression profile towards all known DRG neuron 
subclasses.  
 
I also developed a wild-type mouse model of burn-induced mechanical allodynia, a known 
NaV1.7-independent pain condition, instead of using global NaV1.6 or NaV1.8 knockout mice. 
Global knockout of NaV1.6 is lethal in mice, making it impossible to conduct research using 
these animals. A recent report of the disturbance of opioid analgesic pathways in human 
patients with NaV1.7 loss-of-function mutations also indicate that global knockout of NaV α 
subunits can lead to compensatory changes in other neurological pathways
352
, implying that 
results observed in global gene knockout animals may not necessarily reflect physiological 
responses. Therefore, I used wild-type mice to establish the burn-induced injury model in this 
thesis, and used known inhibitors of various NaV isoforms to elucidate the roles of the 
isoforms in burn-induced pain. 
 
The contribution of individual NaV isoforms in pain are indeed not as clean-cut as previously 
expected, particularly as my investigations in burn-induced pain revealed a functional 
contribution of NaV1.6 to mechanical allodynia, yet no up-regulation of NaV isoforms were 
found on the gene level. It is possible that NaV1.6, as well as other NaV isoforms, exhibits 
functional increases in activity in neuropathic pain that is not reflected in gene expression 
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levels. It is plausible that NaV1.6 may demonstrate kinetic property changes following the 
injury independent of α or β subunit gene expression changes, resulting in an alteration in 
voltage-dependency and action potential firing rate for the axon. It is also possible that NaV 
isoforms could function synergistically with other, yet un-explored proteins, as seen in the 
relationship between opioid analgesia and cholecystokinin receptors
328, 347, 348
, despite the 
previous presumption that cholecystokinin functions exclusively in the digestive system. 
Alternatively, analgesic effects of NaV inhibitors could simply reflect enhanced neuronal 
excitability in pain states that is normalised by functional inhibition or reduction of action 
potential conduction. 
 
NaV1.6 and NaV1.8 undoubtedly function as important modulators in physiological pain 
pathways, as seen in the altered pain responses following local gene knockout
38, 178, 198, 205
 or 
functional inhibition
2
. However, these channels are likely to be potential drug targets only for 
selective pain conditions with proven relationship with NaV1.6 or NaV1.8, such as oxaliplatin- 
or ciguatoxin-induced cold allodynia. It would also be desirable for potential NaV1.6 or 
NaV1.8 clinical inhibitors to remain in the periphery and do not cross the blood-brain barrier 
due to the widespread expression of NaV1.6 in the CNS, especially in the forebrain. Given 
such considerations, it would be perhaps be preferable for future clinical NaV inhibitors to be 
administered via local injections with slow distribution, potentially subcutaneously, that 
allows for the functional inhibition of NaV isoforms in the local area for a long period of time. 
While it remains unclear what conditions will benefit from NaV1.6 and NaV1.8 inhibition, 
these ion channels are still promising targets for specific neuropathic pain conditions that 
remain poorly treated throughout the world. 
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Appendix 1 – Alphabetical List of Materials 
 
Name Source Catalogue # 
A-803467 Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
A3109-10MG 
Acetonitrile VWR International, Tingalpa, Queensland, 
Australia 
34851 
α-Cyano-4-
hydroxycinnamic 
acid (CHCA) 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
C2020 
Adobe Illustrator® 
C56, version 16.0.3 
Adobe, San Jose, CA, USA  
Amitriptylline Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
A8404-25G 
Allyl isothiocyanate Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
36682 
AVPR1B (human) 
plasmid DNA 
OriGene Technologies, MD, USA RG210436 
β-mercaptoethanol Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
M3148-25ml 
Blasticidin Life Technologies, Mulgrave, Victoria, 
Australia 
A11139-03 
Bovine serum 
albumin (BSA) 
Bio-scientific, Kirrawee, New South Wales, 
Australia 
J64944.18 (ALF) - 50g 
CatWalk XT Noldus, Wageningen, The Netherlands  
Capsaicin Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
12084-10MG-F 
Calcium 4 No-Wash 
dye 
Molecular Devices, Sunnyvale, CA, USA R8123 
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CHO cells 
expressing human 
NaV1.8 
ChanTest, Cleveland, OH, USA CT4011 
Chromeleon HPLC 
software 
Dionex, Brendale, Queensland, Australia  
Collagenase Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
C7657-500MG 
Conical tube - 
Falcon 
VWR International, Tingalpa, Queensland, 
Australia 
BDAA352070 
Corning® 384-well 
plates  
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
CLS3657-100EA 
Corning® 384-well 
plates - CellBIND 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
CLS3683-50EA 
Coverslips 13mm 
round 
Thermo Fisher Scientific, Brendale, 
Queensland, Australia 
MENCSC131GP 
Crude venom 
samples 
Dr. Volker Herzig, Institute for Molecular 
Bioscience, University of Queensland 
 
Cryostat Leica Biosystems, New South Wales, 
Australia 
Leica CM3050 S 
DAPI (4',6-
diamidino-2-
phenylindole) 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
D9542 
Deltamethrin Sapphire Bioscience, Redfern, New South 
Wales, Australia 
BML-PR101-0050 
Dimethyl dulfoxide Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
700590 
Donkey- Anti-
Rabbit IgG Alexa 
Fluor® 488 
Abcam, Melbourne, Victoria, Australia Ab150073 
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Donkey serum Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
D9663-10ML 
Dulbecco’s 
Phosphate Buffered 
Saline (DPBS) 
Life Technologies, Mulgrave, Victoria, 
Australia 
14190-144 
Dulbecco’s 
modified eagle 
medium (DMEM) 
Life Technologies, Mulgrave, Victoria, 
Australia 
21068-028 
Ethanol Chem-Supply, Gillman, South Australia, 
Australia 
EA043-2.5L-P 
F-11 cells Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
08062601 
F-12 nutrient 
mixture medium 
Life Technologies, Mulgrave, Victoria, 
Australia 
11765062 
Fluorescent 
microscope 
Olympus BX-51 
Olympus, NY, USA BX51P 
Fluorescent 
mounting media 
Dako, North Sydney, New South Wales, 
Australia 
S3023 
Foetal bovine serum 
(FBS) 
Life Technologies, Mulgrave, Victoria, 
Australia 
26140-079 
Formaldehyde (16% 
methanol-free) 
Thermo Fisher Scientific, Brendale, 
Queensland, Australia 
PIE28906 
Formic acid VWR International, Tingalpa, Queensland, 
Australia 
VWRC20318.297 
Gabapentin Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
G154-10MG 
Geneticin Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
G8168-100ML 
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GIIIA Mr. Zoltan Dekan, , Institute for Molecular 
Bioscience, University of Queensland 
 
Glass slides 
(Superfrost) 
Menzel-Glaser, Braunschweig, Germany MENSF21202 
Glass slides – 
positively-charged 
(Superfrost Plus) 
Menzel-Glaser, Braunschweig, Germany SF41296SP 
GlutaMAX™ 
Supplement 
Life Technologies, Mulgrave, Victoria, 
Australia 
35050061 
GraphPad Prism
TM
, 
version 6.00 
GraphPad Software, La Jolla, CA, USA  
Hargreave’s Plantar 
Analgesia Meter 
IITC Life Science, Woodland Hills, CA, USA 390G 
HEK cells In Vitro Technologies, Noble Park North, 
Victoria, Australia 
ATCCRL1573 
 
HEK cells 
expressing human 
NaV1.1-1.8 
Scottish Biomedical, Glasgow, UK  
HPLC – Ascentis 
column 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
53307-U 
HPLC – Vydac 
column 
Alltech Associates, Eagle Farm, Queensland, 
Australia  
218TP54 
Hybri-MaxTM 
HAT Media 
Supplement (50x)  
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
H0262 
Hygromycin Life Technologies, Mulgrave, Victoria, 
Australia 
10987-010 
ICA-121431 Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
SML1035-5MG 
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Immersion oil (Carl 
Zeiss Immersol
TM
) 
Carl Zeiss, New South Wales, Australia 444960 
Isoflurane Provet Queensland, Queensland, Australia ISOF 04 
Lipofectamine
TM
 
2000 
Life Technologies, Mulgrave, Victoria, 
Australia 
11668-019 
MALDI 4700 
MALDI-TOF 
system 
AB Sciex Australia, Mulgrave, Victoria, 
Australia 
 
MALDI-TOP 192-
well sample plate 
Applied Biosystems, Mulgrave, Victoria, 
Australia 
 
Membrane potential 
FLIPR red dye 
Bio-strategy Distribution, Campbellfield, 
Victoria, Australia 
R8123 
Meloxicam Abcam, Melbourne, Victoria, Australia) Ab141955 
Menthol Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
M2258 
Mice (Wild-type 
C57BL/6) 
University of Queensland Biological 
Resources, St Lucia, Queensland, Australia 
 
Minimum Essential 
Media (MEM) 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
M5650-500ML 
MouseMet 
electronic von Frey 
TopCat Metrology, Cambridgeshire, United 
Kingdom 
 
Mouse house Tecnoplast, Buguggiate, Italy  
NaV1.6 antibody 
(Abcam) 
Sapphire Bioscience, Redfern, New South 
Wales, Australia 
Ab65166 
NaV1.6 antibody 
(Alomone) 
Jomar Life Research, Scoresby, Victoria, 
Australia 
ASC-009 
NanoDrop 
spectrophotometer 
(ND-1000) 
NanoDrop, DE, USA  
228 
 
ND7/23 cells Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
92090903 
Oxycodone Mundipharma, Sydney, New South Wales, 
Australia 
 
Oxytocin Professor Paul Alewood, Institute for 
Molecular Bioscience, University of 
Queensland 
OxyNorm Oral Liquid 
Oxytocin receptor 
(human) plasmid 
DNA 
OriGene Technologies, MD, USA RC211797 
PAP-Pen ProSciTech, Queensland, Australia ID310 
Parafilm Labtek, Brendale, Queensland, Australia PM996 
Parallel Rod Floor 
Apparatus with 
ANY-Maze 
Software 
Stoelting Co., Wood Dale, IL, USA 61000 
Peltier plate Ugo Basile, Varese, Italy 35150 
PCR tubes Point-of-care diagnostics, Artarmon, New 
South Wales, Australia 
0030 124 359 
PDL-coated 
ViewPlate 384-well 
plates 
PerkinElmer, Melbourne, Victoria, Australia 6007710 
Petri dish - Tissue 
Culture Dish 
35x10mm  
Thermo Fisher Scientific, Brendale, 
Queensland, Australia 
NUN153066 
Pnc1a Mr. Zoltan Dekan, , Institute for Molecular 
Bioscience, University of Queensland 
 
Poly-D-lysine 
hydrobromide 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
P6407-5MG 
229 
 
Proglumide Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
M006-100MG 
Protease Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
P8811-1G 
RNALater Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
R0901-500ML 
RNeasy Mini Kit Qiagen, Melbourne, Victoria, Australia 74104 
Roswell Park 
Memorial Institute 
medium (RPMI) 
Life Technologies, Mulgrave, Victoria, 
Australia 
21870-092 
ScreenWorks, 
version 3.2 
Molecular Devices, CA, USA  
SH-SY5Y cells Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
94030304-1VL 
Sucrose Chem-supply, South Australia, Australia SA030-500G 
T75 flasks - 
Corning® 
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
CLS430641-100EA 
T75 flasks – 
Corning® 
CellBIND  
Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
CLS3290-100EA 
T75 flasks - Nunc Thermo Fisher Scientific, Brendale, 
Queensland, Australia 
NUN156499 
Tetracycline Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
7660-5G 
Tetrodotoxin Sapphire Bioscience, Redfern, New South 
Wales, Australia 
AB120055 
Thermal threshold 
probe (MouseMet 
Thermal) 
TopCat Metrology, Cambridgeshire, United 
Kingdom 
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TIIIA Mr. Zoltan Dekan, , Institute for Molecular 
Bioscience, University of Queensland 
 
Tissue-Tek® O.C.T. 
media 
ProSciTech, Townsville. Queensland, 
Australia 
IA018 
Tissue culture 24-
well plate 
Thermo Fisher Scientific, Brendale, 
Queensland, Australia 
NUN142475 
Trifluoroacetic acid Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
T6508-100ML 
Triton
TM
 X-100 Sigma-Aldrich, Castle Hill, New South 
Wales, Australia 
X100-500ML 
TRPA1 (mouse) 
plasmid DNA 
Professor Ardem Patapoutian, The Scripps 
Research Institute, La Jolla, CA, USA 
 
TRPM8 (rat) 
plasmid DNA 
Dr. Katarina Zimmermann, Department of 
Anesthesiology, Friedrich-Alexander-
University, Erlangen-Nuremberg, Erlangen, 
Germany 
 
TRPV1 (rat) 
plasmid DNA 
Professor David Julius, Department of 
Physiology, University of California, 
Berkeley) 
 
Trypsin/EDTA 
(0.25% trypsin with 
EDTA) 
Life Technologies, Mulgrave, Victoria, 
Australia 
25200-072 
UltiMate 3000 
HPLC machine 
Dionex, Brendale, Queensland, Australia  
Vasopressin Professor Paul Alewood, Institute for 
Molecular Bioscience, University of 
Queensland 
 
Veratridine Sapphire Bioscience, Redfern, New South 
Wales, Australia 
AB120279 
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Vernier caliper Kincrome, Carole Park, Queensland, Australia 2311 
Zeocin Jomar Life Research, Scoresby, Victoria, 
Australia 
Ant-zn-1 
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Appendix 2 – Buffer composition 
 
2.1 Physiological Saline Solution (PSS) (Sigma-Aldrich) 
140 mM NaCl 
11.5 mM glucose 
5.9 mM KCl 
1.4 mM MgCl2 
1.2 mM NaH2PO4  
5 mM NaHCO3 
1.8 mM CaCl2 
10 mM HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid); pH 7.4 
 
2.2 Minimum Essential Medium (MEM) (Sigma-Aldrich) 
0.2 g/L CaCl2 
0.10 g/L MgSO4 (anhydrous) 
0.4 g/L KCl 
2.2 g/L NaHCO3 
6.8 g/L NaCl 
0.122 g/L NaH2PO4 (anhydrous) 
8.9 x10
-3
 g/L L-alanine 
0.13 g/L L-arginine • HCl 
0.015 g/L L-Asparagine • H2O 
0.013 g/L L-aspartic acid 
0.031 g/L L-Cystine • 2HCl 
0.015 g/L L-glutamic acid 
7.5 x10
-3
 g/L glycine 
0.042 g/L L-Histidine • HCl • H2O 
0.052 g/L L-isoleucine 
0.052 g/L L-leucine 
0.073 g/L L-lysine • HCl 
0.015 g/L L-methionine 
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0.032 g/L L-phenylalanine 
0.012 g/L L-proline 
0.011 g/L L-serine 
0.048 g/L L-threonine 
0.01 g/L L-tryptophan 
0.052 g/L L-tyrosine • 2Na • 2H2O 
0.046 g/L L-valine 
1.0 x10
-3
 g/L choline chloride 
1.0 x10
-3
 g/L folic acid 
2.0 x10
-3
 g/L myo-inositol 
1.0 x10
-3
 g/L niacinamide 
1.0 x10
-3
 g/L D-pantothenic acid (hemicalcium) 
1.0 x10
-3
 g/L pyridoxal • HCl 
1.0 x10
-4
 g/L riboflavin 
1.0 x10
-3
 g/L thiamine • HCl 
1.0 g/L glucose 
0.011 g/L Phenol Red • HCl 
 
2.3 Ham’s F12 media (Invitrogen) 
0.30 mM CaCl2 
1.0 x10
-6
 mM CuSO4 • 5H2O 
3.0 x10
-3
 mM FeSO4 • 7H2O 
0.60 mM MgCl2 
3.0 mM KCl 
14.0 mM NaHCO3 
131.0 mM NaCl 
1.0 mM Na2HPO4 (anhydrous) 
3.0 x10
-3
 mM ZnSO4 • 7H2O 
0.10 mM Glycine 
0.010 mM L-alanine 
1.0 mM L-arginine hydrochloride 
0.10 mM L-asparagine • H2O 
0.10 mM L-aspartic acid 
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0.20 mM L-cysteine hydrochloride • H2O 
0.10 mM L-glutamic acid 
1.0 mM L-glutamine 
0.10 mM L-histidine hydrochloride • H2O 
0.031 mM L-isoleucine 
0.10 mM L-leucine 
0.20 mM L-lysine hydrochloride 
0.030 mM L-methionine 
0.030 mM L-phenylalanine 
0.30 mM L-proline 
0.10 mM L-serine 
0.10 mM L-threonine 
0.010 mM L-tryptophan 
0.030 mM L-tyrosine disodium salt dihydrate 
0.10 mM L-valine 
3.0 x10
-5 
mM biotin 
0.10 mM choline chloride 
1.0 x10
-3
 D-calcium pantothenate 
2.9 x10
-3
 mM folic acid 
3.0 x10
-4
 mM niacinamide 
2.9 x 10
-4
 mM pyridoxine hydrochloride 
9.8 x10
-5
 mM riboflavin 
8.9 x10
-4
 mM thiamine hydrochloride 
1.0 x10
-3
 mM vitamin B12 
0.10 mM i-Inositol 
10 mM D-glucose 
0.03 mM hypoxanthine sodium 
3.0 x10
-4
 mM linoleic acid 
1.0 x10
-3
 mM lipoic acid 
3.2 x10
-3
 mM Phenol Red 
1.0 x10
-3
 mM putrescine 2HCl 
1.0 mM sodium pyruvate 
2.9 x10
-3
 mM thymidine 
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2.4 Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich) 
0.20 g/L CaCl2 
1.0 x10
-4
 g/L Ferric Nitrate • 9H2O 
0.098 g/L MgSO4 (anhydrous) 
0.40 g/L KCl 
3.7 g/L NaHCO3 
6.4 g/L NaCl 
0.11 g/L NaH2PO4 (anhydrous) 
0.084 g/L L-arginine • HCl 
0.063 g/L L-cystine • 2HCl 
0.58 g/L L-glutamine 
0.03 g/L glycine 
0.042 g/L L-histidine • HCl • H2O 
0.11 g/L L-isoleucine 
0.11 g/L L-leucine 
0.15 g/L L-lysine• HCl 
0.030 g/L L-methionine 
0.066 g/L L-phenylalanine 
0.042 g/L L-serine 
0.095 g/L L-threonine 
0.016 g/L L-tryptophan 
0.10 g/L L-tyrosine • 2Na • 2H2O 
0.094 g/L L-valine 
0.0040 g/L choline chloride 
0.0040 g/L folic acid 
0.0072 g/L myo-inositol 
0.0040 g/L niacinamide 
0.0040 g/L D-pantothenic acid (hemicalcium) 
0.0040 g/L pyridoxine • HCl 
0.00040 g/L riboflavin 
0.0040 g/L thiamine • HCl 
4.5 g/L D-glucose 
0.016 g/L Phenol Red • Na 
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0.11 g/L Pyruvic Acid • Na 
 
2.5 Dulbecco’s Phosphate Buffered Saline (DPBS) (Sigma-Aldrich) 
0.20 g/L KCl 
0.20 g/L KH2PO4 
8.0 g/L NaCl 
1.15 g/L Na2HPO4 (anhydrous) 
 
2.6 0.25% trypsin/EDTA solution (Invitrogen) 
2.5 g/L porcine trypsin 
0.38 g/L EDTA • 4Na • 2H2O 
Dissolved in Hank's Balanced Salt Solution: 
0.40 g/L KCl 
0.060 g/L KH2PO4 
0.35 g/L NaHCO3 
8.0 g/L NaCl 
0.090 g/L Na2HPO4 • 7H2O 
1.0 g/L D-glucose 
0.010 g/L Phenol Red 
 
2.7 Tetracycline solution 
1 mg/mL tetracycline dissolved in DPBS 
 
2.8 Roswell Park Memorial Institute medium (RPMI) (Invitrogen) 
0.10 g/L Ca(NO3)2 • 4H2O 
0.049 g/L MgSO4 (anhydrous) 
0.40 g/L KCl 
2.0 g/L NaHCO3 
6.0 g/L NaCl 
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0.80 g/L Na2HPO4 (anhydrous) 
0.010 g/L glycine 
0.20 g/L L-arginine 
0.050 g/L L-asparagine 
0.020 g/L L-aspartic acid 
0.065 g/L L-cystine • 2HCl 
0.020 g/L L-glutamic acid 
0.30 g/L L-glutamine 
0.015 g/L L-histidine 
0.020 g/L L-hydroxyproline 
0.050 g/L L-isoleucine 
0.050 g/L L-leucine 
0.040 g/L L-lysine hydrochloride 
0.015 g/L L-methionine 
0.015 g/L L-phenylalanine 
0.020 g/L L-proline 
0.030 g/L L-serine 
0.020 g/L L-threonine 
0.0050 g/L L-tryptophan 
0.029 g/L L-tyrosine disodium salt dehydrate 
0.020 g/L L-valine 
2.0 x10
-4
 g/L biotin 
3.0 x10
-3
 g/L choline chloride 
2.5 x10-4 g/L D-calcium pantothenate 
1.0 x10
-3
 g/L folic acid 
1.0 x10
-3
 g/L niacinamide  
1.0 x10
-3
 g/L para-aminobenzoic acid 
1.0 x10
-3
 g/L pyridoxine hydrochloride 
2.0 x10
-4
 g/L riboflavin 
1.0 x10
-3
 g/L thiamine hydrochloride 
5.0 x10
-6
 g/L vitamin B12 
0.035 g/L i-inositol 
2.0 g/L D-glucose 
1.0 x10
-3
 g/L glutathione (reduced) 
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5.0 x10
-3
 g/L Phenol Red 
 
2.9 Hypoxanthine-aminopterin-thymidine (HAT) media supplement (50x) 
Hybri-Max
TM
 (Sigma-Aldrich) 
Supplied as powder, reconstituted in DPBS to 10 mL, which is then added to 500 mL of 
culture media.  
 
Final concentrations in 10 mL reconstituted: 
5.0 x10
-3
 M hypoxanthine 
2.0 x10
-5
 M aminopterin 
8.0 x10
-4
 M thymidine 
 
2.10 DNase I stock solution (Qiagen) 
Lyophilised DNase I (1500 Kunitz units) was dissolved in 550 µL of RNase-free water and 
divided into 10 µL aliquots. 
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Appendix 3 - Supplementary data 
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Appendix Figure 3.1 Veratridine-induced responses in NaV1.6-expressing HEK293 cells 
exposed to scorpion and spider venoms 
Crude venom or the buffer solution was added into the cells as the first addition. Veratridine, 
a known NaV1.6 activator, was added as the second addition. All experiments were conducted 
using membrane potential dye. The buffer solution was composed of  PSS with 1:1000 BSA. 
Traces were normalised to baseline fluorescence readings before the second addition. The X 
axis indicates time (in seconds) after the first addition. 
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Appendix Figure 3.2 Deltamethrin-induced responses in NaV1.8-expressing CHO cells 
exposed to scorpion and spider venoms 
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Crude venom or the buffer solution was added into the cells as the first addition. 
Deltamethrin, a known NaV1.8 activator, was added as the second addition. All experiments 
were conducted using membrane potential dye. The buffer solution was composed of PSS 
with 1:1000 BSA. Traces were normalised to baseline fluorescence readings before the 
second addition. The X axis indicates time (in seconds) after the first addition. 
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Appendix Figure 3.3 Heat map of Ion channels and GPCRs 
The heat map of all ion channel and GPCR genes can be found from  
https://www.dropbox.com/s/btb8gi5b2k8s26v/Appendix%20Figure%203.1.xlsx?dl=0 
 
Appendix Figure 3.4 Description of CatWalk XT parameters used to analyse burn-
induced gait abnormalities 
Paw Pressure Parameters 
Mean intensity The mean light intensity for an individual paw during an 
entire run expressed in arbitrary units (AU).  
Mean intensity of the 15 
most intense pixels 
The mean intensity of the 15 pixels of a paw with the 
highest reflected light intensity during an entire run 
expressed in arbitrary units (AU).  
Max intensity The maximum light intensity for an individual paw 
during a run expressed in arbitrary units (AU). 
Paw Print Area Parameters 
Print area Representative of the average contact area of an 
individual paw with the glass plate during a run 
expressed in cm
2
. 
Maximum contact area The maximum surface area of the print the animal 
placed on the glass plate during a run expressed in cm
2
. 
Dynamic Paw Parameters 
Stand The average duration of contact of an individual paw 
with the glass plate during a run expressed in seconds. 
Swing The average duration in seconds of no contact of a paw 
with the glass plate expressed in seconds. 
Duty Cycle Stand as a percentage of Step Cycle: Duty Cycle = 
Stand / (Stand + Swing) x 100% 
Interlimb Coordination  
Regularity index Percentage of normal step sequences calculated by the 
formula (NSSP x 4)/PP x 100%, where NSSP is the 
number of Normal Step Sequence Patterns and PP is the 
total number of Paw Placements. 
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Appendix Figure 3.5 Location of the burn injury in the mice burn injury model 
 
In the establishment of the murine model of burn-induced pain, a section of the mouse’s left 
hind paw (labelled ‘Location of burn injury’ in the picture) was placed on a heated thermal 
plate to induce the injury. A pair of tweezers, with the tips wrapped in tissue paper, was used 
to press the plantar portion of the paw onto the Peltier plate. Subsequent allodynia was tested 
using electronic von Frey fibres and the thermal threshold probe to assess for secondary 
allodynia at the site labelled ‘Location of allodynia testing and compound injection’. 
Intraplantar injections with clinical compounds, NaV isoform inhibitors, and inhibitors of 
novel pharmacological targets (detailed in chapter 5) were also injected into the site labeled 
‘Location of allodynia testing and compound injection’. 
 
Appendix Figure 3.6 Full list of burn transcriptome 
The full list of differential expression data in the burn transcriptome for all genes can be 
found from 
https://www.dropbox.com/s/s71y56prrg3dpwv/Appendix%20Figure%203.4.xlsx?dl=0 
 
